• Home
  • Industry
  • Clinical
  • CPD
  • People
CPD Login
Sign in
  • Home
  • Industry
  • Clinical
  • CPD
  • People
Sign in
Welcome!Log into your account
Forgot your password?
Password recovery
Recover your password
CPD Login
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
AUSTRALIAN PHARMACIST
  • Home
  • Industry
    • ADHD medicines
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31334
                  [post_author] => 3410
                  [post_date] => 2026-02-11 14:25:30
                  [post_date_gmt] => 2026-02-11 03:25:30
                  [post_content] => Victoria recently announced ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. 
      
      But last week, the Allan Government also unveiled a nation-first initiative. From September, an online emergency prescribing pathway will allow people with an existing ADHD diagnosis to obtain urgent repeat medicine through the Victorian Virtual Emergency Department (VVED).
      
      AP explores what the new model involves, the safeguards that will be in place and what’s happening in other states and territories.
      

      What’s the purpose of the service?

      The telehealth service is designed to address growing concern about long specialist waitlists, escalating costs and the clinical risks associated with abrupt cessation of Schedule 8 ADHD medicines – which can lead to symptom rebound, functional impairment and significant distress. A Department of Health spokesperson told AP that the service would provide a targeted safety net, rather than a substitute for established care arrangements. ‘The Victorian Virtual Emergency Department will offer a safe way for Victorians with an existing ADHD diagnosis to refill an urgent prescription for ADHD medication,’ the spokesperson said. 

      How will urgent ADHD ‘repeats’ be issued?

      Clinicians working within the VVED will verify the patient’s current medicine and dosage before issuing a prescription, the spokesperson said. Scripts will be sent directly to the patient’s local pharmacy, with patients advised of the closest pharmacy in operation at the time of prescribing. The Department of Health emphasised that the pathway will not replace routine ADHD management. ‘This is for emergency situations only and will not replace the important ongoing treatment and relationship between a patient and their clinician,’ the spokesperson said.

      Who will be eligible?

      The Victorian model allows adults and children aged 6 and over with an existing ADHD diagnosis to access the service who cannot secure a timely appointment with their usual clinician. The service will be limited to people who are already prescribed ADHD medicines. The VVED will not initiate ADHD treatment, alter dosages or provide ongoing prescribing. 

      What are the safeguards?

      Existing regulatory requirements and clinical guidelines for ADHD medicines will remain fully in place under the VVED pathway.  ‘The clinicians at the VVED, including paediatricians and psychiatrists, are highly experienced and highly skilled,’ the spokesperson said. ‘They will prescribe the medication within their existing scope of practice and clinical operations.’ Mandatory use of SafeScript for Schedule 8 medicines will continue to operate as a core safeguard. This ensures prescribers and pharmacists can monitor dispensing histories and reduces the risk of patients obtaining excessive prescriptions from multiple clinicians. The Department has stressed that responsibility for ongoing ADHD management remains with the patient’s regular clinician, with the VVED acting solely as a one-off support mechanism that complements broader reforms aimed at expanding GP involvement in ADHD care. And rather than providing a script to the patient, the script will be sent directly to their local pharmacy. When issuing a script, the VVED advises the patient of the closest pharmacy in operation.

      Part of a broader national shift

      Victoria’s online emergency model sits within a wider national trend to rebalance ADHD care away from exclusive reliance on specialist services.  Since 1 December 2025, ‘specialist GPs' in Queensland have been able to initiate, modify and continue stimulant treatment for adults with ADHD under updated Queensland Health guidance. Today (11 February), ACT Health issued an announcement on ADHD prescribing, with GPs who have completed approved training now able to continue prescribing ADHD medicines for eligible patients without requiring repeated reviews from a psychiatrist, paediatrician or neurologist. And other jurisdictions have since followed suit, including New South Wales, Western Australia and South Australia – which are set to roll out similar reforms this year.  Across Australia, governments are seeking to reduce wait times, lower out-of-pocket costs and embed ADHD care more firmly within primary care, while maintaining strong oversight of Schedule 8 stimulants such as methylphenidate, dexamfetamine and lisdexamfetamine via authorised prescribing schemes and real-time prescription monitoring checks. Non-stimulant ADHD medicines remain Schedule 4 and continue to be prescribed under existing arrangements. For more information, complete the PSA online module: ADHD explained. [post_title] => What pharmacists need to know about emergency prescribing for ADHD [post_excerpt] => Victoria is the latest state to announce ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => what-pharmacists-need-to-know-about-emergency-adhd-prescribing [to_ping] => [pinged] => [post_modified] => 2026-02-11 15:45:52 [post_modified_gmt] => 2026-02-11 04:45:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31334 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => What pharmacists need to know about emergency prescribing for ADHD [title] => What pharmacists need to know about emergency prescribing for ADHD [href] => https://www.australianpharmacist.com.au/what-pharmacists-need-to-know-about-emergency-adhd-prescribing/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31336 [authorType] => )

      What pharmacists need to know about emergency prescribing for ADHD

      emergency contraception
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31316
                  [post_author] => 3410
                  [post_date] => 2026-02-09 12:57:25
                  [post_date_gmt] => 2026-02-09 01:57:25
                  [post_content] => The gap between evidence and everyday practice is impacting patient access to emergency contraception.
      
      Community pharmacies are often the first – and sometimes only – point of access for emergency contraception in Australia. 
      
      But a new qualitative study found there are still persistent gaps between what the guidelines say and what happens in practice.
      
      Ruth Nona, pharmacist and researcher at James Cook University, who interviewed community pharmacists about providing emergency contraception services, describes a workforce that is broadly willing to help, but not always set up to deliver consistently equitable care. 
      

      1. Not recommending ulipristal as first-line

      One of the most significant gaps identified in the study was the tendency for pharmacists to default to levonorgestrel, despite guidance in the Australian Pharmaceutical Formulary and Handbook (APF) that ulipristal acetate is generally considered more effective than levonorgestrel and can be used up to 120 hours after unprotected intercourse. ‘Habit definitely plays a role,’ Ms Nona said. ‘Some pharmacists felt more comfortable and confident supplying levonorgestrel. For example, if someone requested emergency contraception within 24 hours, pharmacists felt levonorgestrel was acceptable within that timeframe, without fully considering efficacy.’ [caption id="attachment_31329" align="alignright" width="250"] Ruth Nona[/caption] In some pharmacies, price differences influenced whether ulipristal acetate was presented as an option. ‘In certain socio-economic areas, cost was a driver,’ Ms Nona said. ‘Cost considerations were also sometimes linked to younger people coming in and asking whether there was a cheaper option.’ Sometimes, levonorgestrel was the only medicine on hand. ‘There was research that came out showing that some pharmacies still did not stock ulipristal acetate,’ she said. ‘It’s been an ongoing issue, and something that really needs to be addressed.’ However, patients need to be able to make an informed decision about which medicine to take. ‘As stated in the guidelines, it’s about making sure all patients are given the information they need to make an informed and equitable choice. If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information,’ Ms Nona said. ‘When pharmacists did give the full picture and explained the differences, more often than not the patient chose ulipristal acetate, even though it cost more.’
      ‘If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information.' Ruth nona

      2. Uncertainty when responding to third-party requests

      Pharmacists reported particular uncertainty when providing emergency contraception to third parties, with many wary about consent and unsure whether they could provide it to someone who wasn’t the patient. ‘In most cases, they would follow up and ask to contact the patient directly,’ Ms Nona said. ‘It wasn’t that they didn’t want to provide it – they just felt unsure and they wanted to make sure that the patient had consented.’ While in many cases, speaking to the intended person directly can help provide key information and counselling, in circumstances where this is not possible, it is usually possible to determine the medicine is safe and therapeutically appropriate, and supply in a manner consistent with APF guidance and legal obligations.

      3. Uncertainty providing emergency contraception to adolescents

      Similarly, pharmacists were ‘uncomfortable’ providing the service to adolescents. This uncertainty often centred on fear of making the wrong decision or facing professional consequences. ‘They still wanted to provide the service, but it was more that internal question of, “Should I do this? Am I going to get in trouble?”’ There are no jurisdictions where there’s a legal restriction from supplying emergency contraception to minors. The APF guidance helps pharmacists navigate Gillick competency and consent in adolescents, ensuring they demonstrate sufficient maturity and understanding to provide informed consent. Ms Nona emphasised that the issue was confidence, not capability. ‘It’s about being familiar with the guidelines, making sure we’re as up to date as possible and realising that it’s okay for us to provide these services, provided the adolescent is [assessed as Gillick competent] mentally mature and safe,’ she said.  The APF references Gillick competency provided the adolescent is [assessed as Gillick competent (demonstrating sufficient maturity and understanding to provide informed consent)]

      4. Uncertainty for transgender people on gender affirming hormone therapy

      While pharmacists were generally supportive towards transgender and gender-diverse patients, lack of familiarity with hormone therapy raised hesitation. ‘There are absolutely no interactions between emergency contraception and gender-affirming hormones’ Ms Nona said. ‘It really comes down to knowledge, which builds confidence, and being up to date to make sure the service we provide is timely and equitable.’ In some areas, pharmacists may frequently encounter transgender and gender- diverse patients requesting emergency contraception, while pharmacists in other areas do not. ‘That’s why it’s also about being prepared. You never know when that situation might arise,’ she added. Should pharmacists feel unsure during these consultations, pharmacists can and should engage with the APF. ‘Pharmacists did say that if that situation did occur with a transgender or gender- diverse person that they would be honest and say to them, “Do you mind if I consult my resources?”’ 

      Another reason the APF is a mandatory text for all community pharmacists

      Despite lack of guideline use, pharmacists acknowledged how essential guidelines such as the APF are, Ms Nona said.  ‘And when pharmacists did use them, they found the information provided was invaluable.’ ‘[But] a lot of the challenges stemmed from lack of time and, in some cases, a lack of up-to-date knowledge. We have so many things to do, and we need more time to do everything and to keep ourselves up to date.’ For Ms Nona, the solution lies in supporting pharmacists to use guidelines  confidently and consistently in real-world conditions. Some pharmacists report to PSA that they will often bring up the APF digital on the screen in the consultation room in emergency contraception discussions, particularly in situations which are new or unfamiliar.

      Delivering a critical intervention

      The key to emergency contraception provision is recognising the stakes. ‘The whole picture of providing emergency contraception is to make sure we are preventing pregnancies when people don't want to get pregnant – whatever the reason may be,’ Ms Nona said. ‘That’s why they come to see a pharmacist – to ensure the person has the best possible chance of preventing an unintended pregnancy.’ When pharmacists are supported to provide full information and informed choice, patients respond accordingly.
      The Australian Pharmaceutical Formulary and Handbook (APF) chapter on ‘Emergency Contraception’, provides essential guidance on: 
      • providing timely, confidential, non-judgemental access to emergency contraception, recognising that effectiveness is time-dependent
      • obtaining sufficient patient information to assess safety, effectiveness and the most appropriate emergency contraception option
      • recommending the most effective oral emergency contraception, based on clinical assessment and time since unprotected sexual intercourse
      • supporting informed choice, including discussion of efficacy, cost and suitability, without making assumptions about patient preferences
      • assessing the need for referral where safety, effectiveness or appropriateness cannot be assured
      • providing care to adolescents based on maturity and understanding, in accordance with legislation and professional obligations
      • providing inclusive care for transgender and gender-diverse people with pregnancy risk
      • providing counselling and written information, including how to take emergency contraception, what to expect, and advice on ongoing contraception.
      [post_title] => Where emergency contraception practice falls short [post_excerpt] => The gap between evidence and everyday practice is costing patients access to the most effective emergency contraception. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => where-emergency-contraception-practice-falls-short [to_ping] => [pinged] => [post_modified] => 2026-02-09 16:09:16 [post_modified_gmt] => 2026-02-09 05:09:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31316 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Where emergency contraception practice falls short [title] => Where emergency contraception practice falls short [href] => https://www.australianpharmacist.com.au/where-emergency-contraception-practice-falls-short/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31321 [authorType] => )

      Where emergency contraception practice falls short

      pharmacist prescribing
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31305
                  [post_author] => 1925
                  [post_date] => 2026-02-08 10:38:16
                  [post_date_gmt] => 2026-02-07 23:38:16
                  [post_content] => 

      Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)?

      The range of professional services delivered by community pharmacists has expanded rapidly in recent years, from vaccination to UTI prescribing and beyond. As these services increase in popularity, they are shifting from ancillary service to core business. This widening scope is forcing community pharmacies to review how they conduct their business and the way front-of-house staff interact with patients. No longer is dispensing prescriptions on a first come, first served basis sustainable. With adjustments to workflow, vaccinations and other booked services have been prioritised and run simultaneously, says Queensland-based prescribing pharmacist Kate Gunthorpe MPS.  ‘We are moving away from the mindset that dispensing always comes first. We need to triage effectively and manage expectations, so every patient feels seen and cared for,’ she says. And it isn’t just about sequential processes. Workflow changes also require a shift of communication approaches and pre-existing mindsets around professional service provision.  ‘The biggest pitfall I’ve discovered is apologising for charging or determining that the consultation wasn’t worth charging for,’ Ms Gunthorpe says. ‘That instantly undermines the service’s value. Every consultation, whether the outcome is a prescription, advice or reassurance, involves clinical reasoning, professional judgement and patient care.’ So, how should the profession move forward? The PSA’s foundation documents are clear that all services must remain patient-centric.  That means redesigning workflows on the floor, developing new communication strategies for staff and providing additional training for pharmacy assistants to ensure a consistent, professional patient experience. AP spoke with Ms Gunthorpe and pharmacy assistant Madison Low about adapting workflow to integrate services without disrupting dispensing. product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously. 

      Case 1 Kate Gunthorpe MPS

      Pharmacist prescriber, Implementation and Change Specialist, TerryWhite Chemmart, Samford, Queensland  [caption id="attachment_31312" align="alignright" width="185"]pharmacist prescribing Kate Gunthorpe MPS[/caption] Our team started by mapping our busiest times to understand where bottlenecks occurred. We then built clear workflows – for example, using a booking system for consultations where possible, and ensuring at least one pharmacist remained consult-focused during every day. We trained our assistants to triage appropriately and use consistent language, such as ‘the pharmacist will see you shortly for your consultation’, which helped the process feel deliberate rather than disruptive. Once the team understood that consultations were core services, not interruptions, the process flowed more smoothly. Patients often expect a prescription outcome from a consultation, so I changed the framework, ensuring the consultation became a clinical one, not a product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously.  When we changed our front-of-shop language, patients stopped viewing consultations as waiting in a queue. That one shift in language lifted the professionalism of the whole process; patients were more patient, staff felt more confident explaining the service, and we saw an improvement in how people valued the pharmacist’s time. One thing I would advise other pharmacists about charging appropriately for their time, even when the consultation doesn’t end with a script, is to start valuing their expertise. The consultation is the service, not the outcome. We’re expertly trained to assess, diagnose and provide evidence-based care. That deserves to be remunerated. Once pharmacists stop apologising and start consistently charging for their time and expertise, patients begin to respect that boundary too. I find it is better to be transparent and consistent with pricing. I explain what’s included in the consultation, so patients understand what they’re paying for. Most importantly, I believe in it myself. If you hesitate to charge, your team and patients will pick up on that. The work floor also needs redesigning to normalise consulting services as part of everyday care. It starts with the physical layout and staffing models. Pharmacies should expect consultations to happen and allocate dedicated private spaces, clear booking systems and enough pharmacist coverage, so that one can focus on clinical care, while others oversee dispensing and other services. Culturally, it’s all been about mindset: we stopped treating services as extra and started treating them as central to what we do. That meant redistributing roles, upskilling support staff with more autonomy to triage and manage appointments, and introducing appointment blocks.  The effect of all these new processes has resulted in major change. Our pharmacy assistants are our front line, and their language is setting the tone for the entire patient experience. We have invested time in scripting and role-playing, so that the assistants feel comfortable discussing new services. The staff have learned to understand what each service involves, how long it typically takes, and when to book or triage patients. Scripts no longer automatically take priority over walk-up service requests. They are both core services. Pharmacies are healthcare hubs where patients can expect to have a prescription filled but also be able to discuss their health concerns.  Patients also value honesty and clarity. If a medication is not appropriate, explaining why builds understanding and trust – especially when you provide alternative options or safety net advice.  Because pharmacy staff use consistent, confident language and understand the workflow, everything runs much more smoothly. It has also empowered the staff to take pride in being responsible for a part of the patient care process, not just the retail side.  When staff describe services as core health care, not as ‘extras’ or ‘add-ons’, patients have started to see the pharmacist as a clinician involved in their primary care. It’s a subtle but powerful mindset shift that’s transforming how the pharmacy is perceived.

      Case 2 Madison Low

      Retail manager, TerryWhite Chemmart, Arana Hills, Queensland [caption id="attachment_31313" align="alignright" width="277"]pharmacist prescribing Madison Low[/caption] Since we started offering services like UTI consultations and vaccinations, my role has expanded significantly. We no longer just provide products; we’re delivering a more complete healthcare solution. A person recently came to the counter, visibly frustrated because they had symptoms of a urinary tract infection but couldn’t get in to see their doctor. They were holding a box of Ural.  Rather than just selling them the product, I suggested they talk to the pharmacist, assuring them that in many cases the pharmacist can provide a full treatment without needing a doctor’s visit. I asked a few questions about their symptoms, then checked with the pharmacist to confirm a consultation was possible immediately. It was, and not long afterwards the patient went away happy. Asthma management is one of the most common chronic conditions we see. Many patients believe they understand how to manage the condition, especially because they can access inhalers over the counter. But often that’s not the case. One of my roles is to let patients know there may be better solutions. Our pharmacists can review their current treatment and provide an improved management plan. Since becoming more mindful of the language I use with patients, I’ve noticed a positive change in how they respond to me.  By communicating in a more empathetic and approachable way, I’ve found patients are more comfortable asking questions and discussing their concerns. This has made it easier to identify when a patient might benefit from a review with one of our pharmacists. This change in language has also strengthened trust between patients and the pharmacy team. Patients seem more engaged and confident in the care they receive, and I feel more confident in my role as a link between them and our pharmacists. The biggest challenge has been balancing our time – especially during busy periods like the flu season, when there are lots of vaccines to administer, prescriptions to dispense and consultations to organise. I’m proud of how our team works together to ensure our patients are looked after promptly and get the attention they need. [post_title] => How expanded scope is redefining pharmacy practice [post_excerpt] => Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)? [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => how-expanded-scope-is-redefining-pharmacy-practice [to_ping] => [pinged] => [post_modified] => 2026-02-09 14:54:19 [post_modified_gmt] => 2026-02-09 03:54:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31305 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => How expanded scope is redefining pharmacy practice [title] => How expanded scope is redefining pharmacy practice [href] => https://www.australianpharmacist.com.au/how-expanded-scope-is-redefining-pharmacy-practice/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31310 [authorType] => )

      How expanded scope is redefining pharmacy practice

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31266
                  [post_author] => 11883
                  [post_date] => 2026-02-04 13:01:11
                  [post_date_gmt] => 2026-02-04 02:01:11
                  [post_content] => 

      Case scenario

      Greg, a 28-year-old man, comes into your pharmacy asking for a ‘strong minoxidil hair product’. He explains that his doctor recently diagnosed him with male pattern hair loss and suggested he try an over-the-counter treatment, with a follow-up review in 6 months. Greg has noticed gradual thinning at the temples over the past year but reports no sudden hair loss, scalp irritation or other medical issues. He has no known allergies, takes no medicines and has no chronic conditions.

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the main phases of the hair growth cycle
      • Outline the main types of hair loss and describe their key features
      • Identify pharmacological treatments and non-pharmacological strategies for pattern hair loss in males and females
      • Counsel patients on expected outcomes, timelines and use of common hair loss treatments.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5  Accreditation number: CAP2602DMFK  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. Hair loss can therefore have a major impact on self-esteem and quality of life, with notable psychosocial consequences.1,2 In an era where many people increasingly turn to social media for health information,3 pharmacists are accessible, reliable health professionals who can guide patients towards safe, evidence-based options, clarify treatment outcomes and timelines, and identify when medical referral is required.

      Epidemiology and physiology

      Pattern hair loss, also called androgenetic alopecia, is the most common cause of hair loss in both men and women.2 Approximately 80% of Caucasian men and up to 60% of Caucasian women by the age of 70 years are affected by pattern hair loss.1 Scalp hair follicles cycle through three stages: anagen (active growth), catagen (transition), and telogen (resting/shedding).1 At any given time, most follicles (about 85–90%) are in the growth phase, producing roughly 1 centimetre of hair per month.1 Shedding up to 100 hairs daily is considered normal, usually seen while washing and brushing.1

      Understanding hair loss disorders

      Hair loss disorders typically result from disruptions in the normal hair growth cycle.1 They can be divided into three main categories: patterned, diffuse or localised (patchy) alopecia.1 Patterned alopecia Male or female pattern hair loss is a non-scarring form of alopecia. It manifests as progressive hair thinning in a characteristic pattern and is influenced by genetics and the sensitivity of hair follicles to androgens, primarily dihydrotestosterone. The replacement of terminal hairs with shorter, finer, miniaturised hairs is driven by androgen effects on scalp follicles.1,2 In men, pattern hair loss typically begins with bitemporal hairline recession and may progress to baldness at the vertex (crown).2 In women, it usually presents as diffuse thinning that gradually widens the part line on the crown and reduces ponytail volume.2 Both male and female pattern hair loss commonly comprise of a sparser frontal hairline where episodic bursts of excessive hair shedding are common.1,2 Diffuse alopecia Diffuse alopecia involves hair loss across the scalp without a defined pattern. It can occur during either the telogen or anagen phases of the hair cycle. The most common cause is telogen effluvium, a reactive condition in which a trigger causes anagen hairs to prematurely enter the telogen (resting) phase, resulting in excessive shedding.1,4 Both acute and chronic telogen effluvium typically do not lead to permanent baldness.1 Localised (patchy) alopecia Localised alopecia presents as discrete patches of hair loss. Common causes include alopecia areata and tinea capitis (more common in children), while less common causes include scarring alopecias (e.g. discoid lupus erythematosus or lichen planopilaris) and trichotillomania (compulsive hair-pulling).1 Alopecia areata is a complex polygenic autoimmune disorder and typically produces discrete (often circular) areas of hair loss anywhere on the body.1 The lifetime risk is approximately 2%,5 and spontaneous complete regrowth within 12 months occurs in up to 80% of individuals with a single patch, though relapses are common.1 Alopecia areata can have significant psychosocial impacts. The Australia Alopecia Areata Foundation (AAAF) offers resources and support for affected individuals and their families.1

      Diagnosis and treatment goals

      When a person presents with hair loss, it is important to first confirm the diagnosis and rule out reversible or more serious causes. Medical practitioners may consider contributing factors such as scarring alopecias, nutritional deficiencies, metabolic disorders or drug-induced alopecia. Some implicated medicines in drug-induced alopecia include, but are not limited to, chemotherapy, retinoids, antiepileptics, antidepressants, β-blockers, statins and hormonal agents such as anabolic steroids, testosterone and oral contraceptives.1,2,6 Once pattern hair loss is diagnosed, treatment is generally pursued only if the person wishes to address cosmetic concerns or psychosocial impacts.1 Management aims to slow progression and stimulate regrowth where possible. Emotional and social support should be addressed in their care,1 alongside referral to the medical practitioner when diagnosis is uncertain or comorbidities need management.

      Non-pharmacological management

      Non-pharmacological approaches can improve appearance, protect scalp health and complement medical therapy.  Cosmetic camouflage1,2,7 These strategies aim to conceal thinning and improve appearance:
      • Creative hair styling (e.g. layering, parting adjustments)
      • Cosmetic camouflage products such as keratin fibres or coloured sprays.
      Scalp and hair health1,2,7 These measures focus on preventing further damage and protecting the scalp:
      • Gentle hair care practices (air-drying or cool hairdryer setting, minimising chemical treatments, loose hairstyles to prevent traction injury)
      • Sun protection with a broad-brimmed hat, scarf or sunscreen.
      Procedural interventions1,2,5 These attempt to restore hair density but vary in accessibility and evidence:
      • Hair transplantation can provide permanent restoration, particularly when combined with medical therapy, although cost and access are significant barriers
      • Platelet-rich plasma (PRP) injection uses autologous blood to stimulate growth but is unregulated in Australia; patients considering PRP should consult clinicians experienced in evidence-based alopecia medical management
      • Evidence for other interventions (e.g. laser devices, hair tonics, nutritional supplements) is limited.

      Pharmacological management

      For mild to moderate pattern hair loss, treatment options differ by sex. In males, topical minoxidil or oral finasteride may be used either alone or in combination.1 In females, topical minoxidil or oral spironolactone are commonly prescribed as monotherapy or in combination.1 In more severe cases, combination therapy is generally recommended.1 Before starting therapy, pharmacists should assess for contraindications, precautions and potential adverse effects. Counselling on realistic expectations is essential, as in most cases treatments are not curative but aim to slow progression and promote regrowth.1,2,8 Visible improvement is gradual; topical minoxidil may take 3–6 months while oral finasteride and spironolactone often require 6–12 months.1 Continuous therapy is necessary to maintain benefit, which is usually lost within 6–12 months of treatment cessation.8 Topical minoxidil is Pharmacy Only (Schedule 2) and is available as a foam or lotion.1 The foam is often preferred as it doesn’t contain propylene glycol that can irritate the scalp, is less likely to cause allergic contact dermatitis, and is less greasy than the lotion.1,2 Pre-existing scalp conditions such as eczema, seborrhoeic dermatitis or dandruff should be treated prior to initiating minoxidil, as they may be exacerbated by therapy.1 A temporary increase in hair loss may be seen during the first months of minoxidil therapy; this reactive shedding usually settles after a few weeks. Additionally, minoxidil should only be applied to affected areas, carefully avoiding skin around the forehead and temples to reduce the risk of hypertrichosis (excessive hair growth).1,8

      Knowledge to practice 

      Pharmacists can help people manage hair loss by understanding its various forms, acknowledging the social and cultural importance of hair, and recognising the anxiety it may cause.1 Prior to recommending treatment, pharmacists should screen for red flags and contraindications, making sure they refer patients to their doctor when appropriate.2 Many hair loss treatments require time and continuous application. Pharmacists play an important role in educating patients about realistic expectations and the likely timelines for treatment response, helping them make informed decisions.1 Pharmacists can also discuss non-pharmacological strategies such as healthy hair care practices, creative hair styling, cosmetic camouflage and sun protection, to support patients’ overall wellbeing.2

      Conclusion

      As frontline healthcare professionals, pharmacists play a vital role in supporting people with hair loss disorders. They can facilitate appropriate medical referrals, provide evidence-based information, and guide patients in the safe and effective use of available treatments and supportive strategies.

      Case scenario continued

      After reviewing Greg’s history, you confirm there are no contraindications to minoxidil therapy. You explain the correct use of an over-the-counter foam formulation: applying to a dry scalp, taking care around the forehead and temples, waiting at least 1 hour before using other products and avoiding washing for 4 hours after application. You discuss the treatment timeline, reassuring Greg that initial shedding may increase but usually settles, and that it can take 3–4 months of consistent use before improvement is noticeable. You also emphasise the importance of follow-up with his doctor in 6 months and suggest simple supportive measures, such as protecting the scalp from sun exposure. Throughout the conversation, you address Greg’s concerns, reinforce realistic expectations, and encourage adherence to achieve the best outcome.1,2,8
      [cpd_submit_answer_button]

      Key points

      • Hair follicles cycle through three main stages of hair growth: anagen, catagen and telogen.1
      • Encourage people experiencing hair loss to see their medical practitioner for diagnosis to exclude scarring alopecias, correct underlying nutritional or metabolic deficiencies, and manage concurrent conditions.1,2
      • Hair loss can have significant psychosocial consequences; appropriate social and emotional support is important.1
      • Counsel patients on the potential benefits, risks and regimens of available therapies to support informed decision-making and realistic expectations.1

      References

        1. Dermatology Expert Group. Dermatology. Melbourne: Therapeutic Guidelines; 2022 (Amended July 2024). 
        2. Lyengar L, Li J. Male and female pattern hair loss. Aust Prescr 2025;48:93–7.
        3. Gupta AK, Faour S, Wang T, et al. Pattern hair loss and health care professionals: How well are we connecting with our audience? J Cosmet Dermatol 2024 Sep;23(9):2779-2784. Epub 2024 Apr 26.
        4. Dr Harriet Bell. Diffuse Alopecia. 2019. At: https://dermnetnz.org/topics/diffuse-alopecia
        5. Hon A/Prof Amanda Oakley, Dermatologist, 1997; Updated: Dr Harriet Bell, Medical Registrar, New Zealand, May 2022. Minor update by Ian Coulson, Dermatologist. Alopecia areata. 2024. At: https://dermnetnz.org/topics/alopecia-areata
        6. Dr Delwyn Dyall-Smith FACD, Dermatologist, 2009. Alopecia from drugs. At: https://dermnetnz.org/topics/alopecia-from-drugs#
        7. Honorary Associate Professor Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1998. Further updates: December 2015 and May 2023. Hair loss. At: https://dermnetnz.org/topics/hair-loss
        8. Australian Medicines Handbook. January 2025. At: https://amhonline.amh.net.au

      Our author

      Frieda Kaleel (she/her) BPharm, GradDipHospPharm, CredPharm, MPS is a credentialled pharmacist with over 20 years of experience in a range of pharmacy settings, including community, hospital, medicines reviews and university.

      Our reviewer

      Hana Numan (she/her) BPharm (NZ), PGDipClinPharm (NZ), MPS (NZ)  [post_title] => Managing pattern hair loss in pharmacy [post_excerpt] => Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => managing-pattern-hair-loss-in-pharmacy-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-11 10:41:25 [post_modified_gmt] => 2026-02-10 23:41:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31266 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Managing pattern hair loss in pharmacy [title] => Managing pattern hair loss in pharmacy [href] => https://www.australianpharmacist.com.au/managing-pattern-hair-loss-in-pharmacy-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31268 [authorType] => )

      Managing pattern hair loss in pharmacy

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31273
                  [post_author] => 11884
                  [post_date] => 2026-02-04 12:59:14
                  [post_date_gmt] => 2026-02-04 01:59:14
                  [post_content] => 

      Case scenario

      Alicia, 27, visits your pharmacy regularly for naproxen and heat patches to manage period pain. She confides that her pain has worsened over the past 2 years, radiates down her legs, interferes with work and affects intimacy.  Her periods are heavy, lasting around 9 days, and leave her feeling exhausted and sometimes even bedridden. Alicia has seen several GPs, who told her it was ‘normal for your age’. She says, ‘It feels like someone’s wringing out my insides – nothing helps much. Is this really normal?’

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the epidemiology, aetiology and pathophysiology of endometriosis
      • Identify key clinical features, risk factors and diagnostic considerations
      • Discuss pharmacological and non-pharmacological management options for endometriosis
      • Explain the pharmacist’s role in supporting patients with endometriosis through education, referral and holistic care.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5 Accreditation number: CAP2602DMED  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Endometriosis is a chronic inflammatory condition characterised by the growth of endometrial-like tissue outside the uterus, commonly affecting the ovaries, fallopian tubes and pelvic peritoneum.1,2 It affects 10–15% of all reproductive-aged Australians who were assigned female at birth, and 70% of females with chronic pelvic pain.3 Yet it remains underdiagnosed, underfunded and often misunderstood. Symptoms such as pelvic pain, heavy periods, fatigue and infertility can significantly affect quality of life. Pharmacists, often the first point of contact for pain management and self-care advice, play an important role in recognising potential endometriosis, supporting early referral and helping patients navigate ongoing treatment.

      Epidemiology

      An estimated 1 in 7 females in Australia are currently living with endometriosis.4-6 Onset often begins in adolescence, yet diagnosis is delayed on average by 7–10 years,1,3,7 influenced by menstrual pain normalisation, stigma, and misdiagnosis as irritable bowel syndrome (IBS) or anxiety.1,3,4,7,8 The consequences of these delays extend beyond physical health, affecting fertility, education, relationships and employment, and increasing the likelihood of depression, anxiety and social withdrawal.6,9,10

      Aetiology and pathophysiology

      The pathogenesis of endometriosis is multifactorial. The leading theory is retrograde menstruation, where menstrual blood flows backwards through the fallopian tubes into the pelvic cavity, allowing endometrial cells to implant and grow outside the uterus.2,11 Other contributing mechanisms include2,5,11,12:
      • immune dysfunction
      • coelomic metaplasia (peritoneal cell transformation)
      • genetic predisposition
      • hormonal imbalances 
      • environmental triggers.

      Clinical features  

      Endometriosis occurs when hormonally responsive lesions develop on the ovaries, bowel, bladder, peritoneum, or other pelvic and abdominal structures.1,5,9,13,14 These lesions respond to oestrogen and undergo cyclical changes similar to the endometrial lining, which can trigger inflammation, bleeding, scarring and adhesions. This may lead to chronic pain, organ dysfunction and infertility. Importantly, symptom severity does not always correlate with the number or extent of lesions and may fluctuate with hormonal changes.8,12 Risk factors While the exact cause of endometriosis is unclear, certain factors increase the likelihood of developing the condition1,9,13,14:
      • early menarche
      • short menstrual cycles (<27 days)
      • heavy/prolonged periods
      • nulliparity
      • family history of endometriosis
      • low BMI.
      Clinical presentation1,5,9,13,14 Pharmacists should consider endometriosis in individuals presenting with2,7,8,11,12:
      • moderate-severe dysmenorrhoea 
      • chronic pelvic pain (cyclical or constant)
      • persistent or recurrent pain associated with sexual intercourse (dyspareunia) 
      • menstrual bowel/bladder pain 
      • fatigue, lethargy, irritability
      • bloating
      • painful or altered bowel movements, particularly around the time of menstruation (dyschezia)
      • abnormally heavy or prolonged menstrual bleeding (menorrhagia) or irregular cycles 
      • infertility/conception delays.
      Classification No universally agreed classification exists, though the American Society of Reproductive Medicine (ASRM) system is commonly used15:
      • Stage I (minimal): few superficial implants.
      • Stage II (mild): more, deep implants.
      • Stage III (moderate): many deep implants; filmy adhesions may be present.
      • Stage IV (severe): many deep implants, many dense adhesions.
      Pain mechanisms and central sensitisation Central sensitisation refers to heightened nervous system responsiveness, causing persistent, widespread pain even after lesion removal.16 This can manifest as pelvic floor dysfunction, visceral hypersensitivity, and fatigue, and often overlaps with conditions such as irritable bowel syndrome or bladder pain syndrome.11 Supporting patients involves validating their pain experiences, even when imaging is normal or lesions appear minimal.

      Diagnosis and differential diagnosis 

      Diagnosis of endometriosis is often significantly delayed, with an average lag of 7–10 years from symptom onset.3,7,17 These delays are influenced by multiple systemic and social factors, including1,7,9,17:
      • normalisation of menstrual pain
      • dismissal of symptoms, particularly in adolescents and people of colour
      • lack of rural/remote access to gynaecology services 
      • under-recognition of symptoms in trans, non-binary and gender-diverse individuals
      • cost barriers to imaging, specialist care and private laparoscopies.
      Endometriosis shares symptoms with several other conditions, making diagnosis difficult. Differential diagnoses include IBS, pelvic inflammatory disease, adenomyosis, interstitial cystitis, depression and anxiety.12 Current diagnostic approaches While laparoscopy remains the gold standard, Australian guidelines now support symptom-based clinical diagnosis to reduce delays and improve care.3,7,17 Imaging tools such as transvaginal ultrasound can identify ovarian endometriotic cysts, but a normal ultrasound or MRI does not rule out disease – especially in early-stage or superficial cases. Patients should therefore be encouraged to pursue further care if symptoms significantly impact quality of life.3 Emerging diagnostic tools To address diagnostic challenges, ongoing research is focused on earlier, less invasive detection.4 Emerging approaches include blood-based biomarkers (e.g. proteomic panels, metabolomic profiling, microRNA and menstrual-fluid analysis),18-21 as well as advanced imaging techniques such as transvaginal ultrasound and MRI, which may help reduce reliance on laparoscopy and accelerate accurate diagnosis.3,7,17 When it’s not endometriosis: validating pelvic pain without a diagnosis Pelvic pain affects up to 1 in 4 people assigned female at birth and has many possible causes – endometriosis being only one of them.7,11,22,23 For some, extensive investigations such as imaging or laparoscopy reveal no abnormalities, which can leave patients feeling dismissed, confused or invalidated. Pharmacists can help by acknowledging that pain is real and deserving of care, even in the absence of a definitive diagnosis. Symptom management is the first-line approach for both endometriosis and chronic pelvic pain, and care should aim to improve daily function and quality of life regardless of diagnostic certainty.3 Where appropriate, pharmacists can also support referral to other healthcare providers for further assessment or multidisciplinary management. Although endometriosis itself is not curable, symptoms and recurrences can be effectively managed through person-centred care that considers physical, emotional and reproductive health needs.8

      Management approaches 

      Non-pharmacological treatment  Current treatment is focused on symptom control, rather than elimination of the disease. Non-pharmacological approaches form an essential part of care, particularly for patients who experience persistent pain or treatment adverse effects. Key strategies include8,13,24:
      • pelvic physiotherapy and psychotherapy (e.g. cognitive behavioural therapy [CBT], acceptance and commitment therapy [ACT])
      • heat therapy, TENS and mindfulness-based movement (e.g. yoga, Pilates)
      • anti-inflammatory or low-FODMAP diets, particularly for patients with co-existing irritable bowel syndrome.
      Mental health and emotional wellbeing Chronic pain is both physically and psychologically exhausting. Anxiety and depression rates are significantly higher in people with endometriosis than in the general population.7 Contributing factors include3,5,6,8,10,12,14,25:
      • diagnostic delays and invalidation of symptoms 
      • chronic fatigue and disrupted sleep
      • missed school or work
      • sexual dysfunction and relationship strain
      • fertility concerns or trauma from medical procedures.
      Pharmacists can play an important role in recognising distress and prompting early mental health support. Simple, empathetic questions – such as ‘How’s your sleep been lately?’ or ‘Is the pain affecting your mood?’ – can open conversations and guide appropriate referrals. Support strategies include:
      • recommending mental health care plans via GPs
      • referring to psychologists with chronic pain expertise or interdisciplinary pain teams
      • encouraging peer support groups (e.g. EndoActive, Endometriosis Australia, QENDO)
      • suggesting low-stigma mental health apps (e.g. MindSpot, Smiling Mind)
      • avoiding statements that minimise pain (e.g. ‘it’s just anxiety’) and instead validating the complex relationship between mood and pain.
      Complementary therapies  Patients may enquire about supplements or alternative therapies. Pharmacists should validate interest while clarifying the limited evidence and screening for interactions. Commonly explored options include magnesium, omega-3 fatty acids, turmeric (curcumin), vitex agnus-castus, zinc, vitamin B6, diindolylmethane (DIM) and acupuncture.22,24,26

      Pharmacological treatment 

      Analgesia
      • NSAIDs (e.g. naproxen 500 mg twice daily or ibuprofen 400 mg three times daily) are first line. 
      • Paracetamol may be added for multimodal relief.1,12,13
      Counselling should cover dosing, GI protection and review of OTC combinations (e.g. ibuprofen/paracetamol). Hormonal therapies Hormonal therapies suppress oestrogen-driven growth and reduce pain.11,12,13,27,28 Table 1 provides an overview of commonly used hormonal therapies in endometriosis management. Add-back therapy Treatment with gonadotrophin-releasing hormone (GnRH) analogues induces a temporary, reversible menopause to suppress oestrogen production and reduce endometriosis symptoms.30 However, this hypo-estrogenic state can cause side effects such as vasomotor symptoms, vaginal dryness and bone mineral density loss.30 Add-back therapy involves giving small ‘add-back’ doses of oestrogen, progestogen, or a combination of both, to counteract these effects while maintaining the efficacy of GnRH analogue treatment.13,28 Options include1,12,13,27: 
      • Continuous combined HRT – low-dose estrogen + progestogen. Use in patients with a uterus to protect the endometrium.
      • Sequential combined HRT – estrogen daily + cyclical progestogen. Less preferred, as cyclical hormones may worsen endometriosis symptoms.
      • Progestogen-only – continuous progestogen. Used when estrogen contraindicated.
      • Tibolone – synthetic steroid: estrogenic, progestogenic, and androgenic activity. Often used post-menopause; caution in estrogen-sensitive conditions.
      For add-back therapy, ensure to: 
      • use continuous regimens (not cyclical) to avoid stimulating endometriotic tissue
      • monitor BMD regularly if GnRH therapy continues >6 months
      • start add-back therapy generally at the same time as the GnRH analogue.
      Fertility considerations Up to half of people with endometriosis experience fertility issues, and pain suppression does not necessarily improve fertility.2,3,6,12 Pharmacists can:
      • counsel on hormonal therapy effects on ovulation 
      • encourage early specialist referral if conception delayed >12 months
      • support patients undergoing IVF or assisted reproductive treatment 
      • provide reassurance and empathy around fertility-related distress. 
      Table 1 – Overview of hormonal therapies for endometriosis References: Therapeutic Guidelines1, Buggio et al12, Rossi13 Hornstein26, Vercellini27 Note: Bone mineral density typically recovers within two years of cessation of GnRH therapies.27 Drospirenone currently off-label for endometriosis in Australia.1 The addition of Ryeqo (relugolix, estradiol, norethisterone) (July 2022) and Visanne (dienogest) (December 2024) to the PBS expands accessible hormonal therapy options for endometriosis.29

      The role of the pharmacist in endometriosis care

      Pharmacists play a vital role in improving care for people with endometriosis by addressing barriers through education, advocacy and person-centred support. Key strategies include1,5,8,12:
      • using inclusive language and avoiding assumptions about gender identity or reproductive goals
      • proactively exploring the impact of symptoms on daily life, including school, work and relationships
      • offering accessible symptom-tracking tools to support self-monitoring
      • referring patients to culturally safe services, including First Nations-specific clinics when appropriate
      • advocating for patients and providing education to dispel misconceptions about endometriosis.
      Given the impact of endometriosis on mental health, it is essential for pharmacists to use affirmative language that validates the patient’s experience.  For example, acknowledging that a patient’s pain is real fosters trust, signals active listening and supports collaborative care. Avoiding dismissive statements such as ‘pain is normal for women’ is crucial, as these can reinforce shame and self-doubt, and discourage timely help-seeking.10,14,31 Pharmacists are integral members of multidisciplinary teams managing endometriosis. They facilitate early identification and timely referrals to general practitioners, specialists, pelvic physiotherapists, psychologists and dietitians. The upcoming Endometriosis Management Plan (EMP), a digital clinical tool launching in 2026, is designed to enhance care coordination, streamline documentation, and align treatment goals across providers.4,32 Pharmacists can support EMP implementation through patient counselling, comprehensive medicines reviews and ongoing follow-up.  Pharmacists are also well-positioned to assist patients in navigating newly established specialist clinics funded under the 2025–26 federal health budget.4,32 Home Medicines Reviews (HMRs) can further optimise medicines management and should be actively recommended as part of a comprehensive care strategy. Pharmacists can support shared decision-making by explaining treatment mechanisms, expected onset of action and common adverse effects, helping patients make informed choices.

      Patient resources  

      Pharmacist follow-up and recommendations of patient support resources are beneficial for ongoing management. These include10,12,25,33:
      • inviting patients to check in monthly during early therapy
      • reassessing symptoms, tolerance and goals
      • encouraging use of symptom tracker apps to record symptoms, menstrual changes and evaluate therapy success (e.g. Phendo, Clue, EndoMeter)
      • referring to organisations for education/peer support
      • recommending organisations6,9,10,14,23,34,35:
        • Endometriosis Australia – advocacy/awareness
        • Jean Hailes for Women’s Health – tools/info
        • Pelvic Pain Foundation of Australia – clinician and patient info
        • QENDO – peer support, lived experience, free tracking app
        • EndoZone – clinical decision support, patient-friendly explanations
        • ESHRE patient leaflet – print-friendly patient information.

      Knowledge to practice 

      Pharmacists in primary care can support people with endometriosis by providing early recognition of symptom impact, guidance on medicines and symptom management, and facilitating timely referrals to appropriate healthcare providers.  Pharmacists play a key role in validating patient experiences, promoting self-monitoring through symptom-tracking tools, explaining treatment options and adverse effects, and encouraging engagement with multidisciplinary care.  Pharmacists should also advocate for patients and provide education to dispel misconceptions, helping reduce delays in diagnosis and improving overall quality of care.

      Conclusion

      Endometriosis is far more than painful periods – it’s a complex, chronic condition requiring interdisciplinary, person-centred care. Pharmacists can make a profound difference by recognising early signs, validating lived experience, supporting evidence-based management and facilitating timely referral. Even a single empathetic conversation can empower a patient to seek help and change the trajectory of their care.

      Case scenario continued

      You reassure Alicia that severe period pain is not something she has to accept and suggest tracking her symptoms with a menstrual diary and consulting a women’s health GP. You also provide advice on safe NSAID use and non-pharmacological strategies. Alicia returns 2 months later, now diagnosed with endometriosis and receiving hormonal therapy and pelvic physiotherapy. She continues to experience chronic pelvic pain and questions her medicines, so you organise a Home Medicines Review, identifying potential naproxen overuse and interactions with her sertraline, prompting treatment adjustments. You also recommend a local endometriosis support group, which Alicia joins, and she has since referred two friends with similar symptoms. Through ongoing support, she feels more empowered to manage her condition.
        [cpd_submit_answer_button]

      Key points

      • Lesion severity does not predict pain intensity.
      • Recognise red flags (e.g. cyclical pain, GI symptoms) and enact early referral.
      • Support interdisciplinary, patient-centred management.
      • Review safety, adherence and contraceptive actions of hormonal therapy.
      • Use inclusive, supportive language to reduce stigma and diagnostic delay.
      • Encourage treatment continuity and shared decision-making.

      References

      References 
      1. Therapeutic Guidelines Limited. Endometriosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2024. At: www.tg.org.au.
      2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–9. At: https://pubmed.ncbi.nlm.nih.gov/22819144/
      3. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep 2017;6(1):34–41. At: https://pubmed.ncbi.nlm.nih.gov/29276652/
      4. Australian Government Department of Health and Aged Care. National Action Plan for Endometriosis. Canberra: Department of Health; 2018. At: https://www.health.gov.au/resources/publications/national-action-plan-for-endometriosis?language=en
      5. RANZCOG. Endometriosis: a consensus guideline. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2021. At: https://ranzcog.edu.au
      6. Endometriosis Australia. About Endometriosis. 2023. At: www.endometriosisaustralia.org/about-endometriosis
      7. Armour M et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep 2020. At: https://pubmed.ncbi.nlm.nih.gov/33004965/
      8. Armour M, Sinclair J, Ng CHM, et al. A biopsychosocial approach to endometriosis management. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/2022_PPP_final-handouts.pdf
      9. European Society of Human Reproduction and Embryology. ESHRE. Guideline on endometriosis: patient leaflet. 2022. At: www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline
      10. Jean Hailes for Women’s Health. Endometriosis. 2024. At: www.jeanhailes.org.au/health-a-z/endometriosis
      11. Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol 2017;209:8–13. 
      12. Buggio L, Armour M, Evans S, et al. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract 2024;53(1–2):22–8. At: www1.racgp.org.au/ajgp/2024/january-february/endometriosis
      13. Rossi S, ed. Australian Medicines Handbook. 2025. Endometriosis. At: https://amhonline.amh.net.au
      14. EndoZone. Clinical and patient tools. 2025. At: www.endozone.com.au
      15. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32(2):315–24. At: https://academic.oup.com/humrep/article/32/2/315/2631390?login=false#116936554
      16. Alexander M, Dydyk EC, Michael F. Stretanski, et al. Central Pain Syndrome. StatPearls. 2025. At: www.ncbi.nlm.nih.gov/books/NBK553027/
      17. National Institute for Health and Care Excellence (NICE). Endometriosis: diagnosis and management. NICE guideline NG73. London: NICE; 2024. At: www.nice.org.uk/guidance/ng73/resources/endometriosis-diagnosis-and-management-pdf-1837632548293
      18. Endometriosis News. Current status of non-invasive biomarkers for endometriosis. 2024. At: www.endonews.com/current-status-of-non-invasive-biomarkers-for-endometriosis
      19. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database of Systematic Reviews 2016. Issue 4. 
      20. Proteomics International. PromarkerEndo delivers breakthrough results for endometriosis blood test. Perth: PIQ; 2024. At: ASX-PIQ-Collaboration-expanded-to-advance-Endometriosis-blood-test-251015.pdf
      21. Evans‑Hoeker E, Senapati S, Behera MA. Serum markers for endometriosis: a critical appraisal of current literature. Fertil Steri 2024;121(5):943–56.
      22. Evans S. Introduction to pelvic pain: an introduction to pelvic pain for girls, women, men and families. Pelvic Pain Foundation of Australia; 2024. At: www.pelvicpain.org.au/wp-content/uploads/2024/01/Introduction-to-Pelvic-Pain.pdf
      23. Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews 2017;2017(1):CD004753. At: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004753.pub4/full
      24. Villella S. The use of complementary medicines and therapies in women's health. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/Complementary-medicine-and-therapies
      25. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022(2):hoac009. https://doi.org/10.1093/hropen/hoac009
      26. Malik A, Sinclair J, Ng CHM, et al. Complementary medicine and chronic pelvic pain in Australian women: a national cross-sectional survey. BMJ Open 2021;11:e045768. At: https://pubmed.ncbi.nlm.nih.gov/35148773/
      27. Hornstein MD. Endometriosis: long-term treatment with gonadotropin-releasing hormone agonists. In: Barbieri RL, Eckler K, editors. UpToDate. Waltham (MA): UpToDate Inc.; 2023. At: www.uptodate.com
      28. Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 2016;106(7):1552–71. At: https://pubmed.ncbi.nlm.nih.gov/27817837/.
      29. Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme: New listings and changes – December 2024. Canberra: PBS; 2024. www.pbs.gov.au
      30. Veth VB, van der Karr MM, Duffy JM, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database of Systematic Reviews 2023;6(6).
      31. Australian Commission on Safety and Quality in Health Care. Person-centred care: a toolkit for implementation. Sydney: ACSQHC; 2020.
      32. Australian Government Department of Health and Aged Care. Budget 2025–26: Women’s Health Package. 2025. At: Budget 2025–⁠26: Strengthening Medicare – Women's health | Australian Government Department of Health, Disability and Ageing
      33. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018;19(10):1109–25. At: https://pubmed.ncbi.nlm.nih.gov/29975553/
      34. Endometriosis Australia. Patient stories (2023). At: https://endometriosisaustralia.org/category/endo-stories/
      35. QENDO. About Us. 2025. At: https://www.qendo.org.au/

      Our author

      Erin Downey (she/her) BPharm, GCertDiabEd, CDE, MPS CredPharm (MMR), ANZCAP-Reg (Endo, Generalist) is a clinical pharmacist, credentialled diabetes educator, endocrinology and generalist ANZCAP registrar, practising hospital pharmacist, and private CDE/credentialled MMR pharmacist in Southern Tasmania. 

      Our reviewer

      Elke Smith (she/her) BPharm, MHlthMgt [post_title] => Endometriosis: More than just a bad period [post_excerpt] => Endometriosis is a chronic inflammatory condition which affects 10–15% of all reproductive-aged Australians who were assigned female at birth. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => endometriosis-more-than-just-a-bad-period-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-06 10:09:22 [post_modified_gmt] => 2026-02-05 23:09:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31273 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Endometriosis: More than just a bad period [title] => Endometriosis: More than just a bad period [href] => https://www.australianpharmacist.com.au/endometriosis-more-than-just-a-bad-period-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31300 [authorType] => )

      Endometriosis: More than just a bad period

  • Clinical
    • ADHD medicines
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31334
                  [post_author] => 3410
                  [post_date] => 2026-02-11 14:25:30
                  [post_date_gmt] => 2026-02-11 03:25:30
                  [post_content] => Victoria recently announced ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. 
      
      But last week, the Allan Government also unveiled a nation-first initiative. From September, an online emergency prescribing pathway will allow people with an existing ADHD diagnosis to obtain urgent repeat medicine through the Victorian Virtual Emergency Department (VVED).
      
      AP explores what the new model involves, the safeguards that will be in place and what’s happening in other states and territories.
      

      What’s the purpose of the service?

      The telehealth service is designed to address growing concern about long specialist waitlists, escalating costs and the clinical risks associated with abrupt cessation of Schedule 8 ADHD medicines – which can lead to symptom rebound, functional impairment and significant distress. A Department of Health spokesperson told AP that the service would provide a targeted safety net, rather than a substitute for established care arrangements. ‘The Victorian Virtual Emergency Department will offer a safe way for Victorians with an existing ADHD diagnosis to refill an urgent prescription for ADHD medication,’ the spokesperson said. 

      How will urgent ADHD ‘repeats’ be issued?

      Clinicians working within the VVED will verify the patient’s current medicine and dosage before issuing a prescription, the spokesperson said. Scripts will be sent directly to the patient’s local pharmacy, with patients advised of the closest pharmacy in operation at the time of prescribing. The Department of Health emphasised that the pathway will not replace routine ADHD management. ‘This is for emergency situations only and will not replace the important ongoing treatment and relationship between a patient and their clinician,’ the spokesperson said.

      Who will be eligible?

      The Victorian model allows adults and children aged 6 and over with an existing ADHD diagnosis to access the service who cannot secure a timely appointment with their usual clinician. The service will be limited to people who are already prescribed ADHD medicines. The VVED will not initiate ADHD treatment, alter dosages or provide ongoing prescribing. 

      What are the safeguards?

      Existing regulatory requirements and clinical guidelines for ADHD medicines will remain fully in place under the VVED pathway.  ‘The clinicians at the VVED, including paediatricians and psychiatrists, are highly experienced and highly skilled,’ the spokesperson said. ‘They will prescribe the medication within their existing scope of practice and clinical operations.’ Mandatory use of SafeScript for Schedule 8 medicines will continue to operate as a core safeguard. This ensures prescribers and pharmacists can monitor dispensing histories and reduces the risk of patients obtaining excessive prescriptions from multiple clinicians. The Department has stressed that responsibility for ongoing ADHD management remains with the patient’s regular clinician, with the VVED acting solely as a one-off support mechanism that complements broader reforms aimed at expanding GP involvement in ADHD care. And rather than providing a script to the patient, the script will be sent directly to their local pharmacy. When issuing a script, the VVED advises the patient of the closest pharmacy in operation.

      Part of a broader national shift

      Victoria’s online emergency model sits within a wider national trend to rebalance ADHD care away from exclusive reliance on specialist services.  Since 1 December 2025, ‘specialist GPs' in Queensland have been able to initiate, modify and continue stimulant treatment for adults with ADHD under updated Queensland Health guidance. Today (11 February), ACT Health issued an announcement on ADHD prescribing, with GPs who have completed approved training now able to continue prescribing ADHD medicines for eligible patients without requiring repeated reviews from a psychiatrist, paediatrician or neurologist. And other jurisdictions have since followed suit, including New South Wales, Western Australia and South Australia – which are set to roll out similar reforms this year.  Across Australia, governments are seeking to reduce wait times, lower out-of-pocket costs and embed ADHD care more firmly within primary care, while maintaining strong oversight of Schedule 8 stimulants such as methylphenidate, dexamfetamine and lisdexamfetamine via authorised prescribing schemes and real-time prescription monitoring checks. Non-stimulant ADHD medicines remain Schedule 4 and continue to be prescribed under existing arrangements. For more information, complete the PSA online module: ADHD explained. [post_title] => What pharmacists need to know about emergency prescribing for ADHD [post_excerpt] => Victoria is the latest state to announce ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => what-pharmacists-need-to-know-about-emergency-adhd-prescribing [to_ping] => [pinged] => [post_modified] => 2026-02-11 15:45:52 [post_modified_gmt] => 2026-02-11 04:45:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31334 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => What pharmacists need to know about emergency prescribing for ADHD [title] => What pharmacists need to know about emergency prescribing for ADHD [href] => https://www.australianpharmacist.com.au/what-pharmacists-need-to-know-about-emergency-adhd-prescribing/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31336 [authorType] => )

      What pharmacists need to know about emergency prescribing for ADHD

      emergency contraception
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31316
                  [post_author] => 3410
                  [post_date] => 2026-02-09 12:57:25
                  [post_date_gmt] => 2026-02-09 01:57:25
                  [post_content] => The gap between evidence and everyday practice is impacting patient access to emergency contraception.
      
      Community pharmacies are often the first – and sometimes only – point of access for emergency contraception in Australia. 
      
      But a new qualitative study found there are still persistent gaps between what the guidelines say and what happens in practice.
      
      Ruth Nona, pharmacist and researcher at James Cook University, who interviewed community pharmacists about providing emergency contraception services, describes a workforce that is broadly willing to help, but not always set up to deliver consistently equitable care. 
      

      1. Not recommending ulipristal as first-line

      One of the most significant gaps identified in the study was the tendency for pharmacists to default to levonorgestrel, despite guidance in the Australian Pharmaceutical Formulary and Handbook (APF) that ulipristal acetate is generally considered more effective than levonorgestrel and can be used up to 120 hours after unprotected intercourse. ‘Habit definitely plays a role,’ Ms Nona said. ‘Some pharmacists felt more comfortable and confident supplying levonorgestrel. For example, if someone requested emergency contraception within 24 hours, pharmacists felt levonorgestrel was acceptable within that timeframe, without fully considering efficacy.’ [caption id="attachment_31329" align="alignright" width="250"] Ruth Nona[/caption] In some pharmacies, price differences influenced whether ulipristal acetate was presented as an option. ‘In certain socio-economic areas, cost was a driver,’ Ms Nona said. ‘Cost considerations were also sometimes linked to younger people coming in and asking whether there was a cheaper option.’ Sometimes, levonorgestrel was the only medicine on hand. ‘There was research that came out showing that some pharmacies still did not stock ulipristal acetate,’ she said. ‘It’s been an ongoing issue, and something that really needs to be addressed.’ However, patients need to be able to make an informed decision about which medicine to take. ‘As stated in the guidelines, it’s about making sure all patients are given the information they need to make an informed and equitable choice. If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information,’ Ms Nona said. ‘When pharmacists did give the full picture and explained the differences, more often than not the patient chose ulipristal acetate, even though it cost more.’
      ‘If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information.' Ruth nona

      2. Uncertainty when responding to third-party requests

      Pharmacists reported particular uncertainty when providing emergency contraception to third parties, with many wary about consent and unsure whether they could provide it to someone who wasn’t the patient. ‘In most cases, they would follow up and ask to contact the patient directly,’ Ms Nona said. ‘It wasn’t that they didn’t want to provide it – they just felt unsure and they wanted to make sure that the patient had consented.’ While in many cases, speaking to the intended person directly can help provide key information and counselling, in circumstances where this is not possible, it is usually possible to determine the medicine is safe and therapeutically appropriate, and supply in a manner consistent with APF guidance and legal obligations.

      3. Uncertainty providing emergency contraception to adolescents

      Similarly, pharmacists were ‘uncomfortable’ providing the service to adolescents. This uncertainty often centred on fear of making the wrong decision or facing professional consequences. ‘They still wanted to provide the service, but it was more that internal question of, “Should I do this? Am I going to get in trouble?”’ There are no jurisdictions where there’s a legal restriction from supplying emergency contraception to minors. The APF guidance helps pharmacists navigate Gillick competency and consent in adolescents, ensuring they demonstrate sufficient maturity and understanding to provide informed consent. Ms Nona emphasised that the issue was confidence, not capability. ‘It’s about being familiar with the guidelines, making sure we’re as up to date as possible and realising that it’s okay for us to provide these services, provided the adolescent is [assessed as Gillick competent] mentally mature and safe,’ she said.  The APF references Gillick competency provided the adolescent is [assessed as Gillick competent (demonstrating sufficient maturity and understanding to provide informed consent)]

      4. Uncertainty for transgender people on gender affirming hormone therapy

      While pharmacists were generally supportive towards transgender and gender-diverse patients, lack of familiarity with hormone therapy raised hesitation. ‘There are absolutely no interactions between emergency contraception and gender-affirming hormones’ Ms Nona said. ‘It really comes down to knowledge, which builds confidence, and being up to date to make sure the service we provide is timely and equitable.’ In some areas, pharmacists may frequently encounter transgender and gender- diverse patients requesting emergency contraception, while pharmacists in other areas do not. ‘That’s why it’s also about being prepared. You never know when that situation might arise,’ she added. Should pharmacists feel unsure during these consultations, pharmacists can and should engage with the APF. ‘Pharmacists did say that if that situation did occur with a transgender or gender- diverse person that they would be honest and say to them, “Do you mind if I consult my resources?”’ 

      Another reason the APF is a mandatory text for all community pharmacists

      Despite lack of guideline use, pharmacists acknowledged how essential guidelines such as the APF are, Ms Nona said.  ‘And when pharmacists did use them, they found the information provided was invaluable.’ ‘[But] a lot of the challenges stemmed from lack of time and, in some cases, a lack of up-to-date knowledge. We have so many things to do, and we need more time to do everything and to keep ourselves up to date.’ For Ms Nona, the solution lies in supporting pharmacists to use guidelines  confidently and consistently in real-world conditions. Some pharmacists report to PSA that they will often bring up the APF digital on the screen in the consultation room in emergency contraception discussions, particularly in situations which are new or unfamiliar.

      Delivering a critical intervention

      The key to emergency contraception provision is recognising the stakes. ‘The whole picture of providing emergency contraception is to make sure we are preventing pregnancies when people don't want to get pregnant – whatever the reason may be,’ Ms Nona said. ‘That’s why they come to see a pharmacist – to ensure the person has the best possible chance of preventing an unintended pregnancy.’ When pharmacists are supported to provide full information and informed choice, patients respond accordingly.
      The Australian Pharmaceutical Formulary and Handbook (APF) chapter on ‘Emergency Contraception’, provides essential guidance on: 
      • providing timely, confidential, non-judgemental access to emergency contraception, recognising that effectiveness is time-dependent
      • obtaining sufficient patient information to assess safety, effectiveness and the most appropriate emergency contraception option
      • recommending the most effective oral emergency contraception, based on clinical assessment and time since unprotected sexual intercourse
      • supporting informed choice, including discussion of efficacy, cost and suitability, without making assumptions about patient preferences
      • assessing the need for referral where safety, effectiveness or appropriateness cannot be assured
      • providing care to adolescents based on maturity and understanding, in accordance with legislation and professional obligations
      • providing inclusive care for transgender and gender-diverse people with pregnancy risk
      • providing counselling and written information, including how to take emergency contraception, what to expect, and advice on ongoing contraception.
      [post_title] => Where emergency contraception practice falls short [post_excerpt] => The gap between evidence and everyday practice is costing patients access to the most effective emergency contraception. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => where-emergency-contraception-practice-falls-short [to_ping] => [pinged] => [post_modified] => 2026-02-09 16:09:16 [post_modified_gmt] => 2026-02-09 05:09:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31316 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Where emergency contraception practice falls short [title] => Where emergency contraception practice falls short [href] => https://www.australianpharmacist.com.au/where-emergency-contraception-practice-falls-short/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31321 [authorType] => )

      Where emergency contraception practice falls short

      pharmacist prescribing
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31305
                  [post_author] => 1925
                  [post_date] => 2026-02-08 10:38:16
                  [post_date_gmt] => 2026-02-07 23:38:16
                  [post_content] => 

      Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)?

      The range of professional services delivered by community pharmacists has expanded rapidly in recent years, from vaccination to UTI prescribing and beyond. As these services increase in popularity, they are shifting from ancillary service to core business. This widening scope is forcing community pharmacies to review how they conduct their business and the way front-of-house staff interact with patients. No longer is dispensing prescriptions on a first come, first served basis sustainable. With adjustments to workflow, vaccinations and other booked services have been prioritised and run simultaneously, says Queensland-based prescribing pharmacist Kate Gunthorpe MPS.  ‘We are moving away from the mindset that dispensing always comes first. We need to triage effectively and manage expectations, so every patient feels seen and cared for,’ she says. And it isn’t just about sequential processes. Workflow changes also require a shift of communication approaches and pre-existing mindsets around professional service provision.  ‘The biggest pitfall I’ve discovered is apologising for charging or determining that the consultation wasn’t worth charging for,’ Ms Gunthorpe says. ‘That instantly undermines the service’s value. Every consultation, whether the outcome is a prescription, advice or reassurance, involves clinical reasoning, professional judgement and patient care.’ So, how should the profession move forward? The PSA’s foundation documents are clear that all services must remain patient-centric.  That means redesigning workflows on the floor, developing new communication strategies for staff and providing additional training for pharmacy assistants to ensure a consistent, professional patient experience. AP spoke with Ms Gunthorpe and pharmacy assistant Madison Low about adapting workflow to integrate services without disrupting dispensing. product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously. 

      Case 1 Kate Gunthorpe MPS

      Pharmacist prescriber, Implementation and Change Specialist, TerryWhite Chemmart, Samford, Queensland  [caption id="attachment_31312" align="alignright" width="185"]pharmacist prescribing Kate Gunthorpe MPS[/caption] Our team started by mapping our busiest times to understand where bottlenecks occurred. We then built clear workflows – for example, using a booking system for consultations where possible, and ensuring at least one pharmacist remained consult-focused during every day. We trained our assistants to triage appropriately and use consistent language, such as ‘the pharmacist will see you shortly for your consultation’, which helped the process feel deliberate rather than disruptive. Once the team understood that consultations were core services, not interruptions, the process flowed more smoothly. Patients often expect a prescription outcome from a consultation, so I changed the framework, ensuring the consultation became a clinical one, not a product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously.  When we changed our front-of-shop language, patients stopped viewing consultations as waiting in a queue. That one shift in language lifted the professionalism of the whole process; patients were more patient, staff felt more confident explaining the service, and we saw an improvement in how people valued the pharmacist’s time. One thing I would advise other pharmacists about charging appropriately for their time, even when the consultation doesn’t end with a script, is to start valuing their expertise. The consultation is the service, not the outcome. We’re expertly trained to assess, diagnose and provide evidence-based care. That deserves to be remunerated. Once pharmacists stop apologising and start consistently charging for their time and expertise, patients begin to respect that boundary too. I find it is better to be transparent and consistent with pricing. I explain what’s included in the consultation, so patients understand what they’re paying for. Most importantly, I believe in it myself. If you hesitate to charge, your team and patients will pick up on that. The work floor also needs redesigning to normalise consulting services as part of everyday care. It starts with the physical layout and staffing models. Pharmacies should expect consultations to happen and allocate dedicated private spaces, clear booking systems and enough pharmacist coverage, so that one can focus on clinical care, while others oversee dispensing and other services. Culturally, it’s all been about mindset: we stopped treating services as extra and started treating them as central to what we do. That meant redistributing roles, upskilling support staff with more autonomy to triage and manage appointments, and introducing appointment blocks.  The effect of all these new processes has resulted in major change. Our pharmacy assistants are our front line, and their language is setting the tone for the entire patient experience. We have invested time in scripting and role-playing, so that the assistants feel comfortable discussing new services. The staff have learned to understand what each service involves, how long it typically takes, and when to book or triage patients. Scripts no longer automatically take priority over walk-up service requests. They are both core services. Pharmacies are healthcare hubs where patients can expect to have a prescription filled but also be able to discuss their health concerns.  Patients also value honesty and clarity. If a medication is not appropriate, explaining why builds understanding and trust – especially when you provide alternative options or safety net advice.  Because pharmacy staff use consistent, confident language and understand the workflow, everything runs much more smoothly. It has also empowered the staff to take pride in being responsible for a part of the patient care process, not just the retail side.  When staff describe services as core health care, not as ‘extras’ or ‘add-ons’, patients have started to see the pharmacist as a clinician involved in their primary care. It’s a subtle but powerful mindset shift that’s transforming how the pharmacy is perceived.

      Case 2 Madison Low

      Retail manager, TerryWhite Chemmart, Arana Hills, Queensland [caption id="attachment_31313" align="alignright" width="277"]pharmacist prescribing Madison Low[/caption] Since we started offering services like UTI consultations and vaccinations, my role has expanded significantly. We no longer just provide products; we’re delivering a more complete healthcare solution. A person recently came to the counter, visibly frustrated because they had symptoms of a urinary tract infection but couldn’t get in to see their doctor. They were holding a box of Ural.  Rather than just selling them the product, I suggested they talk to the pharmacist, assuring them that in many cases the pharmacist can provide a full treatment without needing a doctor’s visit. I asked a few questions about their symptoms, then checked with the pharmacist to confirm a consultation was possible immediately. It was, and not long afterwards the patient went away happy. Asthma management is one of the most common chronic conditions we see. Many patients believe they understand how to manage the condition, especially because they can access inhalers over the counter. But often that’s not the case. One of my roles is to let patients know there may be better solutions. Our pharmacists can review their current treatment and provide an improved management plan. Since becoming more mindful of the language I use with patients, I’ve noticed a positive change in how they respond to me.  By communicating in a more empathetic and approachable way, I’ve found patients are more comfortable asking questions and discussing their concerns. This has made it easier to identify when a patient might benefit from a review with one of our pharmacists. This change in language has also strengthened trust between patients and the pharmacy team. Patients seem more engaged and confident in the care they receive, and I feel more confident in my role as a link between them and our pharmacists. The biggest challenge has been balancing our time – especially during busy periods like the flu season, when there are lots of vaccines to administer, prescriptions to dispense and consultations to organise. I’m proud of how our team works together to ensure our patients are looked after promptly and get the attention they need. [post_title] => How expanded scope is redefining pharmacy practice [post_excerpt] => Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)? [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => how-expanded-scope-is-redefining-pharmacy-practice [to_ping] => [pinged] => [post_modified] => 2026-02-09 14:54:19 [post_modified_gmt] => 2026-02-09 03:54:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31305 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => How expanded scope is redefining pharmacy practice [title] => How expanded scope is redefining pharmacy practice [href] => https://www.australianpharmacist.com.au/how-expanded-scope-is-redefining-pharmacy-practice/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31310 [authorType] => )

      How expanded scope is redefining pharmacy practice

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31266
                  [post_author] => 11883
                  [post_date] => 2026-02-04 13:01:11
                  [post_date_gmt] => 2026-02-04 02:01:11
                  [post_content] => 

      Case scenario

      Greg, a 28-year-old man, comes into your pharmacy asking for a ‘strong minoxidil hair product’. He explains that his doctor recently diagnosed him with male pattern hair loss and suggested he try an over-the-counter treatment, with a follow-up review in 6 months. Greg has noticed gradual thinning at the temples over the past year but reports no sudden hair loss, scalp irritation or other medical issues. He has no known allergies, takes no medicines and has no chronic conditions.

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the main phases of the hair growth cycle
      • Outline the main types of hair loss and describe their key features
      • Identify pharmacological treatments and non-pharmacological strategies for pattern hair loss in males and females
      • Counsel patients on expected outcomes, timelines and use of common hair loss treatments.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5  Accreditation number: CAP2602DMFK  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. Hair loss can therefore have a major impact on self-esteem and quality of life, with notable psychosocial consequences.1,2 In an era where many people increasingly turn to social media for health information,3 pharmacists are accessible, reliable health professionals who can guide patients towards safe, evidence-based options, clarify treatment outcomes and timelines, and identify when medical referral is required.

      Epidemiology and physiology

      Pattern hair loss, also called androgenetic alopecia, is the most common cause of hair loss in both men and women.2 Approximately 80% of Caucasian men and up to 60% of Caucasian women by the age of 70 years are affected by pattern hair loss.1 Scalp hair follicles cycle through three stages: anagen (active growth), catagen (transition), and telogen (resting/shedding).1 At any given time, most follicles (about 85–90%) are in the growth phase, producing roughly 1 centimetre of hair per month.1 Shedding up to 100 hairs daily is considered normal, usually seen while washing and brushing.1

      Understanding hair loss disorders

      Hair loss disorders typically result from disruptions in the normal hair growth cycle.1 They can be divided into three main categories: patterned, diffuse or localised (patchy) alopecia.1 Patterned alopecia Male or female pattern hair loss is a non-scarring form of alopecia. It manifests as progressive hair thinning in a characteristic pattern and is influenced by genetics and the sensitivity of hair follicles to androgens, primarily dihydrotestosterone. The replacement of terminal hairs with shorter, finer, miniaturised hairs is driven by androgen effects on scalp follicles.1,2 In men, pattern hair loss typically begins with bitemporal hairline recession and may progress to baldness at the vertex (crown).2 In women, it usually presents as diffuse thinning that gradually widens the part line on the crown and reduces ponytail volume.2 Both male and female pattern hair loss commonly comprise of a sparser frontal hairline where episodic bursts of excessive hair shedding are common.1,2 Diffuse alopecia Diffuse alopecia involves hair loss across the scalp without a defined pattern. It can occur during either the telogen or anagen phases of the hair cycle. The most common cause is telogen effluvium, a reactive condition in which a trigger causes anagen hairs to prematurely enter the telogen (resting) phase, resulting in excessive shedding.1,4 Both acute and chronic telogen effluvium typically do not lead to permanent baldness.1 Localised (patchy) alopecia Localised alopecia presents as discrete patches of hair loss. Common causes include alopecia areata and tinea capitis (more common in children), while less common causes include scarring alopecias (e.g. discoid lupus erythematosus or lichen planopilaris) and trichotillomania (compulsive hair-pulling).1 Alopecia areata is a complex polygenic autoimmune disorder and typically produces discrete (often circular) areas of hair loss anywhere on the body.1 The lifetime risk is approximately 2%,5 and spontaneous complete regrowth within 12 months occurs in up to 80% of individuals with a single patch, though relapses are common.1 Alopecia areata can have significant psychosocial impacts. The Australia Alopecia Areata Foundation (AAAF) offers resources and support for affected individuals and their families.1

      Diagnosis and treatment goals

      When a person presents with hair loss, it is important to first confirm the diagnosis and rule out reversible or more serious causes. Medical practitioners may consider contributing factors such as scarring alopecias, nutritional deficiencies, metabolic disorders or drug-induced alopecia. Some implicated medicines in drug-induced alopecia include, but are not limited to, chemotherapy, retinoids, antiepileptics, antidepressants, β-blockers, statins and hormonal agents such as anabolic steroids, testosterone and oral contraceptives.1,2,6 Once pattern hair loss is diagnosed, treatment is generally pursued only if the person wishes to address cosmetic concerns or psychosocial impacts.1 Management aims to slow progression and stimulate regrowth where possible. Emotional and social support should be addressed in their care,1 alongside referral to the medical practitioner when diagnosis is uncertain or comorbidities need management.

      Non-pharmacological management

      Non-pharmacological approaches can improve appearance, protect scalp health and complement medical therapy.  Cosmetic camouflage1,2,7 These strategies aim to conceal thinning and improve appearance:
      • Creative hair styling (e.g. layering, parting adjustments)
      • Cosmetic camouflage products such as keratin fibres or coloured sprays.
      Scalp and hair health1,2,7 These measures focus on preventing further damage and protecting the scalp:
      • Gentle hair care practices (air-drying or cool hairdryer setting, minimising chemical treatments, loose hairstyles to prevent traction injury)
      • Sun protection with a broad-brimmed hat, scarf or sunscreen.
      Procedural interventions1,2,5 These attempt to restore hair density but vary in accessibility and evidence:
      • Hair transplantation can provide permanent restoration, particularly when combined with medical therapy, although cost and access are significant barriers
      • Platelet-rich plasma (PRP) injection uses autologous blood to stimulate growth but is unregulated in Australia; patients considering PRP should consult clinicians experienced in evidence-based alopecia medical management
      • Evidence for other interventions (e.g. laser devices, hair tonics, nutritional supplements) is limited.

      Pharmacological management

      For mild to moderate pattern hair loss, treatment options differ by sex. In males, topical minoxidil or oral finasteride may be used either alone or in combination.1 In females, topical minoxidil or oral spironolactone are commonly prescribed as monotherapy or in combination.1 In more severe cases, combination therapy is generally recommended.1 Before starting therapy, pharmacists should assess for contraindications, precautions and potential adverse effects. Counselling on realistic expectations is essential, as in most cases treatments are not curative but aim to slow progression and promote regrowth.1,2,8 Visible improvement is gradual; topical minoxidil may take 3–6 months while oral finasteride and spironolactone often require 6–12 months.1 Continuous therapy is necessary to maintain benefit, which is usually lost within 6–12 months of treatment cessation.8 Topical minoxidil is Pharmacy Only (Schedule 2) and is available as a foam or lotion.1 The foam is often preferred as it doesn’t contain propylene glycol that can irritate the scalp, is less likely to cause allergic contact dermatitis, and is less greasy than the lotion.1,2 Pre-existing scalp conditions such as eczema, seborrhoeic dermatitis or dandruff should be treated prior to initiating minoxidil, as they may be exacerbated by therapy.1 A temporary increase in hair loss may be seen during the first months of minoxidil therapy; this reactive shedding usually settles after a few weeks. Additionally, minoxidil should only be applied to affected areas, carefully avoiding skin around the forehead and temples to reduce the risk of hypertrichosis (excessive hair growth).1,8

      Knowledge to practice 

      Pharmacists can help people manage hair loss by understanding its various forms, acknowledging the social and cultural importance of hair, and recognising the anxiety it may cause.1 Prior to recommending treatment, pharmacists should screen for red flags and contraindications, making sure they refer patients to their doctor when appropriate.2 Many hair loss treatments require time and continuous application. Pharmacists play an important role in educating patients about realistic expectations and the likely timelines for treatment response, helping them make informed decisions.1 Pharmacists can also discuss non-pharmacological strategies such as healthy hair care practices, creative hair styling, cosmetic camouflage and sun protection, to support patients’ overall wellbeing.2

      Conclusion

      As frontline healthcare professionals, pharmacists play a vital role in supporting people with hair loss disorders. They can facilitate appropriate medical referrals, provide evidence-based information, and guide patients in the safe and effective use of available treatments and supportive strategies.

      Case scenario continued

      After reviewing Greg’s history, you confirm there are no contraindications to minoxidil therapy. You explain the correct use of an over-the-counter foam formulation: applying to a dry scalp, taking care around the forehead and temples, waiting at least 1 hour before using other products and avoiding washing for 4 hours after application. You discuss the treatment timeline, reassuring Greg that initial shedding may increase but usually settles, and that it can take 3–4 months of consistent use before improvement is noticeable. You also emphasise the importance of follow-up with his doctor in 6 months and suggest simple supportive measures, such as protecting the scalp from sun exposure. Throughout the conversation, you address Greg’s concerns, reinforce realistic expectations, and encourage adherence to achieve the best outcome.1,2,8
      [cpd_submit_answer_button]

      Key points

      • Hair follicles cycle through three main stages of hair growth: anagen, catagen and telogen.1
      • Encourage people experiencing hair loss to see their medical practitioner for diagnosis to exclude scarring alopecias, correct underlying nutritional or metabolic deficiencies, and manage concurrent conditions.1,2
      • Hair loss can have significant psychosocial consequences; appropriate social and emotional support is important.1
      • Counsel patients on the potential benefits, risks and regimens of available therapies to support informed decision-making and realistic expectations.1

      References

        1. Dermatology Expert Group. Dermatology. Melbourne: Therapeutic Guidelines; 2022 (Amended July 2024). 
        2. Lyengar L, Li J. Male and female pattern hair loss. Aust Prescr 2025;48:93–7.
        3. Gupta AK, Faour S, Wang T, et al. Pattern hair loss and health care professionals: How well are we connecting with our audience? J Cosmet Dermatol 2024 Sep;23(9):2779-2784. Epub 2024 Apr 26.
        4. Dr Harriet Bell. Diffuse Alopecia. 2019. At: https://dermnetnz.org/topics/diffuse-alopecia
        5. Hon A/Prof Amanda Oakley, Dermatologist, 1997; Updated: Dr Harriet Bell, Medical Registrar, New Zealand, May 2022. Minor update by Ian Coulson, Dermatologist. Alopecia areata. 2024. At: https://dermnetnz.org/topics/alopecia-areata
        6. Dr Delwyn Dyall-Smith FACD, Dermatologist, 2009. Alopecia from drugs. At: https://dermnetnz.org/topics/alopecia-from-drugs#
        7. Honorary Associate Professor Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1998. Further updates: December 2015 and May 2023. Hair loss. At: https://dermnetnz.org/topics/hair-loss
        8. Australian Medicines Handbook. January 2025. At: https://amhonline.amh.net.au

      Our author

      Frieda Kaleel (she/her) BPharm, GradDipHospPharm, CredPharm, MPS is a credentialled pharmacist with over 20 years of experience in a range of pharmacy settings, including community, hospital, medicines reviews and university.

      Our reviewer

      Hana Numan (she/her) BPharm (NZ), PGDipClinPharm (NZ), MPS (NZ)  [post_title] => Managing pattern hair loss in pharmacy [post_excerpt] => Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => managing-pattern-hair-loss-in-pharmacy-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-11 10:41:25 [post_modified_gmt] => 2026-02-10 23:41:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31266 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Managing pattern hair loss in pharmacy [title] => Managing pattern hair loss in pharmacy [href] => https://www.australianpharmacist.com.au/managing-pattern-hair-loss-in-pharmacy-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31268 [authorType] => )

      Managing pattern hair loss in pharmacy

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31273
                  [post_author] => 11884
                  [post_date] => 2026-02-04 12:59:14
                  [post_date_gmt] => 2026-02-04 01:59:14
                  [post_content] => 

      Case scenario

      Alicia, 27, visits your pharmacy regularly for naproxen and heat patches to manage period pain. She confides that her pain has worsened over the past 2 years, radiates down her legs, interferes with work and affects intimacy.  Her periods are heavy, lasting around 9 days, and leave her feeling exhausted and sometimes even bedridden. Alicia has seen several GPs, who told her it was ‘normal for your age’. She says, ‘It feels like someone’s wringing out my insides – nothing helps much. Is this really normal?’

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the epidemiology, aetiology and pathophysiology of endometriosis
      • Identify key clinical features, risk factors and diagnostic considerations
      • Discuss pharmacological and non-pharmacological management options for endometriosis
      • Explain the pharmacist’s role in supporting patients with endometriosis through education, referral and holistic care.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5 Accreditation number: CAP2602DMED  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Endometriosis is a chronic inflammatory condition characterised by the growth of endometrial-like tissue outside the uterus, commonly affecting the ovaries, fallopian tubes and pelvic peritoneum.1,2 It affects 10–15% of all reproductive-aged Australians who were assigned female at birth, and 70% of females with chronic pelvic pain.3 Yet it remains underdiagnosed, underfunded and often misunderstood. Symptoms such as pelvic pain, heavy periods, fatigue and infertility can significantly affect quality of life. Pharmacists, often the first point of contact for pain management and self-care advice, play an important role in recognising potential endometriosis, supporting early referral and helping patients navigate ongoing treatment.

      Epidemiology

      An estimated 1 in 7 females in Australia are currently living with endometriosis.4-6 Onset often begins in adolescence, yet diagnosis is delayed on average by 7–10 years,1,3,7 influenced by menstrual pain normalisation, stigma, and misdiagnosis as irritable bowel syndrome (IBS) or anxiety.1,3,4,7,8 The consequences of these delays extend beyond physical health, affecting fertility, education, relationships and employment, and increasing the likelihood of depression, anxiety and social withdrawal.6,9,10

      Aetiology and pathophysiology

      The pathogenesis of endometriosis is multifactorial. The leading theory is retrograde menstruation, where menstrual blood flows backwards through the fallopian tubes into the pelvic cavity, allowing endometrial cells to implant and grow outside the uterus.2,11 Other contributing mechanisms include2,5,11,12:
      • immune dysfunction
      • coelomic metaplasia (peritoneal cell transformation)
      • genetic predisposition
      • hormonal imbalances 
      • environmental triggers.

      Clinical features  

      Endometriosis occurs when hormonally responsive lesions develop on the ovaries, bowel, bladder, peritoneum, or other pelvic and abdominal structures.1,5,9,13,14 These lesions respond to oestrogen and undergo cyclical changes similar to the endometrial lining, which can trigger inflammation, bleeding, scarring and adhesions. This may lead to chronic pain, organ dysfunction and infertility. Importantly, symptom severity does not always correlate with the number or extent of lesions and may fluctuate with hormonal changes.8,12 Risk factors While the exact cause of endometriosis is unclear, certain factors increase the likelihood of developing the condition1,9,13,14:
      • early menarche
      • short menstrual cycles (<27 days)
      • heavy/prolonged periods
      • nulliparity
      • family history of endometriosis
      • low BMI.
      Clinical presentation1,5,9,13,14 Pharmacists should consider endometriosis in individuals presenting with2,7,8,11,12:
      • moderate-severe dysmenorrhoea 
      • chronic pelvic pain (cyclical or constant)
      • persistent or recurrent pain associated with sexual intercourse (dyspareunia) 
      • menstrual bowel/bladder pain 
      • fatigue, lethargy, irritability
      • bloating
      • painful or altered bowel movements, particularly around the time of menstruation (dyschezia)
      • abnormally heavy or prolonged menstrual bleeding (menorrhagia) or irregular cycles 
      • infertility/conception delays.
      Classification No universally agreed classification exists, though the American Society of Reproductive Medicine (ASRM) system is commonly used15:
      • Stage I (minimal): few superficial implants.
      • Stage II (mild): more, deep implants.
      • Stage III (moderate): many deep implants; filmy adhesions may be present.
      • Stage IV (severe): many deep implants, many dense adhesions.
      Pain mechanisms and central sensitisation Central sensitisation refers to heightened nervous system responsiveness, causing persistent, widespread pain even after lesion removal.16 This can manifest as pelvic floor dysfunction, visceral hypersensitivity, and fatigue, and often overlaps with conditions such as irritable bowel syndrome or bladder pain syndrome.11 Supporting patients involves validating their pain experiences, even when imaging is normal or lesions appear minimal.

      Diagnosis and differential diagnosis 

      Diagnosis of endometriosis is often significantly delayed, with an average lag of 7–10 years from symptom onset.3,7,17 These delays are influenced by multiple systemic and social factors, including1,7,9,17:
      • normalisation of menstrual pain
      • dismissal of symptoms, particularly in adolescents and people of colour
      • lack of rural/remote access to gynaecology services 
      • under-recognition of symptoms in trans, non-binary and gender-diverse individuals
      • cost barriers to imaging, specialist care and private laparoscopies.
      Endometriosis shares symptoms with several other conditions, making diagnosis difficult. Differential diagnoses include IBS, pelvic inflammatory disease, adenomyosis, interstitial cystitis, depression and anxiety.12 Current diagnostic approaches While laparoscopy remains the gold standard, Australian guidelines now support symptom-based clinical diagnosis to reduce delays and improve care.3,7,17 Imaging tools such as transvaginal ultrasound can identify ovarian endometriotic cysts, but a normal ultrasound or MRI does not rule out disease – especially in early-stage or superficial cases. Patients should therefore be encouraged to pursue further care if symptoms significantly impact quality of life.3 Emerging diagnostic tools To address diagnostic challenges, ongoing research is focused on earlier, less invasive detection.4 Emerging approaches include blood-based biomarkers (e.g. proteomic panels, metabolomic profiling, microRNA and menstrual-fluid analysis),18-21 as well as advanced imaging techniques such as transvaginal ultrasound and MRI, which may help reduce reliance on laparoscopy and accelerate accurate diagnosis.3,7,17 When it’s not endometriosis: validating pelvic pain without a diagnosis Pelvic pain affects up to 1 in 4 people assigned female at birth and has many possible causes – endometriosis being only one of them.7,11,22,23 For some, extensive investigations such as imaging or laparoscopy reveal no abnormalities, which can leave patients feeling dismissed, confused or invalidated. Pharmacists can help by acknowledging that pain is real and deserving of care, even in the absence of a definitive diagnosis. Symptom management is the first-line approach for both endometriosis and chronic pelvic pain, and care should aim to improve daily function and quality of life regardless of diagnostic certainty.3 Where appropriate, pharmacists can also support referral to other healthcare providers for further assessment or multidisciplinary management. Although endometriosis itself is not curable, symptoms and recurrences can be effectively managed through person-centred care that considers physical, emotional and reproductive health needs.8

      Management approaches 

      Non-pharmacological treatment  Current treatment is focused on symptom control, rather than elimination of the disease. Non-pharmacological approaches form an essential part of care, particularly for patients who experience persistent pain or treatment adverse effects. Key strategies include8,13,24:
      • pelvic physiotherapy and psychotherapy (e.g. cognitive behavioural therapy [CBT], acceptance and commitment therapy [ACT])
      • heat therapy, TENS and mindfulness-based movement (e.g. yoga, Pilates)
      • anti-inflammatory or low-FODMAP diets, particularly for patients with co-existing irritable bowel syndrome.
      Mental health and emotional wellbeing Chronic pain is both physically and psychologically exhausting. Anxiety and depression rates are significantly higher in people with endometriosis than in the general population.7 Contributing factors include3,5,6,8,10,12,14,25:
      • diagnostic delays and invalidation of symptoms 
      • chronic fatigue and disrupted sleep
      • missed school or work
      • sexual dysfunction and relationship strain
      • fertility concerns or trauma from medical procedures.
      Pharmacists can play an important role in recognising distress and prompting early mental health support. Simple, empathetic questions – such as ‘How’s your sleep been lately?’ or ‘Is the pain affecting your mood?’ – can open conversations and guide appropriate referrals. Support strategies include:
      • recommending mental health care plans via GPs
      • referring to psychologists with chronic pain expertise or interdisciplinary pain teams
      • encouraging peer support groups (e.g. EndoActive, Endometriosis Australia, QENDO)
      • suggesting low-stigma mental health apps (e.g. MindSpot, Smiling Mind)
      • avoiding statements that minimise pain (e.g. ‘it’s just anxiety’) and instead validating the complex relationship between mood and pain.
      Complementary therapies  Patients may enquire about supplements or alternative therapies. Pharmacists should validate interest while clarifying the limited evidence and screening for interactions. Commonly explored options include magnesium, omega-3 fatty acids, turmeric (curcumin), vitex agnus-castus, zinc, vitamin B6, diindolylmethane (DIM) and acupuncture.22,24,26

      Pharmacological treatment 

      Analgesia
      • NSAIDs (e.g. naproxen 500 mg twice daily or ibuprofen 400 mg three times daily) are first line. 
      • Paracetamol may be added for multimodal relief.1,12,13
      Counselling should cover dosing, GI protection and review of OTC combinations (e.g. ibuprofen/paracetamol). Hormonal therapies Hormonal therapies suppress oestrogen-driven growth and reduce pain.11,12,13,27,28 Table 1 provides an overview of commonly used hormonal therapies in endometriosis management. Add-back therapy Treatment with gonadotrophin-releasing hormone (GnRH) analogues induces a temporary, reversible menopause to suppress oestrogen production and reduce endometriosis symptoms.30 However, this hypo-estrogenic state can cause side effects such as vasomotor symptoms, vaginal dryness and bone mineral density loss.30 Add-back therapy involves giving small ‘add-back’ doses of oestrogen, progestogen, or a combination of both, to counteract these effects while maintaining the efficacy of GnRH analogue treatment.13,28 Options include1,12,13,27: 
      • Continuous combined HRT – low-dose estrogen + progestogen. Use in patients with a uterus to protect the endometrium.
      • Sequential combined HRT – estrogen daily + cyclical progestogen. Less preferred, as cyclical hormones may worsen endometriosis symptoms.
      • Progestogen-only – continuous progestogen. Used when estrogen contraindicated.
      • Tibolone – synthetic steroid: estrogenic, progestogenic, and androgenic activity. Often used post-menopause; caution in estrogen-sensitive conditions.
      For add-back therapy, ensure to: 
      • use continuous regimens (not cyclical) to avoid stimulating endometriotic tissue
      • monitor BMD regularly if GnRH therapy continues >6 months
      • start add-back therapy generally at the same time as the GnRH analogue.
      Fertility considerations Up to half of people with endometriosis experience fertility issues, and pain suppression does not necessarily improve fertility.2,3,6,12 Pharmacists can:
      • counsel on hormonal therapy effects on ovulation 
      • encourage early specialist referral if conception delayed >12 months
      • support patients undergoing IVF or assisted reproductive treatment 
      • provide reassurance and empathy around fertility-related distress. 
      Table 1 – Overview of hormonal therapies for endometriosis References: Therapeutic Guidelines1, Buggio et al12, Rossi13 Hornstein26, Vercellini27 Note: Bone mineral density typically recovers within two years of cessation of GnRH therapies.27 Drospirenone currently off-label for endometriosis in Australia.1 The addition of Ryeqo (relugolix, estradiol, norethisterone) (July 2022) and Visanne (dienogest) (December 2024) to the PBS expands accessible hormonal therapy options for endometriosis.29

      The role of the pharmacist in endometriosis care

      Pharmacists play a vital role in improving care for people with endometriosis by addressing barriers through education, advocacy and person-centred support. Key strategies include1,5,8,12:
      • using inclusive language and avoiding assumptions about gender identity or reproductive goals
      • proactively exploring the impact of symptoms on daily life, including school, work and relationships
      • offering accessible symptom-tracking tools to support self-monitoring
      • referring patients to culturally safe services, including First Nations-specific clinics when appropriate
      • advocating for patients and providing education to dispel misconceptions about endometriosis.
      Given the impact of endometriosis on mental health, it is essential for pharmacists to use affirmative language that validates the patient’s experience.  For example, acknowledging that a patient’s pain is real fosters trust, signals active listening and supports collaborative care. Avoiding dismissive statements such as ‘pain is normal for women’ is crucial, as these can reinforce shame and self-doubt, and discourage timely help-seeking.10,14,31 Pharmacists are integral members of multidisciplinary teams managing endometriosis. They facilitate early identification and timely referrals to general practitioners, specialists, pelvic physiotherapists, psychologists and dietitians. The upcoming Endometriosis Management Plan (EMP), a digital clinical tool launching in 2026, is designed to enhance care coordination, streamline documentation, and align treatment goals across providers.4,32 Pharmacists can support EMP implementation through patient counselling, comprehensive medicines reviews and ongoing follow-up.  Pharmacists are also well-positioned to assist patients in navigating newly established specialist clinics funded under the 2025–26 federal health budget.4,32 Home Medicines Reviews (HMRs) can further optimise medicines management and should be actively recommended as part of a comprehensive care strategy. Pharmacists can support shared decision-making by explaining treatment mechanisms, expected onset of action and common adverse effects, helping patients make informed choices.

      Patient resources  

      Pharmacist follow-up and recommendations of patient support resources are beneficial for ongoing management. These include10,12,25,33:
      • inviting patients to check in monthly during early therapy
      • reassessing symptoms, tolerance and goals
      • encouraging use of symptom tracker apps to record symptoms, menstrual changes and evaluate therapy success (e.g. Phendo, Clue, EndoMeter)
      • referring to organisations for education/peer support
      • recommending organisations6,9,10,14,23,34,35:
        • Endometriosis Australia – advocacy/awareness
        • Jean Hailes for Women’s Health – tools/info
        • Pelvic Pain Foundation of Australia – clinician and patient info
        • QENDO – peer support, lived experience, free tracking app
        • EndoZone – clinical decision support, patient-friendly explanations
        • ESHRE patient leaflet – print-friendly patient information.

      Knowledge to practice 

      Pharmacists in primary care can support people with endometriosis by providing early recognition of symptom impact, guidance on medicines and symptom management, and facilitating timely referrals to appropriate healthcare providers.  Pharmacists play a key role in validating patient experiences, promoting self-monitoring through symptom-tracking tools, explaining treatment options and adverse effects, and encouraging engagement with multidisciplinary care.  Pharmacists should also advocate for patients and provide education to dispel misconceptions, helping reduce delays in diagnosis and improving overall quality of care.

      Conclusion

      Endometriosis is far more than painful periods – it’s a complex, chronic condition requiring interdisciplinary, person-centred care. Pharmacists can make a profound difference by recognising early signs, validating lived experience, supporting evidence-based management and facilitating timely referral. Even a single empathetic conversation can empower a patient to seek help and change the trajectory of their care.

      Case scenario continued

      You reassure Alicia that severe period pain is not something she has to accept and suggest tracking her symptoms with a menstrual diary and consulting a women’s health GP. You also provide advice on safe NSAID use and non-pharmacological strategies. Alicia returns 2 months later, now diagnosed with endometriosis and receiving hormonal therapy and pelvic physiotherapy. She continues to experience chronic pelvic pain and questions her medicines, so you organise a Home Medicines Review, identifying potential naproxen overuse and interactions with her sertraline, prompting treatment adjustments. You also recommend a local endometriosis support group, which Alicia joins, and she has since referred two friends with similar symptoms. Through ongoing support, she feels more empowered to manage her condition.
        [cpd_submit_answer_button]

      Key points

      • Lesion severity does not predict pain intensity.
      • Recognise red flags (e.g. cyclical pain, GI symptoms) and enact early referral.
      • Support interdisciplinary, patient-centred management.
      • Review safety, adherence and contraceptive actions of hormonal therapy.
      • Use inclusive, supportive language to reduce stigma and diagnostic delay.
      • Encourage treatment continuity and shared decision-making.

      References

      References 
      1. Therapeutic Guidelines Limited. Endometriosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2024. At: www.tg.org.au.
      2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–9. At: https://pubmed.ncbi.nlm.nih.gov/22819144/
      3. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep 2017;6(1):34–41. At: https://pubmed.ncbi.nlm.nih.gov/29276652/
      4. Australian Government Department of Health and Aged Care. National Action Plan for Endometriosis. Canberra: Department of Health; 2018. At: https://www.health.gov.au/resources/publications/national-action-plan-for-endometriosis?language=en
      5. RANZCOG. Endometriosis: a consensus guideline. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2021. At: https://ranzcog.edu.au
      6. Endometriosis Australia. About Endometriosis. 2023. At: www.endometriosisaustralia.org/about-endometriosis
      7. Armour M et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep 2020. At: https://pubmed.ncbi.nlm.nih.gov/33004965/
      8. Armour M, Sinclair J, Ng CHM, et al. A biopsychosocial approach to endometriosis management. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/2022_PPP_final-handouts.pdf
      9. European Society of Human Reproduction and Embryology. ESHRE. Guideline on endometriosis: patient leaflet. 2022. At: www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline
      10. Jean Hailes for Women’s Health. Endometriosis. 2024. At: www.jeanhailes.org.au/health-a-z/endometriosis
      11. Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol 2017;209:8–13. 
      12. Buggio L, Armour M, Evans S, et al. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract 2024;53(1–2):22–8. At: www1.racgp.org.au/ajgp/2024/january-february/endometriosis
      13. Rossi S, ed. Australian Medicines Handbook. 2025. Endometriosis. At: https://amhonline.amh.net.au
      14. EndoZone. Clinical and patient tools. 2025. At: www.endozone.com.au
      15. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32(2):315–24. At: https://academic.oup.com/humrep/article/32/2/315/2631390?login=false#116936554
      16. Alexander M, Dydyk EC, Michael F. Stretanski, et al. Central Pain Syndrome. StatPearls. 2025. At: www.ncbi.nlm.nih.gov/books/NBK553027/
      17. National Institute for Health and Care Excellence (NICE). Endometriosis: diagnosis and management. NICE guideline NG73. London: NICE; 2024. At: www.nice.org.uk/guidance/ng73/resources/endometriosis-diagnosis-and-management-pdf-1837632548293
      18. Endometriosis News. Current status of non-invasive biomarkers for endometriosis. 2024. At: www.endonews.com/current-status-of-non-invasive-biomarkers-for-endometriosis
      19. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database of Systematic Reviews 2016. Issue 4. 
      20. Proteomics International. PromarkerEndo delivers breakthrough results for endometriosis blood test. Perth: PIQ; 2024. At: ASX-PIQ-Collaboration-expanded-to-advance-Endometriosis-blood-test-251015.pdf
      21. Evans‑Hoeker E, Senapati S, Behera MA. Serum markers for endometriosis: a critical appraisal of current literature. Fertil Steri 2024;121(5):943–56.
      22. Evans S. Introduction to pelvic pain: an introduction to pelvic pain for girls, women, men and families. Pelvic Pain Foundation of Australia; 2024. At: www.pelvicpain.org.au/wp-content/uploads/2024/01/Introduction-to-Pelvic-Pain.pdf
      23. Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews 2017;2017(1):CD004753. At: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004753.pub4/full
      24. Villella S. The use of complementary medicines and therapies in women's health. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/Complementary-medicine-and-therapies
      25. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022(2):hoac009. https://doi.org/10.1093/hropen/hoac009
      26. Malik A, Sinclair J, Ng CHM, et al. Complementary medicine and chronic pelvic pain in Australian women: a national cross-sectional survey. BMJ Open 2021;11:e045768. At: https://pubmed.ncbi.nlm.nih.gov/35148773/
      27. Hornstein MD. Endometriosis: long-term treatment with gonadotropin-releasing hormone agonists. In: Barbieri RL, Eckler K, editors. UpToDate. Waltham (MA): UpToDate Inc.; 2023. At: www.uptodate.com
      28. Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 2016;106(7):1552–71. At: https://pubmed.ncbi.nlm.nih.gov/27817837/.
      29. Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme: New listings and changes – December 2024. Canberra: PBS; 2024. www.pbs.gov.au
      30. Veth VB, van der Karr MM, Duffy JM, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database of Systematic Reviews 2023;6(6).
      31. Australian Commission on Safety and Quality in Health Care. Person-centred care: a toolkit for implementation. Sydney: ACSQHC; 2020.
      32. Australian Government Department of Health and Aged Care. Budget 2025–26: Women’s Health Package. 2025. At: Budget 2025–⁠26: Strengthening Medicare – Women's health | Australian Government Department of Health, Disability and Ageing
      33. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018;19(10):1109–25. At: https://pubmed.ncbi.nlm.nih.gov/29975553/
      34. Endometriosis Australia. Patient stories (2023). At: https://endometriosisaustralia.org/category/endo-stories/
      35. QENDO. About Us. 2025. At: https://www.qendo.org.au/

      Our author

      Erin Downey (she/her) BPharm, GCertDiabEd, CDE, MPS CredPharm (MMR), ANZCAP-Reg (Endo, Generalist) is a clinical pharmacist, credentialled diabetes educator, endocrinology and generalist ANZCAP registrar, practising hospital pharmacist, and private CDE/credentialled MMR pharmacist in Southern Tasmania. 

      Our reviewer

      Elke Smith (she/her) BPharm, MHlthMgt [post_title] => Endometriosis: More than just a bad period [post_excerpt] => Endometriosis is a chronic inflammatory condition which affects 10–15% of all reproductive-aged Australians who were assigned female at birth. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => endometriosis-more-than-just-a-bad-period-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-06 10:09:22 [post_modified_gmt] => 2026-02-05 23:09:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31273 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Endometriosis: More than just a bad period [title] => Endometriosis: More than just a bad period [href] => https://www.australianpharmacist.com.au/endometriosis-more-than-just-a-bad-period-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31300 [authorType] => )

      Endometriosis: More than just a bad period

  • CPD
    • ADHD medicines
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31334
                  [post_author] => 3410
                  [post_date] => 2026-02-11 14:25:30
                  [post_date_gmt] => 2026-02-11 03:25:30
                  [post_content] => Victoria recently announced ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. 
      
      But last week, the Allan Government also unveiled a nation-first initiative. From September, an online emergency prescribing pathway will allow people with an existing ADHD diagnosis to obtain urgent repeat medicine through the Victorian Virtual Emergency Department (VVED).
      
      AP explores what the new model involves, the safeguards that will be in place and what’s happening in other states and territories.
      

      What’s the purpose of the service?

      The telehealth service is designed to address growing concern about long specialist waitlists, escalating costs and the clinical risks associated with abrupt cessation of Schedule 8 ADHD medicines – which can lead to symptom rebound, functional impairment and significant distress. A Department of Health spokesperson told AP that the service would provide a targeted safety net, rather than a substitute for established care arrangements. ‘The Victorian Virtual Emergency Department will offer a safe way for Victorians with an existing ADHD diagnosis to refill an urgent prescription for ADHD medication,’ the spokesperson said. 

      How will urgent ADHD ‘repeats’ be issued?

      Clinicians working within the VVED will verify the patient’s current medicine and dosage before issuing a prescription, the spokesperson said. Scripts will be sent directly to the patient’s local pharmacy, with patients advised of the closest pharmacy in operation at the time of prescribing. The Department of Health emphasised that the pathway will not replace routine ADHD management. ‘This is for emergency situations only and will not replace the important ongoing treatment and relationship between a patient and their clinician,’ the spokesperson said.

      Who will be eligible?

      The Victorian model allows adults and children aged 6 and over with an existing ADHD diagnosis to access the service who cannot secure a timely appointment with their usual clinician. The service will be limited to people who are already prescribed ADHD medicines. The VVED will not initiate ADHD treatment, alter dosages or provide ongoing prescribing. 

      What are the safeguards?

      Existing regulatory requirements and clinical guidelines for ADHD medicines will remain fully in place under the VVED pathway.  ‘The clinicians at the VVED, including paediatricians and psychiatrists, are highly experienced and highly skilled,’ the spokesperson said. ‘They will prescribe the medication within their existing scope of practice and clinical operations.’ Mandatory use of SafeScript for Schedule 8 medicines will continue to operate as a core safeguard. This ensures prescribers and pharmacists can monitor dispensing histories and reduces the risk of patients obtaining excessive prescriptions from multiple clinicians. The Department has stressed that responsibility for ongoing ADHD management remains with the patient’s regular clinician, with the VVED acting solely as a one-off support mechanism that complements broader reforms aimed at expanding GP involvement in ADHD care. And rather than providing a script to the patient, the script will be sent directly to their local pharmacy. When issuing a script, the VVED advises the patient of the closest pharmacy in operation.

      Part of a broader national shift

      Victoria’s online emergency model sits within a wider national trend to rebalance ADHD care away from exclusive reliance on specialist services.  Since 1 December 2025, ‘specialist GPs' in Queensland have been able to initiate, modify and continue stimulant treatment for adults with ADHD under updated Queensland Health guidance. Today (11 February), ACT Health issued an announcement on ADHD prescribing, with GPs who have completed approved training now able to continue prescribing ADHD medicines for eligible patients without requiring repeated reviews from a psychiatrist, paediatrician or neurologist. And other jurisdictions have since followed suit, including New South Wales, Western Australia and South Australia – which are set to roll out similar reforms this year.  Across Australia, governments are seeking to reduce wait times, lower out-of-pocket costs and embed ADHD care more firmly within primary care, while maintaining strong oversight of Schedule 8 stimulants such as methylphenidate, dexamfetamine and lisdexamfetamine via authorised prescribing schemes and real-time prescription monitoring checks. Non-stimulant ADHD medicines remain Schedule 4 and continue to be prescribed under existing arrangements. For more information, complete the PSA online module: ADHD explained. [post_title] => What pharmacists need to know about emergency prescribing for ADHD [post_excerpt] => Victoria is the latest state to announce ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => what-pharmacists-need-to-know-about-emergency-adhd-prescribing [to_ping] => [pinged] => [post_modified] => 2026-02-11 15:45:52 [post_modified_gmt] => 2026-02-11 04:45:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31334 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => What pharmacists need to know about emergency prescribing for ADHD [title] => What pharmacists need to know about emergency prescribing for ADHD [href] => https://www.australianpharmacist.com.au/what-pharmacists-need-to-know-about-emergency-adhd-prescribing/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31336 [authorType] => )

      What pharmacists need to know about emergency prescribing for ADHD

      emergency contraception
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31316
                  [post_author] => 3410
                  [post_date] => 2026-02-09 12:57:25
                  [post_date_gmt] => 2026-02-09 01:57:25
                  [post_content] => The gap between evidence and everyday practice is impacting patient access to emergency contraception.
      
      Community pharmacies are often the first – and sometimes only – point of access for emergency contraception in Australia. 
      
      But a new qualitative study found there are still persistent gaps between what the guidelines say and what happens in practice.
      
      Ruth Nona, pharmacist and researcher at James Cook University, who interviewed community pharmacists about providing emergency contraception services, describes a workforce that is broadly willing to help, but not always set up to deliver consistently equitable care. 
      

      1. Not recommending ulipristal as first-line

      One of the most significant gaps identified in the study was the tendency for pharmacists to default to levonorgestrel, despite guidance in the Australian Pharmaceutical Formulary and Handbook (APF) that ulipristal acetate is generally considered more effective than levonorgestrel and can be used up to 120 hours after unprotected intercourse. ‘Habit definitely plays a role,’ Ms Nona said. ‘Some pharmacists felt more comfortable and confident supplying levonorgestrel. For example, if someone requested emergency contraception within 24 hours, pharmacists felt levonorgestrel was acceptable within that timeframe, without fully considering efficacy.’ [caption id="attachment_31329" align="alignright" width="250"] Ruth Nona[/caption] In some pharmacies, price differences influenced whether ulipristal acetate was presented as an option. ‘In certain socio-economic areas, cost was a driver,’ Ms Nona said. ‘Cost considerations were also sometimes linked to younger people coming in and asking whether there was a cheaper option.’ Sometimes, levonorgestrel was the only medicine on hand. ‘There was research that came out showing that some pharmacies still did not stock ulipristal acetate,’ she said. ‘It’s been an ongoing issue, and something that really needs to be addressed.’ However, patients need to be able to make an informed decision about which medicine to take. ‘As stated in the guidelines, it’s about making sure all patients are given the information they need to make an informed and equitable choice. If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information,’ Ms Nona said. ‘When pharmacists did give the full picture and explained the differences, more often than not the patient chose ulipristal acetate, even though it cost more.’
      ‘If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information.' Ruth nona

      2. Uncertainty when responding to third-party requests

      Pharmacists reported particular uncertainty when providing emergency contraception to third parties, with many wary about consent and unsure whether they could provide it to someone who wasn’t the patient. ‘In most cases, they would follow up and ask to contact the patient directly,’ Ms Nona said. ‘It wasn’t that they didn’t want to provide it – they just felt unsure and they wanted to make sure that the patient had consented.’ While in many cases, speaking to the intended person directly can help provide key information and counselling, in circumstances where this is not possible, it is usually possible to determine the medicine is safe and therapeutically appropriate, and supply in a manner consistent with APF guidance and legal obligations.

      3. Uncertainty providing emergency contraception to adolescents

      Similarly, pharmacists were ‘uncomfortable’ providing the service to adolescents. This uncertainty often centred on fear of making the wrong decision or facing professional consequences. ‘They still wanted to provide the service, but it was more that internal question of, “Should I do this? Am I going to get in trouble?”’ There are no jurisdictions where there’s a legal restriction from supplying emergency contraception to minors. The APF guidance helps pharmacists navigate Gillick competency and consent in adolescents, ensuring they demonstrate sufficient maturity and understanding to provide informed consent. Ms Nona emphasised that the issue was confidence, not capability. ‘It’s about being familiar with the guidelines, making sure we’re as up to date as possible and realising that it’s okay for us to provide these services, provided the adolescent is [assessed as Gillick competent] mentally mature and safe,’ she said.  The APF references Gillick competency provided the adolescent is [assessed as Gillick competent (demonstrating sufficient maturity and understanding to provide informed consent)]

      4. Uncertainty for transgender people on gender affirming hormone therapy

      While pharmacists were generally supportive towards transgender and gender-diverse patients, lack of familiarity with hormone therapy raised hesitation. ‘There are absolutely no interactions between emergency contraception and gender-affirming hormones’ Ms Nona said. ‘It really comes down to knowledge, which builds confidence, and being up to date to make sure the service we provide is timely and equitable.’ In some areas, pharmacists may frequently encounter transgender and gender- diverse patients requesting emergency contraception, while pharmacists in other areas do not. ‘That’s why it’s also about being prepared. You never know when that situation might arise,’ she added. Should pharmacists feel unsure during these consultations, pharmacists can and should engage with the APF. ‘Pharmacists did say that if that situation did occur with a transgender or gender- diverse person that they would be honest and say to them, “Do you mind if I consult my resources?”’ 

      Another reason the APF is a mandatory text for all community pharmacists

      Despite lack of guideline use, pharmacists acknowledged how essential guidelines such as the APF are, Ms Nona said.  ‘And when pharmacists did use them, they found the information provided was invaluable.’ ‘[But] a lot of the challenges stemmed from lack of time and, in some cases, a lack of up-to-date knowledge. We have so many things to do, and we need more time to do everything and to keep ourselves up to date.’ For Ms Nona, the solution lies in supporting pharmacists to use guidelines  confidently and consistently in real-world conditions. Some pharmacists report to PSA that they will often bring up the APF digital on the screen in the consultation room in emergency contraception discussions, particularly in situations which are new or unfamiliar.

      Delivering a critical intervention

      The key to emergency contraception provision is recognising the stakes. ‘The whole picture of providing emergency contraception is to make sure we are preventing pregnancies when people don't want to get pregnant – whatever the reason may be,’ Ms Nona said. ‘That’s why they come to see a pharmacist – to ensure the person has the best possible chance of preventing an unintended pregnancy.’ When pharmacists are supported to provide full information and informed choice, patients respond accordingly.
      The Australian Pharmaceutical Formulary and Handbook (APF) chapter on ‘Emergency Contraception’, provides essential guidance on: 
      • providing timely, confidential, non-judgemental access to emergency contraception, recognising that effectiveness is time-dependent
      • obtaining sufficient patient information to assess safety, effectiveness and the most appropriate emergency contraception option
      • recommending the most effective oral emergency contraception, based on clinical assessment and time since unprotected sexual intercourse
      • supporting informed choice, including discussion of efficacy, cost and suitability, without making assumptions about patient preferences
      • assessing the need for referral where safety, effectiveness or appropriateness cannot be assured
      • providing care to adolescents based on maturity and understanding, in accordance with legislation and professional obligations
      • providing inclusive care for transgender and gender-diverse people with pregnancy risk
      • providing counselling and written information, including how to take emergency contraception, what to expect, and advice on ongoing contraception.
      [post_title] => Where emergency contraception practice falls short [post_excerpt] => The gap between evidence and everyday practice is costing patients access to the most effective emergency contraception. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => where-emergency-contraception-practice-falls-short [to_ping] => [pinged] => [post_modified] => 2026-02-09 16:09:16 [post_modified_gmt] => 2026-02-09 05:09:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31316 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Where emergency contraception practice falls short [title] => Where emergency contraception practice falls short [href] => https://www.australianpharmacist.com.au/where-emergency-contraception-practice-falls-short/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31321 [authorType] => )

      Where emergency contraception practice falls short

      pharmacist prescribing
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31305
                  [post_author] => 1925
                  [post_date] => 2026-02-08 10:38:16
                  [post_date_gmt] => 2026-02-07 23:38:16
                  [post_content] => 

      Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)?

      The range of professional services delivered by community pharmacists has expanded rapidly in recent years, from vaccination to UTI prescribing and beyond. As these services increase in popularity, they are shifting from ancillary service to core business. This widening scope is forcing community pharmacies to review how they conduct their business and the way front-of-house staff interact with patients. No longer is dispensing prescriptions on a first come, first served basis sustainable. With adjustments to workflow, vaccinations and other booked services have been prioritised and run simultaneously, says Queensland-based prescribing pharmacist Kate Gunthorpe MPS.  ‘We are moving away from the mindset that dispensing always comes first. We need to triage effectively and manage expectations, so every patient feels seen and cared for,’ she says. And it isn’t just about sequential processes. Workflow changes also require a shift of communication approaches and pre-existing mindsets around professional service provision.  ‘The biggest pitfall I’ve discovered is apologising for charging or determining that the consultation wasn’t worth charging for,’ Ms Gunthorpe says. ‘That instantly undermines the service’s value. Every consultation, whether the outcome is a prescription, advice or reassurance, involves clinical reasoning, professional judgement and patient care.’ So, how should the profession move forward? The PSA’s foundation documents are clear that all services must remain patient-centric.  That means redesigning workflows on the floor, developing new communication strategies for staff and providing additional training for pharmacy assistants to ensure a consistent, professional patient experience. AP spoke with Ms Gunthorpe and pharmacy assistant Madison Low about adapting workflow to integrate services without disrupting dispensing. product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously. 

      Case 1 Kate Gunthorpe MPS

      Pharmacist prescriber, Implementation and Change Specialist, TerryWhite Chemmart, Samford, Queensland  [caption id="attachment_31312" align="alignright" width="185"]pharmacist prescribing Kate Gunthorpe MPS[/caption] Our team started by mapping our busiest times to understand where bottlenecks occurred. We then built clear workflows – for example, using a booking system for consultations where possible, and ensuring at least one pharmacist remained consult-focused during every day. We trained our assistants to triage appropriately and use consistent language, such as ‘the pharmacist will see you shortly for your consultation’, which helped the process feel deliberate rather than disruptive. Once the team understood that consultations were core services, not interruptions, the process flowed more smoothly. Patients often expect a prescription outcome from a consultation, so I changed the framework, ensuring the consultation became a clinical one, not a product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously.  When we changed our front-of-shop language, patients stopped viewing consultations as waiting in a queue. That one shift in language lifted the professionalism of the whole process; patients were more patient, staff felt more confident explaining the service, and we saw an improvement in how people valued the pharmacist’s time. One thing I would advise other pharmacists about charging appropriately for their time, even when the consultation doesn’t end with a script, is to start valuing their expertise. The consultation is the service, not the outcome. We’re expertly trained to assess, diagnose and provide evidence-based care. That deserves to be remunerated. Once pharmacists stop apologising and start consistently charging for their time and expertise, patients begin to respect that boundary too. I find it is better to be transparent and consistent with pricing. I explain what’s included in the consultation, so patients understand what they’re paying for. Most importantly, I believe in it myself. If you hesitate to charge, your team and patients will pick up on that. The work floor also needs redesigning to normalise consulting services as part of everyday care. It starts with the physical layout and staffing models. Pharmacies should expect consultations to happen and allocate dedicated private spaces, clear booking systems and enough pharmacist coverage, so that one can focus on clinical care, while others oversee dispensing and other services. Culturally, it’s all been about mindset: we stopped treating services as extra and started treating them as central to what we do. That meant redistributing roles, upskilling support staff with more autonomy to triage and manage appointments, and introducing appointment blocks.  The effect of all these new processes has resulted in major change. Our pharmacy assistants are our front line, and their language is setting the tone for the entire patient experience. We have invested time in scripting and role-playing, so that the assistants feel comfortable discussing new services. The staff have learned to understand what each service involves, how long it typically takes, and when to book or triage patients. Scripts no longer automatically take priority over walk-up service requests. They are both core services. Pharmacies are healthcare hubs where patients can expect to have a prescription filled but also be able to discuss their health concerns.  Patients also value honesty and clarity. If a medication is not appropriate, explaining why builds understanding and trust – especially when you provide alternative options or safety net advice.  Because pharmacy staff use consistent, confident language and understand the workflow, everything runs much more smoothly. It has also empowered the staff to take pride in being responsible for a part of the patient care process, not just the retail side.  When staff describe services as core health care, not as ‘extras’ or ‘add-ons’, patients have started to see the pharmacist as a clinician involved in their primary care. It’s a subtle but powerful mindset shift that’s transforming how the pharmacy is perceived.

      Case 2 Madison Low

      Retail manager, TerryWhite Chemmart, Arana Hills, Queensland [caption id="attachment_31313" align="alignright" width="277"]pharmacist prescribing Madison Low[/caption] Since we started offering services like UTI consultations and vaccinations, my role has expanded significantly. We no longer just provide products; we’re delivering a more complete healthcare solution. A person recently came to the counter, visibly frustrated because they had symptoms of a urinary tract infection but couldn’t get in to see their doctor. They were holding a box of Ural.  Rather than just selling them the product, I suggested they talk to the pharmacist, assuring them that in many cases the pharmacist can provide a full treatment without needing a doctor’s visit. I asked a few questions about their symptoms, then checked with the pharmacist to confirm a consultation was possible immediately. It was, and not long afterwards the patient went away happy. Asthma management is one of the most common chronic conditions we see. Many patients believe they understand how to manage the condition, especially because they can access inhalers over the counter. But often that’s not the case. One of my roles is to let patients know there may be better solutions. Our pharmacists can review their current treatment and provide an improved management plan. Since becoming more mindful of the language I use with patients, I’ve noticed a positive change in how they respond to me.  By communicating in a more empathetic and approachable way, I’ve found patients are more comfortable asking questions and discussing their concerns. This has made it easier to identify when a patient might benefit from a review with one of our pharmacists. This change in language has also strengthened trust between patients and the pharmacy team. Patients seem more engaged and confident in the care they receive, and I feel more confident in my role as a link between them and our pharmacists. The biggest challenge has been balancing our time – especially during busy periods like the flu season, when there are lots of vaccines to administer, prescriptions to dispense and consultations to organise. I’m proud of how our team works together to ensure our patients are looked after promptly and get the attention they need. [post_title] => How expanded scope is redefining pharmacy practice [post_excerpt] => Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)? [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => how-expanded-scope-is-redefining-pharmacy-practice [to_ping] => [pinged] => [post_modified] => 2026-02-09 14:54:19 [post_modified_gmt] => 2026-02-09 03:54:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31305 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => How expanded scope is redefining pharmacy practice [title] => How expanded scope is redefining pharmacy practice [href] => https://www.australianpharmacist.com.au/how-expanded-scope-is-redefining-pharmacy-practice/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31310 [authorType] => )

      How expanded scope is redefining pharmacy practice

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31266
                  [post_author] => 11883
                  [post_date] => 2026-02-04 13:01:11
                  [post_date_gmt] => 2026-02-04 02:01:11
                  [post_content] => 

      Case scenario

      Greg, a 28-year-old man, comes into your pharmacy asking for a ‘strong minoxidil hair product’. He explains that his doctor recently diagnosed him with male pattern hair loss and suggested he try an over-the-counter treatment, with a follow-up review in 6 months. Greg has noticed gradual thinning at the temples over the past year but reports no sudden hair loss, scalp irritation or other medical issues. He has no known allergies, takes no medicines and has no chronic conditions.

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the main phases of the hair growth cycle
      • Outline the main types of hair loss and describe their key features
      • Identify pharmacological treatments and non-pharmacological strategies for pattern hair loss in males and females
      • Counsel patients on expected outcomes, timelines and use of common hair loss treatments.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5  Accreditation number: CAP2602DMFK  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. Hair loss can therefore have a major impact on self-esteem and quality of life, with notable psychosocial consequences.1,2 In an era where many people increasingly turn to social media for health information,3 pharmacists are accessible, reliable health professionals who can guide patients towards safe, evidence-based options, clarify treatment outcomes and timelines, and identify when medical referral is required.

      Epidemiology and physiology

      Pattern hair loss, also called androgenetic alopecia, is the most common cause of hair loss in both men and women.2 Approximately 80% of Caucasian men and up to 60% of Caucasian women by the age of 70 years are affected by pattern hair loss.1 Scalp hair follicles cycle through three stages: anagen (active growth), catagen (transition), and telogen (resting/shedding).1 At any given time, most follicles (about 85–90%) are in the growth phase, producing roughly 1 centimetre of hair per month.1 Shedding up to 100 hairs daily is considered normal, usually seen while washing and brushing.1

      Understanding hair loss disorders

      Hair loss disorders typically result from disruptions in the normal hair growth cycle.1 They can be divided into three main categories: patterned, diffuse or localised (patchy) alopecia.1 Patterned alopecia Male or female pattern hair loss is a non-scarring form of alopecia. It manifests as progressive hair thinning in a characteristic pattern and is influenced by genetics and the sensitivity of hair follicles to androgens, primarily dihydrotestosterone. The replacement of terminal hairs with shorter, finer, miniaturised hairs is driven by androgen effects on scalp follicles.1,2 In men, pattern hair loss typically begins with bitemporal hairline recession and may progress to baldness at the vertex (crown).2 In women, it usually presents as diffuse thinning that gradually widens the part line on the crown and reduces ponytail volume.2 Both male and female pattern hair loss commonly comprise of a sparser frontal hairline where episodic bursts of excessive hair shedding are common.1,2 Diffuse alopecia Diffuse alopecia involves hair loss across the scalp without a defined pattern. It can occur during either the telogen or anagen phases of the hair cycle. The most common cause is telogen effluvium, a reactive condition in which a trigger causes anagen hairs to prematurely enter the telogen (resting) phase, resulting in excessive shedding.1,4 Both acute and chronic telogen effluvium typically do not lead to permanent baldness.1 Localised (patchy) alopecia Localised alopecia presents as discrete patches of hair loss. Common causes include alopecia areata and tinea capitis (more common in children), while less common causes include scarring alopecias (e.g. discoid lupus erythematosus or lichen planopilaris) and trichotillomania (compulsive hair-pulling).1 Alopecia areata is a complex polygenic autoimmune disorder and typically produces discrete (often circular) areas of hair loss anywhere on the body.1 The lifetime risk is approximately 2%,5 and spontaneous complete regrowth within 12 months occurs in up to 80% of individuals with a single patch, though relapses are common.1 Alopecia areata can have significant psychosocial impacts. The Australia Alopecia Areata Foundation (AAAF) offers resources and support for affected individuals and their families.1

      Diagnosis and treatment goals

      When a person presents with hair loss, it is important to first confirm the diagnosis and rule out reversible or more serious causes. Medical practitioners may consider contributing factors such as scarring alopecias, nutritional deficiencies, metabolic disorders or drug-induced alopecia. Some implicated medicines in drug-induced alopecia include, but are not limited to, chemotherapy, retinoids, antiepileptics, antidepressants, β-blockers, statins and hormonal agents such as anabolic steroids, testosterone and oral contraceptives.1,2,6 Once pattern hair loss is diagnosed, treatment is generally pursued only if the person wishes to address cosmetic concerns or psychosocial impacts.1 Management aims to slow progression and stimulate regrowth where possible. Emotional and social support should be addressed in their care,1 alongside referral to the medical practitioner when diagnosis is uncertain or comorbidities need management.

      Non-pharmacological management

      Non-pharmacological approaches can improve appearance, protect scalp health and complement medical therapy.  Cosmetic camouflage1,2,7 These strategies aim to conceal thinning and improve appearance:
      • Creative hair styling (e.g. layering, parting adjustments)
      • Cosmetic camouflage products such as keratin fibres or coloured sprays.
      Scalp and hair health1,2,7 These measures focus on preventing further damage and protecting the scalp:
      • Gentle hair care practices (air-drying or cool hairdryer setting, minimising chemical treatments, loose hairstyles to prevent traction injury)
      • Sun protection with a broad-brimmed hat, scarf or sunscreen.
      Procedural interventions1,2,5 These attempt to restore hair density but vary in accessibility and evidence:
      • Hair transplantation can provide permanent restoration, particularly when combined with medical therapy, although cost and access are significant barriers
      • Platelet-rich plasma (PRP) injection uses autologous blood to stimulate growth but is unregulated in Australia; patients considering PRP should consult clinicians experienced in evidence-based alopecia medical management
      • Evidence for other interventions (e.g. laser devices, hair tonics, nutritional supplements) is limited.

      Pharmacological management

      For mild to moderate pattern hair loss, treatment options differ by sex. In males, topical minoxidil or oral finasteride may be used either alone or in combination.1 In females, topical minoxidil or oral spironolactone are commonly prescribed as monotherapy or in combination.1 In more severe cases, combination therapy is generally recommended.1 Before starting therapy, pharmacists should assess for contraindications, precautions and potential adverse effects. Counselling on realistic expectations is essential, as in most cases treatments are not curative but aim to slow progression and promote regrowth.1,2,8 Visible improvement is gradual; topical minoxidil may take 3–6 months while oral finasteride and spironolactone often require 6–12 months.1 Continuous therapy is necessary to maintain benefit, which is usually lost within 6–12 months of treatment cessation.8 Topical minoxidil is Pharmacy Only (Schedule 2) and is available as a foam or lotion.1 The foam is often preferred as it doesn’t contain propylene glycol that can irritate the scalp, is less likely to cause allergic contact dermatitis, and is less greasy than the lotion.1,2 Pre-existing scalp conditions such as eczema, seborrhoeic dermatitis or dandruff should be treated prior to initiating minoxidil, as they may be exacerbated by therapy.1 A temporary increase in hair loss may be seen during the first months of minoxidil therapy; this reactive shedding usually settles after a few weeks. Additionally, minoxidil should only be applied to affected areas, carefully avoiding skin around the forehead and temples to reduce the risk of hypertrichosis (excessive hair growth).1,8

      Knowledge to practice 

      Pharmacists can help people manage hair loss by understanding its various forms, acknowledging the social and cultural importance of hair, and recognising the anxiety it may cause.1 Prior to recommending treatment, pharmacists should screen for red flags and contraindications, making sure they refer patients to their doctor when appropriate.2 Many hair loss treatments require time and continuous application. Pharmacists play an important role in educating patients about realistic expectations and the likely timelines for treatment response, helping them make informed decisions.1 Pharmacists can also discuss non-pharmacological strategies such as healthy hair care practices, creative hair styling, cosmetic camouflage and sun protection, to support patients’ overall wellbeing.2

      Conclusion

      As frontline healthcare professionals, pharmacists play a vital role in supporting people with hair loss disorders. They can facilitate appropriate medical referrals, provide evidence-based information, and guide patients in the safe and effective use of available treatments and supportive strategies.

      Case scenario continued

      After reviewing Greg’s history, you confirm there are no contraindications to minoxidil therapy. You explain the correct use of an over-the-counter foam formulation: applying to a dry scalp, taking care around the forehead and temples, waiting at least 1 hour before using other products and avoiding washing for 4 hours after application. You discuss the treatment timeline, reassuring Greg that initial shedding may increase but usually settles, and that it can take 3–4 months of consistent use before improvement is noticeable. You also emphasise the importance of follow-up with his doctor in 6 months and suggest simple supportive measures, such as protecting the scalp from sun exposure. Throughout the conversation, you address Greg’s concerns, reinforce realistic expectations, and encourage adherence to achieve the best outcome.1,2,8
      [cpd_submit_answer_button]

      Key points

      • Hair follicles cycle through three main stages of hair growth: anagen, catagen and telogen.1
      • Encourage people experiencing hair loss to see their medical practitioner for diagnosis to exclude scarring alopecias, correct underlying nutritional or metabolic deficiencies, and manage concurrent conditions.1,2
      • Hair loss can have significant psychosocial consequences; appropriate social and emotional support is important.1
      • Counsel patients on the potential benefits, risks and regimens of available therapies to support informed decision-making and realistic expectations.1

      References

        1. Dermatology Expert Group. Dermatology. Melbourne: Therapeutic Guidelines; 2022 (Amended July 2024). 
        2. Lyengar L, Li J. Male and female pattern hair loss. Aust Prescr 2025;48:93–7.
        3. Gupta AK, Faour S, Wang T, et al. Pattern hair loss and health care professionals: How well are we connecting with our audience? J Cosmet Dermatol 2024 Sep;23(9):2779-2784. Epub 2024 Apr 26.
        4. Dr Harriet Bell. Diffuse Alopecia. 2019. At: https://dermnetnz.org/topics/diffuse-alopecia
        5. Hon A/Prof Amanda Oakley, Dermatologist, 1997; Updated: Dr Harriet Bell, Medical Registrar, New Zealand, May 2022. Minor update by Ian Coulson, Dermatologist. Alopecia areata. 2024. At: https://dermnetnz.org/topics/alopecia-areata
        6. Dr Delwyn Dyall-Smith FACD, Dermatologist, 2009. Alopecia from drugs. At: https://dermnetnz.org/topics/alopecia-from-drugs#
        7. Honorary Associate Professor Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1998. Further updates: December 2015 and May 2023. Hair loss. At: https://dermnetnz.org/topics/hair-loss
        8. Australian Medicines Handbook. January 2025. At: https://amhonline.amh.net.au

      Our author

      Frieda Kaleel (she/her) BPharm, GradDipHospPharm, CredPharm, MPS is a credentialled pharmacist with over 20 years of experience in a range of pharmacy settings, including community, hospital, medicines reviews and university.

      Our reviewer

      Hana Numan (she/her) BPharm (NZ), PGDipClinPharm (NZ), MPS (NZ)  [post_title] => Managing pattern hair loss in pharmacy [post_excerpt] => Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => managing-pattern-hair-loss-in-pharmacy-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-11 10:41:25 [post_modified_gmt] => 2026-02-10 23:41:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31266 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Managing pattern hair loss in pharmacy [title] => Managing pattern hair loss in pharmacy [href] => https://www.australianpharmacist.com.au/managing-pattern-hair-loss-in-pharmacy-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31268 [authorType] => )

      Managing pattern hair loss in pharmacy

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31273
                  [post_author] => 11884
                  [post_date] => 2026-02-04 12:59:14
                  [post_date_gmt] => 2026-02-04 01:59:14
                  [post_content] => 

      Case scenario

      Alicia, 27, visits your pharmacy regularly for naproxen and heat patches to manage period pain. She confides that her pain has worsened over the past 2 years, radiates down her legs, interferes with work and affects intimacy.  Her periods are heavy, lasting around 9 days, and leave her feeling exhausted and sometimes even bedridden. Alicia has seen several GPs, who told her it was ‘normal for your age’. She says, ‘It feels like someone’s wringing out my insides – nothing helps much. Is this really normal?’

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the epidemiology, aetiology and pathophysiology of endometriosis
      • Identify key clinical features, risk factors and diagnostic considerations
      • Discuss pharmacological and non-pharmacological management options for endometriosis
      • Explain the pharmacist’s role in supporting patients with endometriosis through education, referral and holistic care.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5 Accreditation number: CAP2602DMED  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Endometriosis is a chronic inflammatory condition characterised by the growth of endometrial-like tissue outside the uterus, commonly affecting the ovaries, fallopian tubes and pelvic peritoneum.1,2 It affects 10–15% of all reproductive-aged Australians who were assigned female at birth, and 70% of females with chronic pelvic pain.3 Yet it remains underdiagnosed, underfunded and often misunderstood. Symptoms such as pelvic pain, heavy periods, fatigue and infertility can significantly affect quality of life. Pharmacists, often the first point of contact for pain management and self-care advice, play an important role in recognising potential endometriosis, supporting early referral and helping patients navigate ongoing treatment.

      Epidemiology

      An estimated 1 in 7 females in Australia are currently living with endometriosis.4-6 Onset often begins in adolescence, yet diagnosis is delayed on average by 7–10 years,1,3,7 influenced by menstrual pain normalisation, stigma, and misdiagnosis as irritable bowel syndrome (IBS) or anxiety.1,3,4,7,8 The consequences of these delays extend beyond physical health, affecting fertility, education, relationships and employment, and increasing the likelihood of depression, anxiety and social withdrawal.6,9,10

      Aetiology and pathophysiology

      The pathogenesis of endometriosis is multifactorial. The leading theory is retrograde menstruation, where menstrual blood flows backwards through the fallopian tubes into the pelvic cavity, allowing endometrial cells to implant and grow outside the uterus.2,11 Other contributing mechanisms include2,5,11,12:
      • immune dysfunction
      • coelomic metaplasia (peritoneal cell transformation)
      • genetic predisposition
      • hormonal imbalances 
      • environmental triggers.

      Clinical features  

      Endometriosis occurs when hormonally responsive lesions develop on the ovaries, bowel, bladder, peritoneum, or other pelvic and abdominal structures.1,5,9,13,14 These lesions respond to oestrogen and undergo cyclical changes similar to the endometrial lining, which can trigger inflammation, bleeding, scarring and adhesions. This may lead to chronic pain, organ dysfunction and infertility. Importantly, symptom severity does not always correlate with the number or extent of lesions and may fluctuate with hormonal changes.8,12 Risk factors While the exact cause of endometriosis is unclear, certain factors increase the likelihood of developing the condition1,9,13,14:
      • early menarche
      • short menstrual cycles (<27 days)
      • heavy/prolonged periods
      • nulliparity
      • family history of endometriosis
      • low BMI.
      Clinical presentation1,5,9,13,14 Pharmacists should consider endometriosis in individuals presenting with2,7,8,11,12:
      • moderate-severe dysmenorrhoea 
      • chronic pelvic pain (cyclical or constant)
      • persistent or recurrent pain associated with sexual intercourse (dyspareunia) 
      • menstrual bowel/bladder pain 
      • fatigue, lethargy, irritability
      • bloating
      • painful or altered bowel movements, particularly around the time of menstruation (dyschezia)
      • abnormally heavy or prolonged menstrual bleeding (menorrhagia) or irregular cycles 
      • infertility/conception delays.
      Classification No universally agreed classification exists, though the American Society of Reproductive Medicine (ASRM) system is commonly used15:
      • Stage I (minimal): few superficial implants.
      • Stage II (mild): more, deep implants.
      • Stage III (moderate): many deep implants; filmy adhesions may be present.
      • Stage IV (severe): many deep implants, many dense adhesions.
      Pain mechanisms and central sensitisation Central sensitisation refers to heightened nervous system responsiveness, causing persistent, widespread pain even after lesion removal.16 This can manifest as pelvic floor dysfunction, visceral hypersensitivity, and fatigue, and often overlaps with conditions such as irritable bowel syndrome or bladder pain syndrome.11 Supporting patients involves validating their pain experiences, even when imaging is normal or lesions appear minimal.

      Diagnosis and differential diagnosis 

      Diagnosis of endometriosis is often significantly delayed, with an average lag of 7–10 years from symptom onset.3,7,17 These delays are influenced by multiple systemic and social factors, including1,7,9,17:
      • normalisation of menstrual pain
      • dismissal of symptoms, particularly in adolescents and people of colour
      • lack of rural/remote access to gynaecology services 
      • under-recognition of symptoms in trans, non-binary and gender-diverse individuals
      • cost barriers to imaging, specialist care and private laparoscopies.
      Endometriosis shares symptoms with several other conditions, making diagnosis difficult. Differential diagnoses include IBS, pelvic inflammatory disease, adenomyosis, interstitial cystitis, depression and anxiety.12 Current diagnostic approaches While laparoscopy remains the gold standard, Australian guidelines now support symptom-based clinical diagnosis to reduce delays and improve care.3,7,17 Imaging tools such as transvaginal ultrasound can identify ovarian endometriotic cysts, but a normal ultrasound or MRI does not rule out disease – especially in early-stage or superficial cases. Patients should therefore be encouraged to pursue further care if symptoms significantly impact quality of life.3 Emerging diagnostic tools To address diagnostic challenges, ongoing research is focused on earlier, less invasive detection.4 Emerging approaches include blood-based biomarkers (e.g. proteomic panels, metabolomic profiling, microRNA and menstrual-fluid analysis),18-21 as well as advanced imaging techniques such as transvaginal ultrasound and MRI, which may help reduce reliance on laparoscopy and accelerate accurate diagnosis.3,7,17 When it’s not endometriosis: validating pelvic pain without a diagnosis Pelvic pain affects up to 1 in 4 people assigned female at birth and has many possible causes – endometriosis being only one of them.7,11,22,23 For some, extensive investigations such as imaging or laparoscopy reveal no abnormalities, which can leave patients feeling dismissed, confused or invalidated. Pharmacists can help by acknowledging that pain is real and deserving of care, even in the absence of a definitive diagnosis. Symptom management is the first-line approach for both endometriosis and chronic pelvic pain, and care should aim to improve daily function and quality of life regardless of diagnostic certainty.3 Where appropriate, pharmacists can also support referral to other healthcare providers for further assessment or multidisciplinary management. Although endometriosis itself is not curable, symptoms and recurrences can be effectively managed through person-centred care that considers physical, emotional and reproductive health needs.8

      Management approaches 

      Non-pharmacological treatment  Current treatment is focused on symptom control, rather than elimination of the disease. Non-pharmacological approaches form an essential part of care, particularly for patients who experience persistent pain or treatment adverse effects. Key strategies include8,13,24:
      • pelvic physiotherapy and psychotherapy (e.g. cognitive behavioural therapy [CBT], acceptance and commitment therapy [ACT])
      • heat therapy, TENS and mindfulness-based movement (e.g. yoga, Pilates)
      • anti-inflammatory or low-FODMAP diets, particularly for patients with co-existing irritable bowel syndrome.
      Mental health and emotional wellbeing Chronic pain is both physically and psychologically exhausting. Anxiety and depression rates are significantly higher in people with endometriosis than in the general population.7 Contributing factors include3,5,6,8,10,12,14,25:
      • diagnostic delays and invalidation of symptoms 
      • chronic fatigue and disrupted sleep
      • missed school or work
      • sexual dysfunction and relationship strain
      • fertility concerns or trauma from medical procedures.
      Pharmacists can play an important role in recognising distress and prompting early mental health support. Simple, empathetic questions – such as ‘How’s your sleep been lately?’ or ‘Is the pain affecting your mood?’ – can open conversations and guide appropriate referrals. Support strategies include:
      • recommending mental health care plans via GPs
      • referring to psychologists with chronic pain expertise or interdisciplinary pain teams
      • encouraging peer support groups (e.g. EndoActive, Endometriosis Australia, QENDO)
      • suggesting low-stigma mental health apps (e.g. MindSpot, Smiling Mind)
      • avoiding statements that minimise pain (e.g. ‘it’s just anxiety’) and instead validating the complex relationship between mood and pain.
      Complementary therapies  Patients may enquire about supplements or alternative therapies. Pharmacists should validate interest while clarifying the limited evidence and screening for interactions. Commonly explored options include magnesium, omega-3 fatty acids, turmeric (curcumin), vitex agnus-castus, zinc, vitamin B6, diindolylmethane (DIM) and acupuncture.22,24,26

      Pharmacological treatment 

      Analgesia
      • NSAIDs (e.g. naproxen 500 mg twice daily or ibuprofen 400 mg three times daily) are first line. 
      • Paracetamol may be added for multimodal relief.1,12,13
      Counselling should cover dosing, GI protection and review of OTC combinations (e.g. ibuprofen/paracetamol). Hormonal therapies Hormonal therapies suppress oestrogen-driven growth and reduce pain.11,12,13,27,28 Table 1 provides an overview of commonly used hormonal therapies in endometriosis management. Add-back therapy Treatment with gonadotrophin-releasing hormone (GnRH) analogues induces a temporary, reversible menopause to suppress oestrogen production and reduce endometriosis symptoms.30 However, this hypo-estrogenic state can cause side effects such as vasomotor symptoms, vaginal dryness and bone mineral density loss.30 Add-back therapy involves giving small ‘add-back’ doses of oestrogen, progestogen, or a combination of both, to counteract these effects while maintaining the efficacy of GnRH analogue treatment.13,28 Options include1,12,13,27: 
      • Continuous combined HRT – low-dose estrogen + progestogen. Use in patients with a uterus to protect the endometrium.
      • Sequential combined HRT – estrogen daily + cyclical progestogen. Less preferred, as cyclical hormones may worsen endometriosis symptoms.
      • Progestogen-only – continuous progestogen. Used when estrogen contraindicated.
      • Tibolone – synthetic steroid: estrogenic, progestogenic, and androgenic activity. Often used post-menopause; caution in estrogen-sensitive conditions.
      For add-back therapy, ensure to: 
      • use continuous regimens (not cyclical) to avoid stimulating endometriotic tissue
      • monitor BMD regularly if GnRH therapy continues >6 months
      • start add-back therapy generally at the same time as the GnRH analogue.
      Fertility considerations Up to half of people with endometriosis experience fertility issues, and pain suppression does not necessarily improve fertility.2,3,6,12 Pharmacists can:
      • counsel on hormonal therapy effects on ovulation 
      • encourage early specialist referral if conception delayed >12 months
      • support patients undergoing IVF or assisted reproductive treatment 
      • provide reassurance and empathy around fertility-related distress. 
      Table 1 – Overview of hormonal therapies for endometriosis References: Therapeutic Guidelines1, Buggio et al12, Rossi13 Hornstein26, Vercellini27 Note: Bone mineral density typically recovers within two years of cessation of GnRH therapies.27 Drospirenone currently off-label for endometriosis in Australia.1 The addition of Ryeqo (relugolix, estradiol, norethisterone) (July 2022) and Visanne (dienogest) (December 2024) to the PBS expands accessible hormonal therapy options for endometriosis.29

      The role of the pharmacist in endometriosis care

      Pharmacists play a vital role in improving care for people with endometriosis by addressing barriers through education, advocacy and person-centred support. Key strategies include1,5,8,12:
      • using inclusive language and avoiding assumptions about gender identity or reproductive goals
      • proactively exploring the impact of symptoms on daily life, including school, work and relationships
      • offering accessible symptom-tracking tools to support self-monitoring
      • referring patients to culturally safe services, including First Nations-specific clinics when appropriate
      • advocating for patients and providing education to dispel misconceptions about endometriosis.
      Given the impact of endometriosis on mental health, it is essential for pharmacists to use affirmative language that validates the patient’s experience.  For example, acknowledging that a patient’s pain is real fosters trust, signals active listening and supports collaborative care. Avoiding dismissive statements such as ‘pain is normal for women’ is crucial, as these can reinforce shame and self-doubt, and discourage timely help-seeking.10,14,31 Pharmacists are integral members of multidisciplinary teams managing endometriosis. They facilitate early identification and timely referrals to general practitioners, specialists, pelvic physiotherapists, psychologists and dietitians. The upcoming Endometriosis Management Plan (EMP), a digital clinical tool launching in 2026, is designed to enhance care coordination, streamline documentation, and align treatment goals across providers.4,32 Pharmacists can support EMP implementation through patient counselling, comprehensive medicines reviews and ongoing follow-up.  Pharmacists are also well-positioned to assist patients in navigating newly established specialist clinics funded under the 2025–26 federal health budget.4,32 Home Medicines Reviews (HMRs) can further optimise medicines management and should be actively recommended as part of a comprehensive care strategy. Pharmacists can support shared decision-making by explaining treatment mechanisms, expected onset of action and common adverse effects, helping patients make informed choices.

      Patient resources  

      Pharmacist follow-up and recommendations of patient support resources are beneficial for ongoing management. These include10,12,25,33:
      • inviting patients to check in monthly during early therapy
      • reassessing symptoms, tolerance and goals
      • encouraging use of symptom tracker apps to record symptoms, menstrual changes and evaluate therapy success (e.g. Phendo, Clue, EndoMeter)
      • referring to organisations for education/peer support
      • recommending organisations6,9,10,14,23,34,35:
        • Endometriosis Australia – advocacy/awareness
        • Jean Hailes for Women’s Health – tools/info
        • Pelvic Pain Foundation of Australia – clinician and patient info
        • QENDO – peer support, lived experience, free tracking app
        • EndoZone – clinical decision support, patient-friendly explanations
        • ESHRE patient leaflet – print-friendly patient information.

      Knowledge to practice 

      Pharmacists in primary care can support people with endometriosis by providing early recognition of symptom impact, guidance on medicines and symptom management, and facilitating timely referrals to appropriate healthcare providers.  Pharmacists play a key role in validating patient experiences, promoting self-monitoring through symptom-tracking tools, explaining treatment options and adverse effects, and encouraging engagement with multidisciplinary care.  Pharmacists should also advocate for patients and provide education to dispel misconceptions, helping reduce delays in diagnosis and improving overall quality of care.

      Conclusion

      Endometriosis is far more than painful periods – it’s a complex, chronic condition requiring interdisciplinary, person-centred care. Pharmacists can make a profound difference by recognising early signs, validating lived experience, supporting evidence-based management and facilitating timely referral. Even a single empathetic conversation can empower a patient to seek help and change the trajectory of their care.

      Case scenario continued

      You reassure Alicia that severe period pain is not something she has to accept and suggest tracking her symptoms with a menstrual diary and consulting a women’s health GP. You also provide advice on safe NSAID use and non-pharmacological strategies. Alicia returns 2 months later, now diagnosed with endometriosis and receiving hormonal therapy and pelvic physiotherapy. She continues to experience chronic pelvic pain and questions her medicines, so you organise a Home Medicines Review, identifying potential naproxen overuse and interactions with her sertraline, prompting treatment adjustments. You also recommend a local endometriosis support group, which Alicia joins, and she has since referred two friends with similar symptoms. Through ongoing support, she feels more empowered to manage her condition.
        [cpd_submit_answer_button]

      Key points

      • Lesion severity does not predict pain intensity.
      • Recognise red flags (e.g. cyclical pain, GI symptoms) and enact early referral.
      • Support interdisciplinary, patient-centred management.
      • Review safety, adherence and contraceptive actions of hormonal therapy.
      • Use inclusive, supportive language to reduce stigma and diagnostic delay.
      • Encourage treatment continuity and shared decision-making.

      References

      References 
      1. Therapeutic Guidelines Limited. Endometriosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2024. At: www.tg.org.au.
      2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–9. At: https://pubmed.ncbi.nlm.nih.gov/22819144/
      3. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep 2017;6(1):34–41. At: https://pubmed.ncbi.nlm.nih.gov/29276652/
      4. Australian Government Department of Health and Aged Care. National Action Plan for Endometriosis. Canberra: Department of Health; 2018. At: https://www.health.gov.au/resources/publications/national-action-plan-for-endometriosis?language=en
      5. RANZCOG. Endometriosis: a consensus guideline. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2021. At: https://ranzcog.edu.au
      6. Endometriosis Australia. About Endometriosis. 2023. At: www.endometriosisaustralia.org/about-endometriosis
      7. Armour M et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep 2020. At: https://pubmed.ncbi.nlm.nih.gov/33004965/
      8. Armour M, Sinclair J, Ng CHM, et al. A biopsychosocial approach to endometriosis management. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/2022_PPP_final-handouts.pdf
      9. European Society of Human Reproduction and Embryology. ESHRE. Guideline on endometriosis: patient leaflet. 2022. At: www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline
      10. Jean Hailes for Women’s Health. Endometriosis. 2024. At: www.jeanhailes.org.au/health-a-z/endometriosis
      11. Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol 2017;209:8–13. 
      12. Buggio L, Armour M, Evans S, et al. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract 2024;53(1–2):22–8. At: www1.racgp.org.au/ajgp/2024/january-february/endometriosis
      13. Rossi S, ed. Australian Medicines Handbook. 2025. Endometriosis. At: https://amhonline.amh.net.au
      14. EndoZone. Clinical and patient tools. 2025. At: www.endozone.com.au
      15. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32(2):315–24. At: https://academic.oup.com/humrep/article/32/2/315/2631390?login=false#116936554
      16. Alexander M, Dydyk EC, Michael F. Stretanski, et al. Central Pain Syndrome. StatPearls. 2025. At: www.ncbi.nlm.nih.gov/books/NBK553027/
      17. National Institute for Health and Care Excellence (NICE). Endometriosis: diagnosis and management. NICE guideline NG73. London: NICE; 2024. At: www.nice.org.uk/guidance/ng73/resources/endometriosis-diagnosis-and-management-pdf-1837632548293
      18. Endometriosis News. Current status of non-invasive biomarkers for endometriosis. 2024. At: www.endonews.com/current-status-of-non-invasive-biomarkers-for-endometriosis
      19. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database of Systematic Reviews 2016. Issue 4. 
      20. Proteomics International. PromarkerEndo delivers breakthrough results for endometriosis blood test. Perth: PIQ; 2024. At: ASX-PIQ-Collaboration-expanded-to-advance-Endometriosis-blood-test-251015.pdf
      21. Evans‑Hoeker E, Senapati S, Behera MA. Serum markers for endometriosis: a critical appraisal of current literature. Fertil Steri 2024;121(5):943–56.
      22. Evans S. Introduction to pelvic pain: an introduction to pelvic pain for girls, women, men and families. Pelvic Pain Foundation of Australia; 2024. At: www.pelvicpain.org.au/wp-content/uploads/2024/01/Introduction-to-Pelvic-Pain.pdf
      23. Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews 2017;2017(1):CD004753. At: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004753.pub4/full
      24. Villella S. The use of complementary medicines and therapies in women's health. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/Complementary-medicine-and-therapies
      25. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022(2):hoac009. https://doi.org/10.1093/hropen/hoac009
      26. Malik A, Sinclair J, Ng CHM, et al. Complementary medicine and chronic pelvic pain in Australian women: a national cross-sectional survey. BMJ Open 2021;11:e045768. At: https://pubmed.ncbi.nlm.nih.gov/35148773/
      27. Hornstein MD. Endometriosis: long-term treatment with gonadotropin-releasing hormone agonists. In: Barbieri RL, Eckler K, editors. UpToDate. Waltham (MA): UpToDate Inc.; 2023. At: www.uptodate.com
      28. Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 2016;106(7):1552–71. At: https://pubmed.ncbi.nlm.nih.gov/27817837/.
      29. Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme: New listings and changes – December 2024. Canberra: PBS; 2024. www.pbs.gov.au
      30. Veth VB, van der Karr MM, Duffy JM, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database of Systematic Reviews 2023;6(6).
      31. Australian Commission on Safety and Quality in Health Care. Person-centred care: a toolkit for implementation. Sydney: ACSQHC; 2020.
      32. Australian Government Department of Health and Aged Care. Budget 2025–26: Women’s Health Package. 2025. At: Budget 2025–⁠26: Strengthening Medicare – Women's health | Australian Government Department of Health, Disability and Ageing
      33. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018;19(10):1109–25. At: https://pubmed.ncbi.nlm.nih.gov/29975553/
      34. Endometriosis Australia. Patient stories (2023). At: https://endometriosisaustralia.org/category/endo-stories/
      35. QENDO. About Us. 2025. At: https://www.qendo.org.au/

      Our author

      Erin Downey (she/her) BPharm, GCertDiabEd, CDE, MPS CredPharm (MMR), ANZCAP-Reg (Endo, Generalist) is a clinical pharmacist, credentialled diabetes educator, endocrinology and generalist ANZCAP registrar, practising hospital pharmacist, and private CDE/credentialled MMR pharmacist in Southern Tasmania. 

      Our reviewer

      Elke Smith (she/her) BPharm, MHlthMgt [post_title] => Endometriosis: More than just a bad period [post_excerpt] => Endometriosis is a chronic inflammatory condition which affects 10–15% of all reproductive-aged Australians who were assigned female at birth. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => endometriosis-more-than-just-a-bad-period-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-06 10:09:22 [post_modified_gmt] => 2026-02-05 23:09:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31273 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Endometriosis: More than just a bad period [title] => Endometriosis: More than just a bad period [href] => https://www.australianpharmacist.com.au/endometriosis-more-than-just-a-bad-period-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31300 [authorType] => )

      Endometriosis: More than just a bad period

  • People
    • ADHD medicines
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31334
                  [post_author] => 3410
                  [post_date] => 2026-02-11 14:25:30
                  [post_date_gmt] => 2026-02-11 03:25:30
                  [post_content] => Victoria recently announced ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. 
      
      But last week, the Allan Government also unveiled a nation-first initiative. From September, an online emergency prescribing pathway will allow people with an existing ADHD diagnosis to obtain urgent repeat medicine through the Victorian Virtual Emergency Department (VVED).
      
      AP explores what the new model involves, the safeguards that will be in place and what’s happening in other states and territories.
      

      What’s the purpose of the service?

      The telehealth service is designed to address growing concern about long specialist waitlists, escalating costs and the clinical risks associated with abrupt cessation of Schedule 8 ADHD medicines – which can lead to symptom rebound, functional impairment and significant distress. A Department of Health spokesperson told AP that the service would provide a targeted safety net, rather than a substitute for established care arrangements. ‘The Victorian Virtual Emergency Department will offer a safe way for Victorians with an existing ADHD diagnosis to refill an urgent prescription for ADHD medication,’ the spokesperson said. 

      How will urgent ADHD ‘repeats’ be issued?

      Clinicians working within the VVED will verify the patient’s current medicine and dosage before issuing a prescription, the spokesperson said. Scripts will be sent directly to the patient’s local pharmacy, with patients advised of the closest pharmacy in operation at the time of prescribing. The Department of Health emphasised that the pathway will not replace routine ADHD management. ‘This is for emergency situations only and will not replace the important ongoing treatment and relationship between a patient and their clinician,’ the spokesperson said.

      Who will be eligible?

      The Victorian model allows adults and children aged 6 and over with an existing ADHD diagnosis to access the service who cannot secure a timely appointment with their usual clinician. The service will be limited to people who are already prescribed ADHD medicines. The VVED will not initiate ADHD treatment, alter dosages or provide ongoing prescribing. 

      What are the safeguards?

      Existing regulatory requirements and clinical guidelines for ADHD medicines will remain fully in place under the VVED pathway.  ‘The clinicians at the VVED, including paediatricians and psychiatrists, are highly experienced and highly skilled,’ the spokesperson said. ‘They will prescribe the medication within their existing scope of practice and clinical operations.’ Mandatory use of SafeScript for Schedule 8 medicines will continue to operate as a core safeguard. This ensures prescribers and pharmacists can monitor dispensing histories and reduces the risk of patients obtaining excessive prescriptions from multiple clinicians. The Department has stressed that responsibility for ongoing ADHD management remains with the patient’s regular clinician, with the VVED acting solely as a one-off support mechanism that complements broader reforms aimed at expanding GP involvement in ADHD care. And rather than providing a script to the patient, the script will be sent directly to their local pharmacy. When issuing a script, the VVED advises the patient of the closest pharmacy in operation.

      Part of a broader national shift

      Victoria’s online emergency model sits within a wider national trend to rebalance ADHD care away from exclusive reliance on specialist services.  Since 1 December 2025, ‘specialist GPs' in Queensland have been able to initiate, modify and continue stimulant treatment for adults with ADHD under updated Queensland Health guidance. Today (11 February), ACT Health issued an announcement on ADHD prescribing, with GPs who have completed approved training now able to continue prescribing ADHD medicines for eligible patients without requiring repeated reviews from a psychiatrist, paediatrician or neurologist. And other jurisdictions have since followed suit, including New South Wales, Western Australia and South Australia – which are set to roll out similar reforms this year.  Across Australia, governments are seeking to reduce wait times, lower out-of-pocket costs and embed ADHD care more firmly within primary care, while maintaining strong oversight of Schedule 8 stimulants such as methylphenidate, dexamfetamine and lisdexamfetamine via authorised prescribing schemes and real-time prescription monitoring checks. Non-stimulant ADHD medicines remain Schedule 4 and continue to be prescribed under existing arrangements. For more information, complete the PSA online module: ADHD explained. [post_title] => What pharmacists need to know about emergency prescribing for ADHD [post_excerpt] => Victoria is the latest state to announce ADHD reforms, with ‘specialist GPs’ now able to continue ADHD prescriptions for existing patients. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => what-pharmacists-need-to-know-about-emergency-adhd-prescribing [to_ping] => [pinged] => [post_modified] => 2026-02-11 15:45:52 [post_modified_gmt] => 2026-02-11 04:45:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31334 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => What pharmacists need to know about emergency prescribing for ADHD [title] => What pharmacists need to know about emergency prescribing for ADHD [href] => https://www.australianpharmacist.com.au/what-pharmacists-need-to-know-about-emergency-adhd-prescribing/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31336 [authorType] => )

      What pharmacists need to know about emergency prescribing for ADHD

      emergency contraception
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31316
                  [post_author] => 3410
                  [post_date] => 2026-02-09 12:57:25
                  [post_date_gmt] => 2026-02-09 01:57:25
                  [post_content] => The gap between evidence and everyday practice is impacting patient access to emergency contraception.
      
      Community pharmacies are often the first – and sometimes only – point of access for emergency contraception in Australia. 
      
      But a new qualitative study found there are still persistent gaps between what the guidelines say and what happens in practice.
      
      Ruth Nona, pharmacist and researcher at James Cook University, who interviewed community pharmacists about providing emergency contraception services, describes a workforce that is broadly willing to help, but not always set up to deliver consistently equitable care. 
      

      1. Not recommending ulipristal as first-line

      One of the most significant gaps identified in the study was the tendency for pharmacists to default to levonorgestrel, despite guidance in the Australian Pharmaceutical Formulary and Handbook (APF) that ulipristal acetate is generally considered more effective than levonorgestrel and can be used up to 120 hours after unprotected intercourse. ‘Habit definitely plays a role,’ Ms Nona said. ‘Some pharmacists felt more comfortable and confident supplying levonorgestrel. For example, if someone requested emergency contraception within 24 hours, pharmacists felt levonorgestrel was acceptable within that timeframe, without fully considering efficacy.’ [caption id="attachment_31329" align="alignright" width="250"] Ruth Nona[/caption] In some pharmacies, price differences influenced whether ulipristal acetate was presented as an option. ‘In certain socio-economic areas, cost was a driver,’ Ms Nona said. ‘Cost considerations were also sometimes linked to younger people coming in and asking whether there was a cheaper option.’ Sometimes, levonorgestrel was the only medicine on hand. ‘There was research that came out showing that some pharmacies still did not stock ulipristal acetate,’ she said. ‘It’s been an ongoing issue, and something that really needs to be addressed.’ However, patients need to be able to make an informed decision about which medicine to take. ‘As stated in the guidelines, it’s about making sure all patients are given the information they need to make an informed and equitable choice. If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information,’ Ms Nona said. ‘When pharmacists did give the full picture and explained the differences, more often than not the patient chose ulipristal acetate, even though it cost more.’
      ‘If the patient wants a particular option, that’s fine, but they need to be able to make that decision with the full information.' Ruth nona

      2. Uncertainty when responding to third-party requests

      Pharmacists reported particular uncertainty when providing emergency contraception to third parties, with many wary about consent and unsure whether they could provide it to someone who wasn’t the patient. ‘In most cases, they would follow up and ask to contact the patient directly,’ Ms Nona said. ‘It wasn’t that they didn’t want to provide it – they just felt unsure and they wanted to make sure that the patient had consented.’ While in many cases, speaking to the intended person directly can help provide key information and counselling, in circumstances where this is not possible, it is usually possible to determine the medicine is safe and therapeutically appropriate, and supply in a manner consistent with APF guidance and legal obligations.

      3. Uncertainty providing emergency contraception to adolescents

      Similarly, pharmacists were ‘uncomfortable’ providing the service to adolescents. This uncertainty often centred on fear of making the wrong decision or facing professional consequences. ‘They still wanted to provide the service, but it was more that internal question of, “Should I do this? Am I going to get in trouble?”’ There are no jurisdictions where there’s a legal restriction from supplying emergency contraception to minors. The APF guidance helps pharmacists navigate Gillick competency and consent in adolescents, ensuring they demonstrate sufficient maturity and understanding to provide informed consent. Ms Nona emphasised that the issue was confidence, not capability. ‘It’s about being familiar with the guidelines, making sure we’re as up to date as possible and realising that it’s okay for us to provide these services, provided the adolescent is [assessed as Gillick competent] mentally mature and safe,’ she said.  The APF references Gillick competency provided the adolescent is [assessed as Gillick competent (demonstrating sufficient maturity and understanding to provide informed consent)]

      4. Uncertainty for transgender people on gender affirming hormone therapy

      While pharmacists were generally supportive towards transgender and gender-diverse patients, lack of familiarity with hormone therapy raised hesitation. ‘There are absolutely no interactions between emergency contraception and gender-affirming hormones’ Ms Nona said. ‘It really comes down to knowledge, which builds confidence, and being up to date to make sure the service we provide is timely and equitable.’ In some areas, pharmacists may frequently encounter transgender and gender- diverse patients requesting emergency contraception, while pharmacists in other areas do not. ‘That’s why it’s also about being prepared. You never know when that situation might arise,’ she added. Should pharmacists feel unsure during these consultations, pharmacists can and should engage with the APF. ‘Pharmacists did say that if that situation did occur with a transgender or gender- diverse person that they would be honest and say to them, “Do you mind if I consult my resources?”’ 

      Another reason the APF is a mandatory text for all community pharmacists

      Despite lack of guideline use, pharmacists acknowledged how essential guidelines such as the APF are, Ms Nona said.  ‘And when pharmacists did use them, they found the information provided was invaluable.’ ‘[But] a lot of the challenges stemmed from lack of time and, in some cases, a lack of up-to-date knowledge. We have so many things to do, and we need more time to do everything and to keep ourselves up to date.’ For Ms Nona, the solution lies in supporting pharmacists to use guidelines  confidently and consistently in real-world conditions. Some pharmacists report to PSA that they will often bring up the APF digital on the screen in the consultation room in emergency contraception discussions, particularly in situations which are new or unfamiliar.

      Delivering a critical intervention

      The key to emergency contraception provision is recognising the stakes. ‘The whole picture of providing emergency contraception is to make sure we are preventing pregnancies when people don't want to get pregnant – whatever the reason may be,’ Ms Nona said. ‘That’s why they come to see a pharmacist – to ensure the person has the best possible chance of preventing an unintended pregnancy.’ When pharmacists are supported to provide full information and informed choice, patients respond accordingly.
      The Australian Pharmaceutical Formulary and Handbook (APF) chapter on ‘Emergency Contraception’, provides essential guidance on: 
      • providing timely, confidential, non-judgemental access to emergency contraception, recognising that effectiveness is time-dependent
      • obtaining sufficient patient information to assess safety, effectiveness and the most appropriate emergency contraception option
      • recommending the most effective oral emergency contraception, based on clinical assessment and time since unprotected sexual intercourse
      • supporting informed choice, including discussion of efficacy, cost and suitability, without making assumptions about patient preferences
      • assessing the need for referral where safety, effectiveness or appropriateness cannot be assured
      • providing care to adolescents based on maturity and understanding, in accordance with legislation and professional obligations
      • providing inclusive care for transgender and gender-diverse people with pregnancy risk
      • providing counselling and written information, including how to take emergency contraception, what to expect, and advice on ongoing contraception.
      [post_title] => Where emergency contraception practice falls short [post_excerpt] => The gap between evidence and everyday practice is costing patients access to the most effective emergency contraception. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => where-emergency-contraception-practice-falls-short [to_ping] => [pinged] => [post_modified] => 2026-02-09 16:09:16 [post_modified_gmt] => 2026-02-09 05:09:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31316 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Where emergency contraception practice falls short [title] => Where emergency contraception practice falls short [href] => https://www.australianpharmacist.com.au/where-emergency-contraception-practice-falls-short/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31321 [authorType] => )

      Where emergency contraception practice falls short

      pharmacist prescribing
      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31305
                  [post_author] => 1925
                  [post_date] => 2026-02-08 10:38:16
                  [post_date_gmt] => 2026-02-07 23:38:16
                  [post_content] => 

      Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)?

      The range of professional services delivered by community pharmacists has expanded rapidly in recent years, from vaccination to UTI prescribing and beyond. As these services increase in popularity, they are shifting from ancillary service to core business. This widening scope is forcing community pharmacies to review how they conduct their business and the way front-of-house staff interact with patients. No longer is dispensing prescriptions on a first come, first served basis sustainable. With adjustments to workflow, vaccinations and other booked services have been prioritised and run simultaneously, says Queensland-based prescribing pharmacist Kate Gunthorpe MPS.  ‘We are moving away from the mindset that dispensing always comes first. We need to triage effectively and manage expectations, so every patient feels seen and cared for,’ she says. And it isn’t just about sequential processes. Workflow changes also require a shift of communication approaches and pre-existing mindsets around professional service provision.  ‘The biggest pitfall I’ve discovered is apologising for charging or determining that the consultation wasn’t worth charging for,’ Ms Gunthorpe says. ‘That instantly undermines the service’s value. Every consultation, whether the outcome is a prescription, advice or reassurance, involves clinical reasoning, professional judgement and patient care.’ So, how should the profession move forward? The PSA’s foundation documents are clear that all services must remain patient-centric.  That means redesigning workflows on the floor, developing new communication strategies for staff and providing additional training for pharmacy assistants to ensure a consistent, professional patient experience. AP spoke with Ms Gunthorpe and pharmacy assistant Madison Low about adapting workflow to integrate services without disrupting dispensing. product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously. 

      Case 1 Kate Gunthorpe MPS

      Pharmacist prescriber, Implementation and Change Specialist, TerryWhite Chemmart, Samford, Queensland  [caption id="attachment_31312" align="alignright" width="185"]pharmacist prescribing Kate Gunthorpe MPS[/caption] Our team started by mapping our busiest times to understand where bottlenecks occurred. We then built clear workflows – for example, using a booking system for consultations where possible, and ensuring at least one pharmacist remained consult-focused during every day. We trained our assistants to triage appropriately and use consistent language, such as ‘the pharmacist will see you shortly for your consultation’, which helped the process feel deliberate rather than disruptive. Once the team understood that consultations were core services, not interruptions, the process flowed more smoothly. Patients often expect a prescription outcome from a consultation, so I changed the framework, ensuring the consultation became a clinical one, not a product or medicines transaction. I now explain that I will assess their presentation, then create a unique shared management plan for them – which may or may not involve a prescription. Setting that expectation upfront helps enormously.  When we changed our front-of-shop language, patients stopped viewing consultations as waiting in a queue. That one shift in language lifted the professionalism of the whole process; patients were more patient, staff felt more confident explaining the service, and we saw an improvement in how people valued the pharmacist’s time. One thing I would advise other pharmacists about charging appropriately for their time, even when the consultation doesn’t end with a script, is to start valuing their expertise. The consultation is the service, not the outcome. We’re expertly trained to assess, diagnose and provide evidence-based care. That deserves to be remunerated. Once pharmacists stop apologising and start consistently charging for their time and expertise, patients begin to respect that boundary too. I find it is better to be transparent and consistent with pricing. I explain what’s included in the consultation, so patients understand what they’re paying for. Most importantly, I believe in it myself. If you hesitate to charge, your team and patients will pick up on that. The work floor also needs redesigning to normalise consulting services as part of everyday care. It starts with the physical layout and staffing models. Pharmacies should expect consultations to happen and allocate dedicated private spaces, clear booking systems and enough pharmacist coverage, so that one can focus on clinical care, while others oversee dispensing and other services. Culturally, it’s all been about mindset: we stopped treating services as extra and started treating them as central to what we do. That meant redistributing roles, upskilling support staff with more autonomy to triage and manage appointments, and introducing appointment blocks.  The effect of all these new processes has resulted in major change. Our pharmacy assistants are our front line, and their language is setting the tone for the entire patient experience. We have invested time in scripting and role-playing, so that the assistants feel comfortable discussing new services. The staff have learned to understand what each service involves, how long it typically takes, and when to book or triage patients. Scripts no longer automatically take priority over walk-up service requests. They are both core services. Pharmacies are healthcare hubs where patients can expect to have a prescription filled but also be able to discuss their health concerns.  Patients also value honesty and clarity. If a medication is not appropriate, explaining why builds understanding and trust – especially when you provide alternative options or safety net advice.  Because pharmacy staff use consistent, confident language and understand the workflow, everything runs much more smoothly. It has also empowered the staff to take pride in being responsible for a part of the patient care process, not just the retail side.  When staff describe services as core health care, not as ‘extras’ or ‘add-ons’, patients have started to see the pharmacist as a clinician involved in their primary care. It’s a subtle but powerful mindset shift that’s transforming how the pharmacy is perceived.

      Case 2 Madison Low

      Retail manager, TerryWhite Chemmart, Arana Hills, Queensland [caption id="attachment_31313" align="alignright" width="277"]pharmacist prescribing Madison Low[/caption] Since we started offering services like UTI consultations and vaccinations, my role has expanded significantly. We no longer just provide products; we’re delivering a more complete healthcare solution. A person recently came to the counter, visibly frustrated because they had symptoms of a urinary tract infection but couldn’t get in to see their doctor. They were holding a box of Ural.  Rather than just selling them the product, I suggested they talk to the pharmacist, assuring them that in many cases the pharmacist can provide a full treatment without needing a doctor’s visit. I asked a few questions about their symptoms, then checked with the pharmacist to confirm a consultation was possible immediately. It was, and not long afterwards the patient went away happy. Asthma management is one of the most common chronic conditions we see. Many patients believe they understand how to manage the condition, especially because they can access inhalers over the counter. But often that’s not the case. One of my roles is to let patients know there may be better solutions. Our pharmacists can review their current treatment and provide an improved management plan. Since becoming more mindful of the language I use with patients, I’ve noticed a positive change in how they respond to me.  By communicating in a more empathetic and approachable way, I’ve found patients are more comfortable asking questions and discussing their concerns. This has made it easier to identify when a patient might benefit from a review with one of our pharmacists. This change in language has also strengthened trust between patients and the pharmacy team. Patients seem more engaged and confident in the care they receive, and I feel more confident in my role as a link between them and our pharmacists. The biggest challenge has been balancing our time – especially during busy periods like the flu season, when there are lots of vaccines to administer, prescriptions to dispense and consultations to organise. I’m proud of how our team works together to ensure our patients are looked after promptly and get the attention they need. [post_title] => How expanded scope is redefining pharmacy practice [post_excerpt] => Rapidly evolving scope of practice means that traditional community pharmacy workflows need review. What works (and what doesn’t)? [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => how-expanded-scope-is-redefining-pharmacy-practice [to_ping] => [pinged] => [post_modified] => 2026-02-09 14:54:19 [post_modified_gmt] => 2026-02-09 03:54:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31305 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => How expanded scope is redefining pharmacy practice [title] => How expanded scope is redefining pharmacy practice [href] => https://www.australianpharmacist.com.au/how-expanded-scope-is-redefining-pharmacy-practice/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 31310 [authorType] => )

      How expanded scope is redefining pharmacy practice

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31266
                  [post_author] => 11883
                  [post_date] => 2026-02-04 13:01:11
                  [post_date_gmt] => 2026-02-04 02:01:11
                  [post_content] => 

      Case scenario

      Greg, a 28-year-old man, comes into your pharmacy asking for a ‘strong minoxidil hair product’. He explains that his doctor recently diagnosed him with male pattern hair loss and suggested he try an over-the-counter treatment, with a follow-up review in 6 months. Greg has noticed gradual thinning at the temples over the past year but reports no sudden hair loss, scalp irritation or other medical issues. He has no known allergies, takes no medicines and has no chronic conditions.

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the main phases of the hair growth cycle
      • Outline the main types of hair loss and describe their key features
      • Identify pharmacological treatments and non-pharmacological strategies for pattern hair loss in males and females
      • Counsel patients on expected outcomes, timelines and use of common hair loss treatments.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5  Accreditation number: CAP2602DMFK  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. Hair loss can therefore have a major impact on self-esteem and quality of life, with notable psychosocial consequences.1,2 In an era where many people increasingly turn to social media for health information,3 pharmacists are accessible, reliable health professionals who can guide patients towards safe, evidence-based options, clarify treatment outcomes and timelines, and identify when medical referral is required.

      Epidemiology and physiology

      Pattern hair loss, also called androgenetic alopecia, is the most common cause of hair loss in both men and women.2 Approximately 80% of Caucasian men and up to 60% of Caucasian women by the age of 70 years are affected by pattern hair loss.1 Scalp hair follicles cycle through three stages: anagen (active growth), catagen (transition), and telogen (resting/shedding).1 At any given time, most follicles (about 85–90%) are in the growth phase, producing roughly 1 centimetre of hair per month.1 Shedding up to 100 hairs daily is considered normal, usually seen while washing and brushing.1

      Understanding hair loss disorders

      Hair loss disorders typically result from disruptions in the normal hair growth cycle.1 They can be divided into three main categories: patterned, diffuse or localised (patchy) alopecia.1 Patterned alopecia Male or female pattern hair loss is a non-scarring form of alopecia. It manifests as progressive hair thinning in a characteristic pattern and is influenced by genetics and the sensitivity of hair follicles to androgens, primarily dihydrotestosterone. The replacement of terminal hairs with shorter, finer, miniaturised hairs is driven by androgen effects on scalp follicles.1,2 In men, pattern hair loss typically begins with bitemporal hairline recession and may progress to baldness at the vertex (crown).2 In women, it usually presents as diffuse thinning that gradually widens the part line on the crown and reduces ponytail volume.2 Both male and female pattern hair loss commonly comprise of a sparser frontal hairline where episodic bursts of excessive hair shedding are common.1,2 Diffuse alopecia Diffuse alopecia involves hair loss across the scalp without a defined pattern. It can occur during either the telogen or anagen phases of the hair cycle. The most common cause is telogen effluvium, a reactive condition in which a trigger causes anagen hairs to prematurely enter the telogen (resting) phase, resulting in excessive shedding.1,4 Both acute and chronic telogen effluvium typically do not lead to permanent baldness.1 Localised (patchy) alopecia Localised alopecia presents as discrete patches of hair loss. Common causes include alopecia areata and tinea capitis (more common in children), while less common causes include scarring alopecias (e.g. discoid lupus erythematosus or lichen planopilaris) and trichotillomania (compulsive hair-pulling).1 Alopecia areata is a complex polygenic autoimmune disorder and typically produces discrete (often circular) areas of hair loss anywhere on the body.1 The lifetime risk is approximately 2%,5 and spontaneous complete regrowth within 12 months occurs in up to 80% of individuals with a single patch, though relapses are common.1 Alopecia areata can have significant psychosocial impacts. The Australia Alopecia Areata Foundation (AAAF) offers resources and support for affected individuals and their families.1

      Diagnosis and treatment goals

      When a person presents with hair loss, it is important to first confirm the diagnosis and rule out reversible or more serious causes. Medical practitioners may consider contributing factors such as scarring alopecias, nutritional deficiencies, metabolic disorders or drug-induced alopecia. Some implicated medicines in drug-induced alopecia include, but are not limited to, chemotherapy, retinoids, antiepileptics, antidepressants, β-blockers, statins and hormonal agents such as anabolic steroids, testosterone and oral contraceptives.1,2,6 Once pattern hair loss is diagnosed, treatment is generally pursued only if the person wishes to address cosmetic concerns or psychosocial impacts.1 Management aims to slow progression and stimulate regrowth where possible. Emotional and social support should be addressed in their care,1 alongside referral to the medical practitioner when diagnosis is uncertain or comorbidities need management.

      Non-pharmacological management

      Non-pharmacological approaches can improve appearance, protect scalp health and complement medical therapy.  Cosmetic camouflage1,2,7 These strategies aim to conceal thinning and improve appearance:
      • Creative hair styling (e.g. layering, parting adjustments)
      • Cosmetic camouflage products such as keratin fibres or coloured sprays.
      Scalp and hair health1,2,7 These measures focus on preventing further damage and protecting the scalp:
      • Gentle hair care practices (air-drying or cool hairdryer setting, minimising chemical treatments, loose hairstyles to prevent traction injury)
      • Sun protection with a broad-brimmed hat, scarf or sunscreen.
      Procedural interventions1,2,5 These attempt to restore hair density but vary in accessibility and evidence:
      • Hair transplantation can provide permanent restoration, particularly when combined with medical therapy, although cost and access are significant barriers
      • Platelet-rich plasma (PRP) injection uses autologous blood to stimulate growth but is unregulated in Australia; patients considering PRP should consult clinicians experienced in evidence-based alopecia medical management
      • Evidence for other interventions (e.g. laser devices, hair tonics, nutritional supplements) is limited.

      Pharmacological management

      For mild to moderate pattern hair loss, treatment options differ by sex. In males, topical minoxidil or oral finasteride may be used either alone or in combination.1 In females, topical minoxidil or oral spironolactone are commonly prescribed as monotherapy or in combination.1 In more severe cases, combination therapy is generally recommended.1 Before starting therapy, pharmacists should assess for contraindications, precautions and potential adverse effects. Counselling on realistic expectations is essential, as in most cases treatments are not curative but aim to slow progression and promote regrowth.1,2,8 Visible improvement is gradual; topical minoxidil may take 3–6 months while oral finasteride and spironolactone often require 6–12 months.1 Continuous therapy is necessary to maintain benefit, which is usually lost within 6–12 months of treatment cessation.8 Topical minoxidil is Pharmacy Only (Schedule 2) and is available as a foam or lotion.1 The foam is often preferred as it doesn’t contain propylene glycol that can irritate the scalp, is less likely to cause allergic contact dermatitis, and is less greasy than the lotion.1,2 Pre-existing scalp conditions such as eczema, seborrhoeic dermatitis or dandruff should be treated prior to initiating minoxidil, as they may be exacerbated by therapy.1 A temporary increase in hair loss may be seen during the first months of minoxidil therapy; this reactive shedding usually settles after a few weeks. Additionally, minoxidil should only be applied to affected areas, carefully avoiding skin around the forehead and temples to reduce the risk of hypertrichosis (excessive hair growth).1,8

      Knowledge to practice 

      Pharmacists can help people manage hair loss by understanding its various forms, acknowledging the social and cultural importance of hair, and recognising the anxiety it may cause.1 Prior to recommending treatment, pharmacists should screen for red flags and contraindications, making sure they refer patients to their doctor when appropriate.2 Many hair loss treatments require time and continuous application. Pharmacists play an important role in educating patients about realistic expectations and the likely timelines for treatment response, helping them make informed decisions.1 Pharmacists can also discuss non-pharmacological strategies such as healthy hair care practices, creative hair styling, cosmetic camouflage and sun protection, to support patients’ overall wellbeing.2

      Conclusion

      As frontline healthcare professionals, pharmacists play a vital role in supporting people with hair loss disorders. They can facilitate appropriate medical referrals, provide evidence-based information, and guide patients in the safe and effective use of available treatments and supportive strategies.

      Case scenario continued

      After reviewing Greg’s history, you confirm there are no contraindications to minoxidil therapy. You explain the correct use of an over-the-counter foam formulation: applying to a dry scalp, taking care around the forehead and temples, waiting at least 1 hour before using other products and avoiding washing for 4 hours after application. You discuss the treatment timeline, reassuring Greg that initial shedding may increase but usually settles, and that it can take 3–4 months of consistent use before improvement is noticeable. You also emphasise the importance of follow-up with his doctor in 6 months and suggest simple supportive measures, such as protecting the scalp from sun exposure. Throughout the conversation, you address Greg’s concerns, reinforce realistic expectations, and encourage adherence to achieve the best outcome.1,2,8
      [cpd_submit_answer_button]

      Key points

      • Hair follicles cycle through three main stages of hair growth: anagen, catagen and telogen.1
      • Encourage people experiencing hair loss to see their medical practitioner for diagnosis to exclude scarring alopecias, correct underlying nutritional or metabolic deficiencies, and manage concurrent conditions.1,2
      • Hair loss can have significant psychosocial consequences; appropriate social and emotional support is important.1
      • Counsel patients on the potential benefits, risks and regimens of available therapies to support informed decision-making and realistic expectations.1

      References

        1. Dermatology Expert Group. Dermatology. Melbourne: Therapeutic Guidelines; 2022 (Amended July 2024). 
        2. Lyengar L, Li J. Male and female pattern hair loss. Aust Prescr 2025;48:93–7.
        3. Gupta AK, Faour S, Wang T, et al. Pattern hair loss and health care professionals: How well are we connecting with our audience? J Cosmet Dermatol 2024 Sep;23(9):2779-2784. Epub 2024 Apr 26.
        4. Dr Harriet Bell. Diffuse Alopecia. 2019. At: https://dermnetnz.org/topics/diffuse-alopecia
        5. Hon A/Prof Amanda Oakley, Dermatologist, 1997; Updated: Dr Harriet Bell, Medical Registrar, New Zealand, May 2022. Minor update by Ian Coulson, Dermatologist. Alopecia areata. 2024. At: https://dermnetnz.org/topics/alopecia-areata
        6. Dr Delwyn Dyall-Smith FACD, Dermatologist, 2009. Alopecia from drugs. At: https://dermnetnz.org/topics/alopecia-from-drugs#
        7. Honorary Associate Professor Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1998. Further updates: December 2015 and May 2023. Hair loss. At: https://dermnetnz.org/topics/hair-loss
        8. Australian Medicines Handbook. January 2025. At: https://amhonline.amh.net.au

      Our author

      Frieda Kaleel (she/her) BPharm, GradDipHospPharm, CredPharm, MPS is a credentialled pharmacist with over 20 years of experience in a range of pharmacy settings, including community, hospital, medicines reviews and university.

      Our reviewer

      Hana Numan (she/her) BPharm (NZ), PGDipClinPharm (NZ), MPS (NZ)  [post_title] => Managing pattern hair loss in pharmacy [post_excerpt] => Hair is closely linked to appearance and identity, and changes to it often carry strong emotional significance. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => managing-pattern-hair-loss-in-pharmacy-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-11 10:41:25 [post_modified_gmt] => 2026-02-10 23:41:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31266 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Managing pattern hair loss in pharmacy [title] => Managing pattern hair loss in pharmacy [href] => https://www.australianpharmacist.com.au/managing-pattern-hair-loss-in-pharmacy-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31268 [authorType] => )

      Managing pattern hair loss in pharmacy

      td_module_mega_menu Object
      (
          [post] => WP_Post Object
              (
                  [ID] => 31273
                  [post_author] => 11884
                  [post_date] => 2026-02-04 12:59:14
                  [post_date_gmt] => 2026-02-04 01:59:14
                  [post_content] => 

      Case scenario

      Alicia, 27, visits your pharmacy regularly for naproxen and heat patches to manage period pain. She confides that her pain has worsened over the past 2 years, radiates down her legs, interferes with work and affects intimacy.  Her periods are heavy, lasting around 9 days, and leave her feeling exhausted and sometimes even bedridden. Alicia has seen several GPs, who told her it was ‘normal for your age’. She says, ‘It feels like someone’s wringing out my insides – nothing helps much. Is this really normal?’

      Learning objectives

      After reading this article, pharmacists should be able to:
      • Describe the epidemiology, aetiology and pathophysiology of endometriosis
      • Identify key clinical features, risk factors and diagnostic considerations
      • Discuss pharmacological and non-pharmacological management options for endometriosis
      • Explain the pharmacist’s role in supporting patients with endometriosis through education, referral and holistic care.
      Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5 Accreditation number: CAP2602DMED  Accreditation expiry: 31/01/2029 
      Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

      Introduction

      Endometriosis is a chronic inflammatory condition characterised by the growth of endometrial-like tissue outside the uterus, commonly affecting the ovaries, fallopian tubes and pelvic peritoneum.1,2 It affects 10–15% of all reproductive-aged Australians who were assigned female at birth, and 70% of females with chronic pelvic pain.3 Yet it remains underdiagnosed, underfunded and often misunderstood. Symptoms such as pelvic pain, heavy periods, fatigue and infertility can significantly affect quality of life. Pharmacists, often the first point of contact for pain management and self-care advice, play an important role in recognising potential endometriosis, supporting early referral and helping patients navigate ongoing treatment.

      Epidemiology

      An estimated 1 in 7 females in Australia are currently living with endometriosis.4-6 Onset often begins in adolescence, yet diagnosis is delayed on average by 7–10 years,1,3,7 influenced by menstrual pain normalisation, stigma, and misdiagnosis as irritable bowel syndrome (IBS) or anxiety.1,3,4,7,8 The consequences of these delays extend beyond physical health, affecting fertility, education, relationships and employment, and increasing the likelihood of depression, anxiety and social withdrawal.6,9,10

      Aetiology and pathophysiology

      The pathogenesis of endometriosis is multifactorial. The leading theory is retrograde menstruation, where menstrual blood flows backwards through the fallopian tubes into the pelvic cavity, allowing endometrial cells to implant and grow outside the uterus.2,11 Other contributing mechanisms include2,5,11,12:
      • immune dysfunction
      • coelomic metaplasia (peritoneal cell transformation)
      • genetic predisposition
      • hormonal imbalances 
      • environmental triggers.

      Clinical features  

      Endometriosis occurs when hormonally responsive lesions develop on the ovaries, bowel, bladder, peritoneum, or other pelvic and abdominal structures.1,5,9,13,14 These lesions respond to oestrogen and undergo cyclical changes similar to the endometrial lining, which can trigger inflammation, bleeding, scarring and adhesions. This may lead to chronic pain, organ dysfunction and infertility. Importantly, symptom severity does not always correlate with the number or extent of lesions and may fluctuate with hormonal changes.8,12 Risk factors While the exact cause of endometriosis is unclear, certain factors increase the likelihood of developing the condition1,9,13,14:
      • early menarche
      • short menstrual cycles (<27 days)
      • heavy/prolonged periods
      • nulliparity
      • family history of endometriosis
      • low BMI.
      Clinical presentation1,5,9,13,14 Pharmacists should consider endometriosis in individuals presenting with2,7,8,11,12:
      • moderate-severe dysmenorrhoea 
      • chronic pelvic pain (cyclical or constant)
      • persistent or recurrent pain associated with sexual intercourse (dyspareunia) 
      • menstrual bowel/bladder pain 
      • fatigue, lethargy, irritability
      • bloating
      • painful or altered bowel movements, particularly around the time of menstruation (dyschezia)
      • abnormally heavy or prolonged menstrual bleeding (menorrhagia) or irregular cycles 
      • infertility/conception delays.
      Classification No universally agreed classification exists, though the American Society of Reproductive Medicine (ASRM) system is commonly used15:
      • Stage I (minimal): few superficial implants.
      • Stage II (mild): more, deep implants.
      • Stage III (moderate): many deep implants; filmy adhesions may be present.
      • Stage IV (severe): many deep implants, many dense adhesions.
      Pain mechanisms and central sensitisation Central sensitisation refers to heightened nervous system responsiveness, causing persistent, widespread pain even after lesion removal.16 This can manifest as pelvic floor dysfunction, visceral hypersensitivity, and fatigue, and often overlaps with conditions such as irritable bowel syndrome or bladder pain syndrome.11 Supporting patients involves validating their pain experiences, even when imaging is normal or lesions appear minimal.

      Diagnosis and differential diagnosis 

      Diagnosis of endometriosis is often significantly delayed, with an average lag of 7–10 years from symptom onset.3,7,17 These delays are influenced by multiple systemic and social factors, including1,7,9,17:
      • normalisation of menstrual pain
      • dismissal of symptoms, particularly in adolescents and people of colour
      • lack of rural/remote access to gynaecology services 
      • under-recognition of symptoms in trans, non-binary and gender-diverse individuals
      • cost barriers to imaging, specialist care and private laparoscopies.
      Endometriosis shares symptoms with several other conditions, making diagnosis difficult. Differential diagnoses include IBS, pelvic inflammatory disease, adenomyosis, interstitial cystitis, depression and anxiety.12 Current diagnostic approaches While laparoscopy remains the gold standard, Australian guidelines now support symptom-based clinical diagnosis to reduce delays and improve care.3,7,17 Imaging tools such as transvaginal ultrasound can identify ovarian endometriotic cysts, but a normal ultrasound or MRI does not rule out disease – especially in early-stage or superficial cases. Patients should therefore be encouraged to pursue further care if symptoms significantly impact quality of life.3 Emerging diagnostic tools To address diagnostic challenges, ongoing research is focused on earlier, less invasive detection.4 Emerging approaches include blood-based biomarkers (e.g. proteomic panels, metabolomic profiling, microRNA and menstrual-fluid analysis),18-21 as well as advanced imaging techniques such as transvaginal ultrasound and MRI, which may help reduce reliance on laparoscopy and accelerate accurate diagnosis.3,7,17 When it’s not endometriosis: validating pelvic pain without a diagnosis Pelvic pain affects up to 1 in 4 people assigned female at birth and has many possible causes – endometriosis being only one of them.7,11,22,23 For some, extensive investigations such as imaging or laparoscopy reveal no abnormalities, which can leave patients feeling dismissed, confused or invalidated. Pharmacists can help by acknowledging that pain is real and deserving of care, even in the absence of a definitive diagnosis. Symptom management is the first-line approach for both endometriosis and chronic pelvic pain, and care should aim to improve daily function and quality of life regardless of diagnostic certainty.3 Where appropriate, pharmacists can also support referral to other healthcare providers for further assessment or multidisciplinary management. Although endometriosis itself is not curable, symptoms and recurrences can be effectively managed through person-centred care that considers physical, emotional and reproductive health needs.8

      Management approaches 

      Non-pharmacological treatment  Current treatment is focused on symptom control, rather than elimination of the disease. Non-pharmacological approaches form an essential part of care, particularly for patients who experience persistent pain or treatment adverse effects. Key strategies include8,13,24:
      • pelvic physiotherapy and psychotherapy (e.g. cognitive behavioural therapy [CBT], acceptance and commitment therapy [ACT])
      • heat therapy, TENS and mindfulness-based movement (e.g. yoga, Pilates)
      • anti-inflammatory or low-FODMAP diets, particularly for patients with co-existing irritable bowel syndrome.
      Mental health and emotional wellbeing Chronic pain is both physically and psychologically exhausting. Anxiety and depression rates are significantly higher in people with endometriosis than in the general population.7 Contributing factors include3,5,6,8,10,12,14,25:
      • diagnostic delays and invalidation of symptoms 
      • chronic fatigue and disrupted sleep
      • missed school or work
      • sexual dysfunction and relationship strain
      • fertility concerns or trauma from medical procedures.
      Pharmacists can play an important role in recognising distress and prompting early mental health support. Simple, empathetic questions – such as ‘How’s your sleep been lately?’ or ‘Is the pain affecting your mood?’ – can open conversations and guide appropriate referrals. Support strategies include:
      • recommending mental health care plans via GPs
      • referring to psychologists with chronic pain expertise or interdisciplinary pain teams
      • encouraging peer support groups (e.g. EndoActive, Endometriosis Australia, QENDO)
      • suggesting low-stigma mental health apps (e.g. MindSpot, Smiling Mind)
      • avoiding statements that minimise pain (e.g. ‘it’s just anxiety’) and instead validating the complex relationship between mood and pain.
      Complementary therapies  Patients may enquire about supplements or alternative therapies. Pharmacists should validate interest while clarifying the limited evidence and screening for interactions. Commonly explored options include magnesium, omega-3 fatty acids, turmeric (curcumin), vitex agnus-castus, zinc, vitamin B6, diindolylmethane (DIM) and acupuncture.22,24,26

      Pharmacological treatment 

      Analgesia
      • NSAIDs (e.g. naproxen 500 mg twice daily or ibuprofen 400 mg three times daily) are first line. 
      • Paracetamol may be added for multimodal relief.1,12,13
      Counselling should cover dosing, GI protection and review of OTC combinations (e.g. ibuprofen/paracetamol). Hormonal therapies Hormonal therapies suppress oestrogen-driven growth and reduce pain.11,12,13,27,28 Table 1 provides an overview of commonly used hormonal therapies in endometriosis management. Add-back therapy Treatment with gonadotrophin-releasing hormone (GnRH) analogues induces a temporary, reversible menopause to suppress oestrogen production and reduce endometriosis symptoms.30 However, this hypo-estrogenic state can cause side effects such as vasomotor symptoms, vaginal dryness and bone mineral density loss.30 Add-back therapy involves giving small ‘add-back’ doses of oestrogen, progestogen, or a combination of both, to counteract these effects while maintaining the efficacy of GnRH analogue treatment.13,28 Options include1,12,13,27: 
      • Continuous combined HRT – low-dose estrogen + progestogen. Use in patients with a uterus to protect the endometrium.
      • Sequential combined HRT – estrogen daily + cyclical progestogen. Less preferred, as cyclical hormones may worsen endometriosis symptoms.
      • Progestogen-only – continuous progestogen. Used when estrogen contraindicated.
      • Tibolone – synthetic steroid: estrogenic, progestogenic, and androgenic activity. Often used post-menopause; caution in estrogen-sensitive conditions.
      For add-back therapy, ensure to: 
      • use continuous regimens (not cyclical) to avoid stimulating endometriotic tissue
      • monitor BMD regularly if GnRH therapy continues >6 months
      • start add-back therapy generally at the same time as the GnRH analogue.
      Fertility considerations Up to half of people with endometriosis experience fertility issues, and pain suppression does not necessarily improve fertility.2,3,6,12 Pharmacists can:
      • counsel on hormonal therapy effects on ovulation 
      • encourage early specialist referral if conception delayed >12 months
      • support patients undergoing IVF or assisted reproductive treatment 
      • provide reassurance and empathy around fertility-related distress. 
      Table 1 – Overview of hormonal therapies for endometriosis References: Therapeutic Guidelines1, Buggio et al12, Rossi13 Hornstein26, Vercellini27 Note: Bone mineral density typically recovers within two years of cessation of GnRH therapies.27 Drospirenone currently off-label for endometriosis in Australia.1 The addition of Ryeqo (relugolix, estradiol, norethisterone) (July 2022) and Visanne (dienogest) (December 2024) to the PBS expands accessible hormonal therapy options for endometriosis.29

      The role of the pharmacist in endometriosis care

      Pharmacists play a vital role in improving care for people with endometriosis by addressing barriers through education, advocacy and person-centred support. Key strategies include1,5,8,12:
      • using inclusive language and avoiding assumptions about gender identity or reproductive goals
      • proactively exploring the impact of symptoms on daily life, including school, work and relationships
      • offering accessible symptom-tracking tools to support self-monitoring
      • referring patients to culturally safe services, including First Nations-specific clinics when appropriate
      • advocating for patients and providing education to dispel misconceptions about endometriosis.
      Given the impact of endometriosis on mental health, it is essential for pharmacists to use affirmative language that validates the patient’s experience.  For example, acknowledging that a patient’s pain is real fosters trust, signals active listening and supports collaborative care. Avoiding dismissive statements such as ‘pain is normal for women’ is crucial, as these can reinforce shame and self-doubt, and discourage timely help-seeking.10,14,31 Pharmacists are integral members of multidisciplinary teams managing endometriosis. They facilitate early identification and timely referrals to general practitioners, specialists, pelvic physiotherapists, psychologists and dietitians. The upcoming Endometriosis Management Plan (EMP), a digital clinical tool launching in 2026, is designed to enhance care coordination, streamline documentation, and align treatment goals across providers.4,32 Pharmacists can support EMP implementation through patient counselling, comprehensive medicines reviews and ongoing follow-up.  Pharmacists are also well-positioned to assist patients in navigating newly established specialist clinics funded under the 2025–26 federal health budget.4,32 Home Medicines Reviews (HMRs) can further optimise medicines management and should be actively recommended as part of a comprehensive care strategy. Pharmacists can support shared decision-making by explaining treatment mechanisms, expected onset of action and common adverse effects, helping patients make informed choices.

      Patient resources  

      Pharmacist follow-up and recommendations of patient support resources are beneficial for ongoing management. These include10,12,25,33:
      • inviting patients to check in monthly during early therapy
      • reassessing symptoms, tolerance and goals
      • encouraging use of symptom tracker apps to record symptoms, menstrual changes and evaluate therapy success (e.g. Phendo, Clue, EndoMeter)
      • referring to organisations for education/peer support
      • recommending organisations6,9,10,14,23,34,35:
        • Endometriosis Australia – advocacy/awareness
        • Jean Hailes for Women’s Health – tools/info
        • Pelvic Pain Foundation of Australia – clinician and patient info
        • QENDO – peer support, lived experience, free tracking app
        • EndoZone – clinical decision support, patient-friendly explanations
        • ESHRE patient leaflet – print-friendly patient information.

      Knowledge to practice 

      Pharmacists in primary care can support people with endometriosis by providing early recognition of symptom impact, guidance on medicines and symptom management, and facilitating timely referrals to appropriate healthcare providers.  Pharmacists play a key role in validating patient experiences, promoting self-monitoring through symptom-tracking tools, explaining treatment options and adverse effects, and encouraging engagement with multidisciplinary care.  Pharmacists should also advocate for patients and provide education to dispel misconceptions, helping reduce delays in diagnosis and improving overall quality of care.

      Conclusion

      Endometriosis is far more than painful periods – it’s a complex, chronic condition requiring interdisciplinary, person-centred care. Pharmacists can make a profound difference by recognising early signs, validating lived experience, supporting evidence-based management and facilitating timely referral. Even a single empathetic conversation can empower a patient to seek help and change the trajectory of their care.

      Case scenario continued

      You reassure Alicia that severe period pain is not something she has to accept and suggest tracking her symptoms with a menstrual diary and consulting a women’s health GP. You also provide advice on safe NSAID use and non-pharmacological strategies. Alicia returns 2 months later, now diagnosed with endometriosis and receiving hormonal therapy and pelvic physiotherapy. She continues to experience chronic pelvic pain and questions her medicines, so you organise a Home Medicines Review, identifying potential naproxen overuse and interactions with her sertraline, prompting treatment adjustments. You also recommend a local endometriosis support group, which Alicia joins, and she has since referred two friends with similar symptoms. Through ongoing support, she feels more empowered to manage her condition.
        [cpd_submit_answer_button]

      Key points

      • Lesion severity does not predict pain intensity.
      • Recognise red flags (e.g. cyclical pain, GI symptoms) and enact early referral.
      • Support interdisciplinary, patient-centred management.
      • Review safety, adherence and contraceptive actions of hormonal therapy.
      • Use inclusive, supportive language to reduce stigma and diagnostic delay.
      • Encourage treatment continuity and shared decision-making.

      References

      References 
      1. Therapeutic Guidelines Limited. Endometriosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2024. At: www.tg.org.au.
      2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–9. At: https://pubmed.ncbi.nlm.nih.gov/22819144/
      3. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep 2017;6(1):34–41. At: https://pubmed.ncbi.nlm.nih.gov/29276652/
      4. Australian Government Department of Health and Aged Care. National Action Plan for Endometriosis. Canberra: Department of Health; 2018. At: https://www.health.gov.au/resources/publications/national-action-plan-for-endometriosis?language=en
      5. RANZCOG. Endometriosis: a consensus guideline. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2021. At: https://ranzcog.edu.au
      6. Endometriosis Australia. About Endometriosis. 2023. At: www.endometriosisaustralia.org/about-endometriosis
      7. Armour M et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep 2020. At: https://pubmed.ncbi.nlm.nih.gov/33004965/
      8. Armour M, Sinclair J, Ng CHM, et al. A biopsychosocial approach to endometriosis management. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/2022_PPP_final-handouts.pdf
      9. European Society of Human Reproduction and Embryology. ESHRE. Guideline on endometriosis: patient leaflet. 2022. At: www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline
      10. Jean Hailes for Women’s Health. Endometriosis. 2024. At: www.jeanhailes.org.au/health-a-z/endometriosis
      11. Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol 2017;209:8–13. 
      12. Buggio L, Armour M, Evans S, et al. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract 2024;53(1–2):22–8. At: www1.racgp.org.au/ajgp/2024/january-february/endometriosis
      13. Rossi S, ed. Australian Medicines Handbook. 2025. Endometriosis. At: https://amhonline.amh.net.au
      14. EndoZone. Clinical and patient tools. 2025. At: www.endozone.com.au
      15. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32(2):315–24. At: https://academic.oup.com/humrep/article/32/2/315/2631390?login=false#116936554
      16. Alexander M, Dydyk EC, Michael F. Stretanski, et al. Central Pain Syndrome. StatPearls. 2025. At: www.ncbi.nlm.nih.gov/books/NBK553027/
      17. National Institute for Health and Care Excellence (NICE). Endometriosis: diagnosis and management. NICE guideline NG73. London: NICE; 2024. At: www.nice.org.uk/guidance/ng73/resources/endometriosis-diagnosis-and-management-pdf-1837632548293
      18. Endometriosis News. Current status of non-invasive biomarkers for endometriosis. 2024. At: www.endonews.com/current-status-of-non-invasive-biomarkers-for-endometriosis
      19. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database of Systematic Reviews 2016. Issue 4. 
      20. Proteomics International. PromarkerEndo delivers breakthrough results for endometriosis blood test. Perth: PIQ; 2024. At: ASX-PIQ-Collaboration-expanded-to-advance-Endometriosis-blood-test-251015.pdf
      21. Evans‑Hoeker E, Senapati S, Behera MA. Serum markers for endometriosis: a critical appraisal of current literature. Fertil Steri 2024;121(5):943–56.
      22. Evans S. Introduction to pelvic pain: an introduction to pelvic pain for girls, women, men and families. Pelvic Pain Foundation of Australia; 2024. At: www.pelvicpain.org.au/wp-content/uploads/2024/01/Introduction-to-Pelvic-Pain.pdf
      23. Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews 2017;2017(1):CD004753. At: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004753.pub4/full
      24. Villella S. The use of complementary medicines and therapies in women's health. Jean Hailes for Women’s Health; 2022. At: www.jeanhailes.org.au/uploads/Webinars/Complementary-medicine-and-therapies
      25. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022(2):hoac009. https://doi.org/10.1093/hropen/hoac009
      26. Malik A, Sinclair J, Ng CHM, et al. Complementary medicine and chronic pelvic pain in Australian women: a national cross-sectional survey. BMJ Open 2021;11:e045768. At: https://pubmed.ncbi.nlm.nih.gov/35148773/
      27. Hornstein MD. Endometriosis: long-term treatment with gonadotropin-releasing hormone agonists. In: Barbieri RL, Eckler K, editors. UpToDate. Waltham (MA): UpToDate Inc.; 2023. At: www.uptodate.com
      28. Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 2016;106(7):1552–71. At: https://pubmed.ncbi.nlm.nih.gov/27817837/.
      29. Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme: New listings and changes – December 2024. Canberra: PBS; 2024. www.pbs.gov.au
      30. Veth VB, van der Karr MM, Duffy JM, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database of Systematic Reviews 2023;6(6).
      31. Australian Commission on Safety and Quality in Health Care. Person-centred care: a toolkit for implementation. Sydney: ACSQHC; 2020.
      32. Australian Government Department of Health and Aged Care. Budget 2025–26: Women’s Health Package. 2025. At: Budget 2025–⁠26: Strengthening Medicare – Women's health | Australian Government Department of Health, Disability and Ageing
      33. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018;19(10):1109–25. At: https://pubmed.ncbi.nlm.nih.gov/29975553/
      34. Endometriosis Australia. Patient stories (2023). At: https://endometriosisaustralia.org/category/endo-stories/
      35. QENDO. About Us. 2025. At: https://www.qendo.org.au/

      Our author

      Erin Downey (she/her) BPharm, GCertDiabEd, CDE, MPS CredPharm (MMR), ANZCAP-Reg (Endo, Generalist) is a clinical pharmacist, credentialled diabetes educator, endocrinology and generalist ANZCAP registrar, practising hospital pharmacist, and private CDE/credentialled MMR pharmacist in Southern Tasmania. 

      Our reviewer

      Elke Smith (she/her) BPharm, MHlthMgt [post_title] => Endometriosis: More than just a bad period [post_excerpt] => Endometriosis is a chronic inflammatory condition which affects 10–15% of all reproductive-aged Australians who were assigned female at birth. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => endometriosis-more-than-just-a-bad-period-cpd [to_ping] => [pinged] => [post_modified] => 2026-02-06 10:09:22 [post_modified_gmt] => 2026-02-05 23:09:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=31273 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Endometriosis: More than just a bad period [title] => Endometriosis: More than just a bad period [href] => https://www.australianpharmacist.com.au/endometriosis-more-than-just-a-bad-period-cpd/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 31300 [authorType] => )

      Endometriosis: More than just a bad period

AUSTRALIAN PHARMACIST Australian Pharmacist
Home Uncategorised Amitriptyline for Irritable Bowel Syndrome

Amitriptyline for Irritable Bowel Syndrome

Uncategorised
By
AP Staff
-
6 February 2000
  • SHARE
  • SHARE
Previous articleCommunicating safely
Next articleAre unconscious gender biases widening the Australian gender pain gap?
AP Staff

Subscribe to our newsletter

Get your weekly dose of the news and research you need to help advance your practice.

Please only use letters and spaces

Please include a valid email address

What pharmacists need to know about emergency prescribing for ADHD

Industry Chloe Hava - 11 February 2026
0

Where emergency contraception practice falls short

Industry Chloe Hava - 9 February 2026
0

How expanded scope is redefining pharmacy practice

Industry Brian Bigg - 8 February 2026
0

RELATED ARTICLESMORE FROM AUTHOR

People

Meet the 2023 NSW PSA Excellence Awards winners

UTI pilot
Industry

UTI pilot decision a step forward in pharmacy prescribing

Industry

More surprising updates to Continued Dispensing arrangements

Subscribe to our newsletter

Get your weekly dose of the news and research you need to help advance your practice.

Please only use letters and spaces

Please include a valid email address

Subscribe to our newsletter

Get your weekly dose of the news and research you need to help advance your practice.

Protected by Google reCAPTCHA v3.

Loading
PSA Logo

Australian Pharmacist is the official journal for Pharmaceutical Society of Australia Ltd.

CPD Info psa.org.au Advertising

Writing for Australian Pharmacist

CONTACT

(02) 6283 4777
australianpharmacist@psa.org.au

PO Box 42
Deakin West ACT, 2600

FOLLOW US

fk tr ln im
© Copyright 2024 - Pharmaceutical Society of Australia
  • Privacy Policy
  • Terms and Conditions
SHARE